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Summary 
Potent-selective peptidomimetic inhibitors of tissue transglutaminase (TG2) were developed 
through a combination of protein-ligand docking and molecular dynamic techniques. Derivatives 
of these inhibitors were made with the aim of specific TG2 targeting to the  ntra-  and  extracellular  
space. A cell-permeable  fluorescently  labelled  derivative  enabled  detection  of in situ  cellular  
TG2 activity  in human  umbilical  cord  endothelial  cells  and  TG2-transduced NIH3T3 cells,  
which could be enhanced by treatment  of cells  with ionomycin.  Reaction of TG2 with this  
fluorescent  inhibitor in NIH3T3 cells  resulted in loss  of binding of TG2 to cell surface syndecan-
4 and inhibition of translocation of the  enzyme into  the  extracellular  matrix,  with a parallel  
reduction  in fibronectin  deposition.  In  human  umbilical  cord  endothelial  cells,  this  same 
fluorescent  inhibitor  also  demonstrated  a reduction  in fibronectin  deposition,  cell motility, and 
cord formation in Matrigel. Use of the same inhibitor in a mouse model of hypertensive 
nephrosclerosis showed over a 40% reduction in collagen deposition. 
In Brief 
Badarau et al. design and develop high potency TG2-specific irreversible inhibitors that show reactivity 
with the intracellular active form of TG2, leading to inhibition of its translocation into the extracellular 
matrix. The compounds are effective in inhibiting in vitro angiogenesis and hypertensive. 
nephrosclerosis in animal models. 
 
Highlights 
• Irreversible tissue transglutaminase (TG2) inhibitors of high selectivity and potency 
• Target the Ca2+ activated form of TG2 in the intra- and/or extracellular space 
• Reactive with intracellular TG2 and block its translocation into the matrix 
• Effective in blocking hypertensive nephrosclerosis in animal models 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
Potent-selective peptidomimetic inhibitors of tissue transglutaminase (TG2) were developed through a 
combination of protein-ligand docking and molecular dynamic techniques. Derivatives of these 
inhibitors were made with the aim of specific TG2 targeting to the intra- and extracellular space. A cell-
permeable fluorescently labeled derivative enabled detection of in situ cellular TG2 activity in human 
umbilical cord endothelial cells and TG2-transduced NIH3T3 cells, which could be enhanced by 
treatment of cells with ionomycin. Reaction of TG2 with this fluorescent inhibitor in NIH3T3 cells 
resulted in loss of binding of TG2 to cell surface syndecan-4 and inhibition of translocation of the 
enzyme into the extracellular matrix, with a parallel reduction in fibronectin deposition. 
In human umbilical cord endothelial cells, this same fluorescent inhibitor also demonstrated a reduction 
in fibronectin deposition, cell motility, and cord formation in Matrigel. Use of the same inhibitor in a 
mouse model of hypertensive nephrosclerosis showed over a 40% reduction in collagen deposition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
Transglutaminases (TGs) belong to a family of protein crosslinking enzymes that catalyze an acyl 
transfer reaction between the γ-carboxamide group of peptide-bound glutamine and the ε-amino group 
of peptide-bound lysine (or a suitable primary amine) resulting in formation of a ε(γ-glutamyl)lysine 
isopeptide bond (Griffin et al., 2002). In mammals, eight catalytically active TGs, each Ca2+-dependent, 
are found in this family, of which tissue transglutaminase (TG2) is probably the most ubiquitous in 
human tissues. The current challenges in studying the role of TG2 are to (1) develop inhibitors that 
target TG2 and not other members of the TG family (specificity); (2) investigate independently the 
intracellular and extracellular roles of the enzyme (cell permeability); (3) characterize the effect of 
specifically inhibiting TG2 crosslinking activity in physiological/ pathological conditions. TG2 is 
involved in a host of human diseases such as celiac disease, cancer, fibrosis, multiple sclerosis, and 
neurodegeneration (Wang and Griffin, 2012). As a consequence, TG2 has become a potential 
therapeutic target for the treatment of these pathological conditions (Badarau et al., 
2013a). Moreover, since TG2 is found both in the intra- and extracellular space, both targeted specificity 
for TG2 itself and specific targeting to a particular subcellular space are needed. We recently described 
inhibitors aimed at targeting only the extracellular space (Badarau et al., 2013b; Griffin et al., 2008). 
These molecules incorporate two key polar groups in their structure in order to assure their high 
hydrophilic character: a carboxylate moiety and a charged warhead represented either by a 
dimethylsulfonium (Griffin et al., 2008) or by an imidazolium function (Badarau et al., 2013b). Despite 
their activities in the low micromolar range, these derivatives have great potential because of their high 
aqueous solubility and their excellent cellular toxicity profile. In fact, since their intracellular access is 
restrained, these inhibitors show very little toxicity in cells up to 750 µM over 72 hr (Wang and Griffin, 
2013). They have also shown considerable success in proof-of-concept studies in animal models of 
kidney fibrosis over 120 days without any signs of toxicity but with significant improvements in kidney 
function (Huang et al., 2009; Johnson et al., 2007). However, the major drawback with these 
extracellular acting TG inhibitors is potency and specificity. Therefore, the first objective of our work 
was to design potent, highly specific TG2 inhibitors that could be used for targeting the intra- and/or 
extracellular space, were not toxic in cellular systems, and had the potential to be used in preclinical 
studies. 
 
In the design of this new family of inhibitors, we were also very much aware that, once deposited into 
the extracellular matrix (ECM), TG2 is tightly associated with its potential substrates and is not easily 
accessible; and that the secretion and translocation of TG2 onto the cell surface and into the extracellular 
matrix ECM, which is independent of the conventional ER/Golgi pathway, requires the binding of TG2 
to the cell surface heparan sulfate proteoglycan syndecan-4. Importantly, the binding of TG2 to this 
proteoglycan is highly favoured by its compact closed conformation (Wang et al., 2012; Lortat-Jacob 
et al., 2012). Hence, a further objective in this work was to assess whether suitably labeled irreversible 
TG2 specific inhibitors that can permeate the cell can also bind TG2 inside the cell thus both inhibiting 
enzyme activity and locking it into its open confirmation. This is particularly important when 
considering TG2 as a therapeutic target since TG2 in its open confirmation is likely to be blocked in its 
translocation to the cell surface and into the ECM because it is unable to bind effectively to cell surface 
heparan sulfates (Wang et al., 2012). Moreover, if it does manage to reach the ECM, e.g. from cell lysis, 
it reaches it in an inactive form. Such inhibitors are likely to have a broad spectrum of application in 
TG2-mediated human pathologic conditions in which TG2 is acting either inside or outside the cell. 
 
RESULTS 
In developing the TG2 inhibitors, the work was divided into two interlinked processes: in silico 
molecular modeling to first design and then synthesize the inhibitors and then a series of studies on their 
characterization. The latter included enzyme potency, specificity, cell permeability, solubility, and in 
vitro ADME (absorption, distribution, metabolism, excretion) characterization followed by an 
assessment of their potential application in biological systems using cell-based and in vivo preclinical 
models. 
Generation of New Peptidomimetic TG2 Inhibitors 
Molecular modelling was used to yield insights into the probable binding pattern of our previous 
peptidic water-soluble derivatives. The modelling approach was based on the Michaelis- Menten 
complexes generated by docking of these compounds with the open conformation of TG2 (PDB: 2Q3Z). 
These were then subsequently ‘‘relaxed’’ by molecular  dynamics conducted in explicit water at 300 K 
(see Supplemental Experimental Procedures). 
The trajectories generated provided a rich source of information that helped in the development of the 
new TG2 inhibitors. One of the successfully exploited pathways relied on the observation that, during 
the dynamics trajectory, the water-soluble ligands tend to adopt a specific conformation in the central 
amino acid region. In fact, the dihedral N1-C2-C3-N4 emphasized in Figure 1A stabilized around 0_ 
with a limited variation of ±20_. This key observation was the starting point for the design of a new 
series of inhibitors. 
In order to mimic the observed conformation for the central N1-C2-C3-N4 region, we next introduced 
a piperazine scaffold, as indicated in Figure 1B. The same three-atom linker was preserved between N4 
and the carbonyl (vicinal to the warhead), however, in order to facilitate the subsequent chemical 
modifications, a new nitrogen atom was introduced. One of the first structures synthesized to validate 
this ‘‘restrained conformation’’ hypothesis exhibited the same activity range as the initial water soluble 
substrates (1a, Figure 1B). The irreversibility of the inhibitors was first confirmed by prior incubation 
of the compounds with recombinant purified human TG2 and then subsequent dilution prior to assay of 
the incubated enzyme as previously described (Griffin et al., 2008). An indication of the hydrophilic 
character of this derivative was observed experimentally during the isolation step by freeze-drying the 
aqueous layer after separation from the organic layer. In addition, an indication of its cellular toxicity 
profile was undertaken in human umbilical cord endothelial cells (HUVECs). As very little cellular 
toxicity was observed after 72 hr at concentrations up to 100 mM (Figure S1), this new molecule (1a) 
represented the starting point for subsequent modifications. To rule out the effect of any potential TG2 
and FXIII present in the serum from the cell culture medium, which could eliminate the effect of the 
compounds in the toxicity assay, the HUVECs were cultured in serum-free endothelial cell medium in 
the presence of compounds 3h, 1h, and 3e up to 72 hr, with no significant toxicity detected at the 
concentrations used (Figure S2). 
 
Optimization of Inhibitor Potency 
The first step of our modification strategy focused on the central amino acid region of the newly 
designed ligands. In order to evaluate the effect of steric hindrance that could be generated by additional 
substituents in this position, derivatives bearing new core amino acids were synthesized (Figure 1C, 
Schemes 1 and 2). As summarized in Table 1A, the activity was lost when using bulky substituents 
arising from phenylalanine (1l, 1k), the same but more moderate trend being observed for small 
substituents (1i, 1j). It should also be mentioned that the chirality of the stereogenic carbon atom seemed 
important, the analog in the L-Ala series (1i) being favored over its D isomer (1j). 
Our attention next focused on the electrophilic warhead region. Different groups were tested in order to 
evaluate their influence on the binding process. As a possible means of targeting the extracellular space 
by limiting cell permeability, highly polar warheads were attached to the newly designed skeleton. As 
shown in Table 1B, the dialkylsulfonium moieties retained a good inhibition range (1a, 1q), while the 
imidazolium warhead induced a complete loss of activity (1s). It should be noted that, in our initial 
water-soluble peptidic inhibitors, the same imidazolium warhead maintained a good TG2 inhibition 
range (Badarau et al., 2013b), suggesting the binding patterns of the two classes of inhibitors are very 
different. 
Our next approach was to design inhibitors containing lipophilic warheads, which were more likely to 
be cell permeable and could be used to target the intracellular space. As the catalytic CYS residue was 
revealed by the different available crystal structures of TG2 to be hosted in a narrow tunnel (PDB: 
2Q3Z, Pinkas et al., 2007; PDB: 1KV3, Liu et al., 2002; PDB: 3LY6, Han et al., 2010), our choice was 
focused on terminal Michael acceptors such as acrylamides and vinylsulfonamides. Such warheads 
possess an additional carbon atom in the electrophilic region of the ligand, and it is likely that this will 
induce a different conformation of the warhead around the catalytic CYS residue compared with the 
sulfonium-based inhibitors. Table 1B shows that both of these new warheads preserved a good 
inhibition range (2a, 3a), the vinylsulfonamide having a more favourable effect on binding. 
Other modifications were performed in the carbamate region (Table 1C). As this moiety was predicted 
by modelling to bind in the hydrophobic pocket of the binding site (as revealed by the crystal structure 
of the open-form conformation; (Pinkas et al., 2007), different-size aromatic carbamates were tested in 
the first instance. In this case, the corresponding bromide precursors originally developed for inhibiting 
the serine proteases (Schoellmann and Shaw, 1963), and which have high reactivity with the enzymatic 
nucleophile, were also biologically evaluated. If for the dimethylsulfonium and acrylamide warheads 
the inhibition varies in the lower micromolar range, for the corresponding halomethylketones the 
potency was increased to the lower nanomolar range. However, their high cellular toxicity profile for 
the halide precursors, particularly the more reactive bromides, confirmed their limited pharmacological 
use. 
A new set of inhibitors was prepared following the same hypothesis of targeting the hydrophobic pocket 
of the active site. An adamantyl moiety was chosen as the reference substituent and its distance from 
the piperazine ring was systematically varied in order to find an optimum for the interaction with the 
enzyme. The corresponding tert-butyl carbamate was also synthesized. The best median inhibitory 
concentration (IC50) in the ‘‘lipophilic’’ series was obtained for the acrylamide warhead (3e), while in 
the ‘‘hydrophilic’’ series, the tert-butyl carbamate (1m) outperformed its analogs (Table 1C). 
Design and Characterization of a Fluorescent Probe and Further Characterization of Lead 
Compounds 
A dansyl fluorescent tag was attached to the central piperazine scaffold to fully exploit the biological 
potential of this new class of TG2-specific inhibitors, with the view to being able to pin point and 
visualize the presence of the inhibitors, most importantly the presence of the active enzyme located at 
a cellular level. Analogs in both water-soluble and lipophilic series were obtained and evaluated for 
their activity on a battery of TGs (Table 2A). Compound 3h had an excellent IC50 of _6 nM for TG2, 
as well as a good toxicity profile when tested up to 100 µM (Figure 1E), and showed selectivity for 
TG2 when assayed against TG1, TG3, TG6, and Factor XIIIa (FXIIIa). A comparable TG selectivity 
profile was also shown for 1h with an IC50 value of 380 nM, again with a good toxicity profile (Figure 
S1). 
Measurement of the Ki and Kinact of 3h and 1h using the glutamate dehydrogenase coupled assay 
indicated high potency, particularly 3h, with a Kinact of 0.387 min-1, a Ki of 1.31 mM, and a Kinact/Ki 
of 297,692 min-1M-1. This was comparable with the other high-potency non-dansylated inhibitor 3e 
(IC50 125 nM), which had a calculated Kinact of 0.275 min-1, a Ki of 1.63 mM, and a Kinact/Ki of 
171,875 min-1M-1. The other fluorescent inhibitor, 1h, in line with its lower IC50 (380 nM), had a Ki of 
57 mM, a Kinact of 0.337 min-1 and a Kinact/Ki of 5,830 min-1M-1. Given the potential application of 
3h and 1h in TG2 conformational studies, it was important to demonstrate that their reactivity was Ca2+ 
dependent. For this, recombinant human TG2 was incubated for 30 min at 4°C with either Ca2+ (1 mM) 
or GTP (1 mM), and then for a further 30 min in the presence of compound 3h (10 nM) or 1h (1 mM). 
Spin columns were then used to remove excess inhibitor. Evaluation of TG2 activity after removal of 
the excess inhibitor indicated that only the enzyme incubated with GTP was active (Figure 2A), thus 
confirming the requirement of Ca2+ for the inhibitors 3h and 1h to access the transamidating active site. 
To rule out potential off-target effects of the inhibitors, inhibition of the cysteine proteases Caspase 3 
and 7 was undertaken. HUVECs were induced into apoptosis and the caspase activity measured in situ 
in the presence and absence of 3h and 1h. No inhibition of Caspase 3 or 7 was shown (Figure 2B). The 
same results were obtained for the inhibitors 1e and 3e, which carry the dimethylsulfonium and the 
acrylamide warheads, respectively. 
Other potent compounds were also tested for their specificity toward TG2 compared with other TG 
family members. Biotinylated TG-specific glutamine-containing peptides specific for TG family 
members, including TG1, FXIIIa, TG3, and TG6, were used in these assays (CovTests; Perez Alea et 
al., 2009). Comparable IC50 values of these inhibitors for TG2 were detected in both the CovTest and 
the biotin-cadaverine incorporation assay. All derivatives from this series proved selective over  the 
TG1, TG3, and FXIIIa TGs with selectivity shown against TG6 for compounds 1e, 1f, and 3f although 
less selectivity was shown for TG6 with compound 3e (Table 2B). A moderate TG1 inhibition trend 
was observed for the halomethylamides. In the case of TG2, however, the inhibition activities are in the 
lower nanomolar range (>100-fold selectivity ratio). To rule out any non-specific reaction of the 
inhibitors with TG1, TG3, and FXIIIa, the dansylated probes 3h and 1h were incubated with these three 
isoforms in the presence of Ca2+ and with EDTA, enzymes were then separated by denaturing SDS gel 
electrophoresis and western blotted for the detection of the dansyl group, which showed negligible 
reactivity of the TG isoforms with either inhibitor (Figure S3). 
Further Characterization of the TG2 Inhibitors Toxicity Studies 
The toxicity profile of some of these new potent inhibitors was evaluated in HUVECs using the XTT-
based assay as described previously (Wang and Griffin, 2013). The toxicity varied between 25 and 100 
µM (Table S1 and Figure S1). As expected, in relation to their high reactivity, the halomethylketones 
(6n, 6o) were the most toxic compounds. The more hydrophilic inhibitors bearing  the 
dimethylsulfonium warhead were well tolerated by the same cell lines with toxicity thresholds of <100 
µM. Encouraging results were also obtained for the compounds designed to be more lipophilic, 
especially 3e, which has an inhibition activity for TG2 in the nanomolar range (IC50 = 0.125 ± 0.066 
mM).Different toxicity profiles were observed between the acrylamide-and vinylsulfonamide-based 
derivatives (3e vs 2e), which might be explained in part by their different chemical reactivities. 
Confirmation of Covalent Interaction and Targeting the Active Site Cys277 by 1h and 3h 
The fluorescent inhibitor probes allowed us to demonstrate that these compounds were targeting the 
active site Cys277 in their covalent reactivity. Pure recombinant wild-type (wt) TG2 and its active site 
mutant Cys277Ser were incubated with the compound 1h in the presence of Ca2+ for 3 hr. As a positive 
control, the wt enzyme was incubated with the competitive amine substrate monodansylcadaverine 
(MDC), which becomes enzymatically incorporated into available g-glutamyl residues on neighboring 
TG2 molecules. 
Following incubation, TG2 was separated on denaturing SDSPAGE and western blotted using an anti-
dansyl antibody (Figure 2C). Bands were seen in the positive control containing the MDCand in the wt 
enzyme where the active site Cys277 is intact, indicating covalent interaction of the inhibitor with TG2. 
In the Cys277Ser mutant, no incorporation of MDC was detected in a band that was indicative for TG2. 
Presence of the inhibitor was not detected with the Cys277Ser mutant, suggesting that fluorescent 
inhibitor 1h is specifically targeting the active site Cys277. 
Cellular Permeability 
The cellular permeability profile for a subset of compounds was investigated using the irreversible 
imidazolium-based inhibitor R283 (Freund et al., 1994), which is cell permeable, and the peptidic 
inhibitor R281, which is cell impermeable, as reference as described previously (Baumgartner et al., 
2004). This assay is based on the ability of compounds to permeate the cell and inhibit intracellular 
TG2 activity after its activation by the elevation of intracellular Ca2+ using ionomycin. As initially 
designed, the assay confirmed that acrylamide-based inhibitors 3e, 3f and the fluorescent probe 3h 
penetrate the cell and inhibit intracellular TG2 activity, contrary to the charged compounds 1e and 1f 
(Figure 2D). As a means of validating the permeability assay used in these studies, the cell permeability 
of compounds 3h, 3e, and 1h was also determined in MDCKII-MDR1 cells. The assay was conducted 
in the presence of the efflux transporter inhibitor GF120918. Using this assay, the passive permeability 
(P exact) of compounds 3h, 1h, and 3e was 649, 1.3, and 676 nm/s respectively, confirming that the 
acrylamide inhibitors 3h and 3e are cell permeable. In contrast, the positively charged 1h is cell 
impermeable. Measurement of the thermodynamic solubility of these same three compounds in PBS 
(pH 7.4) over 24 hr was 24 µM for 3h, 1594.6 µM for 1h, and 698 µM for 3e. 
In Vitro ADME Properties of Compounds 3h, 1h, and 3e 
Further characterization of lead compounds 3h, 1h and 3e by in vitro ADME assays are shown in Table 
S2. Microsomal stability assessed in human microsomes indicated that compounds 3h and 1h exhibited 
low and high stability, respectively, with compound 3e demonstrating moderate stability. In contrast in 
the cell health screen assessed in the hepatic cell line HepG2, no significant effect was observed for any 
of the compounds on mitochondrial potential, nuclear morphology, and membrane permeability. 
Importantly, no significant effect was observed for hERG liability with any of the compounds and their 
binding to human serum albumin and a-glycoprotein indicated that none of them had very high binding. 
Assaying for the Presence of Potential Intracellular In Situ TG2 Activity/Open Conformation 
Using Dansyl Derivative 3h 
The measured cell permeability of the fluorescent inhibitor 3h, which requires TG2 to be in its Ca2+ 
bound open conformation prior to its irreversible binding, should enable the detection of TG2 in its 
open/relaxed conformation inside the cell when combined with fluorescent microscopy and/or co-
immunoprecipitation (co-IP) studies. NIH3T3 cells transduced with wt TG2 were used to confirm 
whether the intracellular reaction of 3h with TG2 could take place. Figure 2E shows that inhibitor 3h 
permeates into NIH3T3 cells and reacts with intracellular TG2, which can be increased further in the 
presence of the Ca2+ ionophore ionomycin (Figure 2E). This is demonstrated by co-IP of the 
inhibitor/TG2 complex in the cytosolic fraction of cells using an anti-dansyl antibody and TG2 revealed 
in this complex using an anti-TG2 antibody by western blotting. Importantly, the reactivity of 3h with 
intracellular TG2 was reduced by incubating in the presence of the cell-permeable inhibitor 3e (Figure 
2E). 
To confirm that the newly developed fluorescent inhibitors 3h or 1h only interact with TG2 in its open 
Ca2+ bound  conformation and lock the enzyme into this conformation, wt recombinant TG2 pre-treated 
with Ca2+ or GTP was incubated with inhibitor 3h and then separated by native PAGE. As shown in 
Figure 2F, 3h and 1h in the presence of Ca2+ bind to TG2 and hold it in its open conformation, while 
the binding of GTP, which holds TG2 in its closed conformation, blocks the interaction of 3h or 1h with 
TG2 and gives rise to increased mobility. 
HUVECs, which contain high levels of endogenous TG2, were also used to verify our observations in 
TG2-transduced NIH3T3 cells. Cells were incubated in the absence or presence of the Ca2+ ionophore 
ionomycin (positive control). Mouse endothelial cells isolated from TG2-/- mice were used as the 
negative control together with HUVECs incubated with 3h in the presence of the cell-permeable non-
dansylated inhibitor 3e. After fixation of the cells and removal of any excess inhibitor by washing, 
fluorescence microscopy revealed a faint intracellular dansyl signal in the HUVECs without ionomycin 
treatment, which was increased with ionomycin and reduced in the presence of inhibitor 3e. No dansyl 
signal was detected in the negative control mouse endothelial cells, which are null for TG2 after fixing 
and washing out any excess inhibitor (Figure 3A). Further confirmation that the dansyl inhibitor is 
targeting TG2 was obtained by co-IP of the dansyl-labeled proteins in the cell cytosol fractions of cell 
lysates and the detection of TG2 by western blotting. TG2 was found to be present in the HUVECs with 
or without ionomycin. The signal was reduced in the cells treated with the inhibitor 3e and, importantly, 
as found with immunofluorescent microscopy, totally absent in the TG2-/- mouse endothelial cells 
(Figure 3B). Hence, in both TG2-transduced NIH3T3 cells and in HUVECs, TG2 appears to be present 
in  the intracellular environment in an open conformation and able to react with inhibitor 3h, suggesting 
that the enzyme could be active if suitable substrates are available to it, or, dependent on its 
environment, is simply alternating between the open and closed conformation. 
Effect of 3h on TG2 Interaction with Syndecan-4 and its Translocation to the Cell Surface and 
ECM 
The interaction between TG2 and syndecan-4 has been reported to be not only essential for the 
externalization of the enzyme onto the cell surface and deposition into the ECM (Wang et al., 2012) but 
also for its pathological roles in fibrosis (Scarpellini et al., 2014). Previous work from us and others 
suggested the importance of TG2 crosslinking activity in pathological conditions such as fibrosis, 
angiogenesis, and multiple sclerosis. Therefore, we next studied the effect of inhibitor 3h on the binding 
of TG2 to syndecan-4 and its subsequent translocation into the ECM. 
It has been reported that TG2 binding to syndecan-4 is favoured by the compact conformation (Wang 
et al., 2012) of the enzyme. It has been shown in Figure 2F that the inhibitor 3h locks TG2 into its open 
conformation, which would have a significant impact on the binding of the enzyme to syndecan-4. 
Therefore, we next studied the effect of 3h binding to TG2 on the enzyme’s binding to cell surface 
heparan sulfates. Figure 3C shows that in NIH3T3 cells, previously used to show TG2 binding to cell 
surface syndecan-4, 3h significantly reduced the interaction between TG2 and cell surface syndecan-4 
following co-IP of TG2 with anti-syndecan-4 antibody as previously documented (Wang et al., 2012). 
Importantly, in these same cells, binding of  TG2 to 3h led to a dramatic reduction in the presence of 
the enzyme on the cell surface and in the ECM (Figure 3D), which paralleled a dramatic reduction in 
the deposition of fibronectin (FN) into the ECM (Figure 3D). 
Effects of Fluorescent TG2 Inhibitor 3h on Endothelial Cell Function 
In our previous report, using our first generation of peptidic TG inhibitors, we showed that extracellular 
TG2 could be a potential target in the treatment of VEGF-induced angiogenesis due to its ability to 
block the deposition of FN, which is one of the important ECM proteins required for matrix-bound 
VEGF signalling (Wang et al., 2013). Given the ability of compound 3h to react with both intracellular 
and extracellular HUVEC TG2, we tested the effects of compound 3h on different but related 
endothelial cell functions. Figure 4A shows that inhibitor 3h reduced the deposition of FN into the ECM 
by HUVECs, which agrees with its effect in NIH3T3 cells (Figure 3D). One further role of TG2 in 
endothelial cell angiogenesis is in cell migration during tubule formation (Wang et al., 2013), which is 
dependent on the crosslinking activity of the enzyme. Figures 4B and 4C demonstrate that compound 
3h inhibited HUVEC migration in the wound healing assay and in Matrigel cord formation assays. 
Potency of Inhibitor 3h in an In Vivo Model of Hypertensive Nephrosclerosis 
As a further means of demonstrating the potential application of these new peptidomimetic inhibitors 
in human disease where TG2 has been shown to act extracellularly, we next looked at the effects of 
inhibitor 3h, which blocks both intracellular and extracellular TG2 activity, on angiotensin II (AngII)-
induced hypertensive nephrosclerosis in mice. Before undertaking these studies, we first gained an 
approximate cell IC50 for 3h by looking at the inhibition of FN deposition in HUVECs and in mouse 
endothelial cells, which in both cases gave an approximate IC50 for 3h of 0.3 µM in human HUVECs 
and 0.4 µM in mouse endothelial cells (Figure S4). 
AngII and 3h were delivered using a subcutaneously implanted osmotic minipump (Azlet) over 14 days. 
Mice receiving AngII alone together with inhibitor vehicle showed signs of increased collagen 
deposition around the arterioles and, in some cases, in the glomeruli and interstitial tubular space. In 
contrast, animals receiving AngII plus compound 3h showed significantly reduced (approx. 40%) 
collagen deposition in all these regions (Figure 5A) with around 45% reduction around the blood vessels 
(Figure 5B) in the kidneys of inhibitor-treated animals. No obvious signs of toxicity were observed in 
the animals after inhibitor treatment.  
DISCUSSION 
In this paper, we report a new series of small-molecule peptidomimetic inhibitors that are selective for 
TG2 activity. Importantly, we also demonstrate the biological impact of these inhibitors and 
demonstrate their potential application in both cell and animal models for the targeting of TG2 in 
diseases such as fibrosis and pathological angiogenesis. 
Contrary to the classic family of TG2 inhibitors represented mainly by the peptidic inhibitors, this new 
series adds a new member to the modest, but continuously increasing, family of non-peptidic TG2 
inhibitors. Sporadic examples have been disclosed so far (Duval et al., 2005; Klock et al., 2011; Ozaki 
et al., 2010, 2011; Pardin et al., 2008a, 2008b; Prime et al., 2012; Schaertl et al., 2010). Their 
pharmacological characterization in terms of potency, specificity, binding-site targeting, toxicity, and 
cellular permeability still remains to be revealed. In addition, a more recent report screening existing 
TG2 inhibitors based on a weak electrophilic 3-bromo-4,5-dihydroisoxazole (DHI) scaffold showed 
poor selectivity against TG1 (Klock et al., 2014). Constructed on a piperazine core, this new scaffold 
presented here has the advantage of an excellent selectivity profile at least against four other members 
of the TG family that were evaluated during our studies (TG1, TG3, TG6, and FXIIIa). It should be 
noted, however, that another two groups (Prime et al., 2012; Wityak et al., 2012) have reported 
piperazine-based derivatives with interesting TG2 activities; however, Prime et al. (2012) reported that 
their selectivity over the other TGs (especially over FXIIIa) requires further optimization. Wityak et al. 
(2012) reported that their lead inhibitor had an IC50 for TG2 of 14 nM with selectivity over TG1, TG3, 
TG6, and FXIIIa but no cell or animal studies were undertaken on these compounds although in vitro 
DMPK studies indicated they had low toxicity; the authors indicated that improved ADME profiling 
was still required for in vivo applications because of their low plasma stability. Importantly, the 
straightforward synthetic route of the compounds presented in this report gives easy access to various 
modulations, allowing us to improve the toxicity profile of our inhibitors up to 100 µM/72 hr, while 
controlling their cellular access. However, like the compounds reported by Wityak et al. (2012), further 
improvements on ADME characteristics are still necessary for some of our lead compounds, in 
particular improvements in microsomal stability and aqueous solubility for 3h, although solubility may 
not be such an issue for in vivo potency given that the solubility of 3h is >3,000 times the IC50 of 3h. 
Moreover, the poor microsomal stability of 3h is unlikely to be due to the piperazinyl moiety as 
suggested by Wityak et al. (2012) given that compound 1h, which is a comparable structure apart from 
the warhead, is microsomal stable. 
Physiologically, TG2 is an enzyme that exists both in the intra and extracellular environment. Inside 
the cell, its Ca2+-dependent crosslinking activity is thought to be tightly controlled by the binding of 
GTP/GDP, which holds the enzyme in a compact closed inactive conformation (Bergamini et al., 2011; 
Wang and Griffin, 2012). However, TG2 is reported to be involved in a number of human diseases 
where it acts both intracellularly (e.g. cystic fibrosis, cancer progression, epidermal growth factor 
receptor recycling) (Bergamini et al., 2011; Zhang et al., 2013) and/or extracellularly, including matrix 
deposition, tissue fibrosis, VEGF-dependent angiogenesis, and multiple sclerosis (Wang and Griffin, 
2012; Wang et al., 2013). The development of a highly potent cell-permeable fluorescent inhibitor 
specific for TG2, allowed us to test for the first time whether TG2, when inside the cell, can indeed 
exist in both its potentially active open conformation as well as its closed/compact conformation. Our 
data suggest that reactivity of TG2 with the fluorescent inhibitor probe can take place in the low Ca2+ 
intracellular environment of both HUVECs and NIH3T3 cells, which can be further enhanced by using 
the Ca2+ ionophore ionomycin. Given that the reported Km app for Ca2+ for TG2 is around 3 µM (Hand 
et al., 1985), this suggests that the conformation of the enzyme may also be regulated by other binding 
factors in addition to Ca2+, which permits flexibility between the open and compact conformation and 
which, when in the open conformation, allows the irreversible reaction with the fluorescent TG2 
inhibitor probe. Earlier fluorescence resonance energy transfer studies with TG2 have also suggested 
that,in certain localities of the cell, the enzyme may exist in its open conformation (Pavlyukov et al., 
2012). This may explain a number of observations where TG2 has been reported to regulate a several 
cellular processes either through conformational changes that regulate protein binding (Zhang et al., 
2013) or via its transamidating activity (Colak et al., 2011). 
As referred to earlier, TG2 can be secreted into the ECM by a non-conventional mechanism, which 
requires the cell surface binding of heparan sulfates, such as syndecan-4, for its translocation into the 
ECM. This binding of TG2 to syndecan-4 at the cell surface is favored by the enzyme being in its 
compact closed conformation, suggesting that the enzyme is secreted in this conformation or that this 
conformation is assumed once it reaches the cell surface (Wang et al., 2012). Therefore, our next 
question was to ask if the binding of an irreversible inhibitor inside the cell, which would hold the 
enzyme in its open conformation, would interfere with both its translocation to the cell surface and its 
deposition into the ECM. 
Using NIH3T3 cells, we clearly show that treatment of these cells with the fluorescent permeable 
inhibitor 3h reduces the presence of TG2 at the cell surface and nearly completely blocks translocation 
of the enzyme into the ECM, a finding that is accompanied by the reduced deposition of FN. In 
HUVECs, where we know TG2 also reacts with our fluorescent probe inside the cell, we also observed 
a large reduction in the deposition of FN in the presence of this TG2 inhibitor. In relation to biological 
functions of endothelial cells, this intracellular acting probe is also a potent inhibitor of endothelial cord 
formation on Matrigel and a potent inhibitor of endothelial motility, which is required for endothelial 
tube formation (Wang et al., 2013). As a further means of demonstrating the potential application of the 
new peptidomimetic inhibitors in in vivo studies in a disease state where TG2 acts extracellularly, we 
next looked at the effects of inhibitor 3h on AngII-induced hypertensive nephrosclerosis in mice. Mice 
receiving AngII plus compound 3h showed significantly reduced (approx. 40%) collagen deposition 
across all regions of the kidney with around a 45% reduction in collagen deposition around the kidney 
arterioles when compared with mice receiving AngII and vehicle. 
Hence, our findings demonstrate that our new peptidomimetic TG2 small-molecule inhibitors, which 
can react with TG2 inside the cell and prevent export of the enzyme as well as block its activity, provide 
an ideal therapeutic avenue for the treatment of human diseases involving TG2. 
SIGNIFICANCE 
TG2 has been shown to be essential in a number of human disease states, including fibrosis and 
angiogenesis. However, other transglutaminase family members sharing a similarity in their structures 
generate obstacles in generating TG2-specific inhibitors with high potency and low toxicity. Using 
molecular dynamics techniques, a series of new peptidomimetic inhibitors against TG2 were produced 
with excellent selectivity when tested against four other members of the transglutaminase family (TG1, 
TG3, TG6, and FXIIIa). A highly potent TG2 cell-permeable fluorescent probe (IC50 = 6 nM; Kinact/Ki 
of 297,692 min–1 M–1) was designed and exploited in several biological studies. We demonstrate that 
the reactivity of the inhibitor can take place with TG2 in the low Ca2+ intracellular environment of 
HUVECs and NIH3T3 cells, which is enhanced by using the Ca2+ ionophore ionomycin. Importantly, 
reaction of TG2 with this fluorescent inhibitor led to a loss of binding of TG2 to cell surface syndecan-
4 in NIH3T3 cells and inhibition of TG2 translocation into the ECM, which was paralleled by a 
reduction in the deposition of matrix FN. Further studies with HUVECs treated with this cell-permeable 
fluorescent inhibitor revealed a significant reduction in FN deposition, cord formation on Matrigel, and 
cell motility. As a means of demonstrating the potential application of the new peptidomimetic 
inhibitors in vivo, where TG2 acts extracellularly (Huang et al., 2009; Johnson et al., 2007), the effects 
of inhibitor 3h on Angiotensin II (AngII)-induced hypertensive nephrosclerosis in mice was 
investigated. Mice receiving AngII plus compound 3h showed significantly reduced (approx. 40%) 
collagen deposition across all regions of the kidney with around 45% reduction around blood vessels. 
Hence, this new series of TG2-specific cell-permeable peptidomimetic inhibitors may be highly 
effective in targeting human diseases involving extracellular TG2 via their ability to block both protein 
crosslinking activity and enzyme export. 
EXPERIMENTAL PROCEDURES 
Synthetic and analytical methodology 
The newly synthesized derivatives were characterised by infra-red spectroscopy (IR), proton and 
carbon-13 NMR spectroscopy (1H- and 13C-NMR), melting points (Mp), high resolution mass 
spectrometry (HRMS), and had properties consistent with the proposed structures (see Supplemental 
Experimental Procedures).  
Biological methodology 
General Experimental procedures were performed as described previously (Wang et al., 2012 and 2013, 
Wang and Griffin, 2012) and experimental information is detailed in Supplemental Experimental 
Procedures. 
Reagents and antibodies 
The general reagents were purchased from Sigma-Aldrich (UK), unless stated below. 
Chemical synthesis of the inhibitors 
The synthesis of the inhibitors is described in Supplemental Experimental Procedures.  
Cell culture 
Human umbilical vein endothelial cells (HUVECs) (Lonza, Belgium) (Wang et al., 2013) and NIH3T3 
cells (Wang et al., 2012) were cultured as described previously (Supplemental Experimental 
Procedures).  
TG2 activity assays 
For measurement of TG2 activity the incorporation of biotinylated cadaverine into immobilised N,N –
dimethylcasein was used as previously  described (Wang et al., 2012).  
For determination of the activity of TG1, TG3, TG6 and FXIIIa, commercial microassays TG-CovTest 
were used (Covalab, Lyon, France) (Hitomi et al., 2009), according to the manufacturer’s instructions. 
For comparable purposes, a number of TG2 assays were also undertaken using this assay. Briefly, TG-
specific biotinylated peptides, including pepF11KA (FXIII pre-activated with thrombin), pepK5 (TG1), 
pepT26 (TG2), pepE51 (TG3) or pepY25 (TG6) (Hitomi et al., 2009; Fukui et al., 2013), were incubated 
with the suitable TG family members in the presence of polyamine substrates immobilized onto 96-well 
microplates. The incorporated biotinylated peptides were measured using HRP-conjugated streptavidin 
and then measured using OPD substrates. The absorbance was measured at 490 nm using a microplate 
reader.   
Glutamate Dehydrogenase coupled assay used for Kinact/ki calculations  
TG2 inhibitors were assayed in accordance with the method of Choi et al using the glutamate 
dehydrogenase coupled assay (Choi et al., K. 2005.). Briefly, a reaction mixture containing 4 mM 
CaCl2, 10 mM α-ketoglutarate, 0.2 U/ml glutamate dehydrogenase, 0.12 mM NADH, 20µg TG2, and 
10 mM Cbz-Gln-Gly in 200 mM MOPS, pH 7.1, was used in the assay. The enzyme reaction was 
initiated by the addition of TG2 and the consumption of NADH was monitored using different 
concentrations of inhibitor (10-500 nM) by UV spectroscopy (340 nm, ε= 6220 cm−1M−1). Kinetic 
parameters (kinact and ki) were obtained by using the software Dynafit 4.05.129 (Kuzmic, 2009 and 
Kuzmic, 1996). 
Cell permeability assay 
1. By measuring inactivation of intracellular TG2. To induce  intracellular TG2 activity, HUVECs 
with high endogenous TG2 were incubated with fresh growth media with 0.5% FBS containing given 
1 µM ionomycin and 1 mM biotin-cadaverine (Zedira, Germany) in the presence or absence of 50 µM 
of TG2 inhibitors 3h, 1f, 3f, 3e and 1e. The non-cell permeable inhibitor R281 and cell permeable 
inhibitor R283 were used as the negative and positive controls, respectively. After a 3 h incubation, the 
cells were collected in homogenization buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA) 
and sonicated on ice. The cell membrane was pelleted at 60,000 ×g for 60 min and the supernatant (the 
cytosol fraction) was used for the assay. 50 µg of total protein in 100 µl of the homogenization buffer 
was used in the biotin-cadaverine incorporation assay as described previously by Wang et al (2012).  
2. By the in vitro passive cellular permeability (“MDCK assay”) 
The permeability (P exact.) of 3h, 1h, 3e across an MDCK-MDR1 cell monolayer was measured at a 
starting concentration of 3µM in the presence of GF120918, an efflux inhibitor. The pH of the donor 
and receiver compartments was 7.4 (Hank's Balanced Salt Solution).  
Incubations were carried out in an atmosphere of 5% CO2 with a relative humidity of 95% at 37°C for 
60 min. Apical and basolateral samples were diluted for analysis by LC-MS/MS. The integrity of the 
monolayers throughout the experiment was checked by monitoring Lucifer yellow permeation using 
fluorimetric analysis (Tran et al., 2004). 
Western blotting for the dansyl inhibitor interaction with rhTG2 
1 μg of recombinant human TG2 (rhTG2), wt or the active site C277S mutant protein, was incubated 
with the dansylated TG2 inhibitor 1h at 100 μM and 50 μM  in the presence of 10 mM Ca2+ and 1 mM 
DTT in Tris-HCl buffer, pH 7.4 for 30 min at room temperature. The primary amine substrate MDC, 
which will be incorporated into the available γ-glutamyl residues of TG2 by the enzyme was used as 
the positive signal control sample, while non-labelled rhTG2 was used as the negative control. The 
reaction was stopped by diluting the samples into 2× Laemmli buffer and boiling at 95°C for 5 min. 
The presence of dansyl was detected via Western blotting (Wang et al., 2012; Wang et al., 2013) by 
using a specific anti-dansyl antibody (Invitrogen, UK).    
The targeting of in situ TG2 activity by fluorescence microscopy using the dansyl inhibitor 3h  
HUVEC cells and TG2 -/- mouse endothelial cells were used in this study. HUVECs were treated with 
1 µM ionomycin in the presence or absence of 50 µM of 3e to pre-block the intracellular active TG2 
for 3 h and the cells were further treated with 5 µM 3h for another 2 h. TG2 -/- endothelial cells were 
treated in a comparable manner but were not exposed to the inhibitor 3e. For detection of endogenous 
TG2 activity, HUVECs were incubated without ionomycin. After the incubation, the cells were washed 
3 times with pre-chilled methanol and fixed with methanol for 20 min at -20ºC. Following blocking 
with 3% BSA in PBS, pH 7.4 for 30 min at 37ºC, the cells were incubated with rabbit anti-dansyl 
antibody and revealed using a secondary TRITC-conjugated antibody for a 2 h/incubation at 37ºC. The 
fluorescence signal was visualized using a Zeiss epifluorescent microscope using a 60× objective. 
Detection of TG2 activity using co-IP 
Immunoprecipitation (IP) of the intracellular TG2-dansyl inhibitor complex was performed following 
the treatment of cells with 3h with or without pre-treatment of 50 µM 3e (as described above). Cytosol 
fractions of HUVEC or NIH3T3 cells transduced with TG2 were collected as described above. Anti-
TG2 antibody was used to pull down the TG2 immuno-complex and SDS-PAGE and Western blotting 
was then performed to detect the presence of the dansyl group of 3h. TG2 knockout (ko) endothelial 
cells or non-TG2 transduced NIH3T3 cells, as well as a mouse IgG negative control antibody, were 
used as the negative controls.  
Animal study 
Animal studies were undertaken with full ethical approval and all procedures carried out under license 
according to regulations laid down by Her Majesty’s Government, United Kingdom (Animals Scientific 
Procedures Act, 1986) and undertaken in accordance with the 3Rs. Two groups of five animals were 
used. In the first group C57BL/6 male mice (14-weeks old) were infused with AngII 1.1mg/kg/day in 
50% DMSO in PBS pH 7.4 for 2 weeks without TG2 inhibitor via a subcutaneously implanted osmotic 
pump (Alzet1002) as previously described (Murdoch et al., 2011). In the second group compound 3h 
was infused in a similar manner at 25mg/kg/day together with AngII in 50% DMSO in PBS pH7.4 over 
14 days. Following 14 days kidneys from the treated mice were frozen in O.C.T (CellPath) at an optimal 
temperature (-150⁰C) using isopentane subsequently 6μm sections were prepared. Picrosirius red 
staining was preformed to measure collagen staining as previously reported (Murdoch et al., 2011). The 
collagen content was quantified as the percentage in a minimum of 10 images per mouse of area using 
ImageProPlus (v5.0). The concentration (270mM) of inhibitor used in the pump was approximated from 
computer simulations to give the steady state concentration in the mouse assuming an extensive 
distribution of the drug at 5 µM with a half-life of 1hr. 
Statistical analysis 
Data are expressed as the mean ± S.E. for at least three independent replicate experiments (n ≥ 3). 
Statistical tests were undertaken using InStat (GraphPad, La Jolla, CA, USA). Statistical analysis of 
results was undertaken using one-way analysis of variance (ANOVA) using a post-test depending on 
the requirement. 
FUNDING SOURCES 
Eduard Badarau was supported by the Marie Curie research grant: "TRANSCOM", FP7 No: 251506. 
Andrea Costanzi was supported by the Marie Curie research grant “TRANSPATH “FP7 No 289964. 
AUTHOR CONTRIBUTION 
MG was the major grant holder that funded the work. M.G. and Z.W., D.R. designed the experiments. 
E.B. performed the compound synthesis and with D.R the modelling. Z.W., A.C., T.T., C.M., M.B. and 
S.E.L. performed the biological experiments, and all authors analyzed the data. M.G., Z.W., E.B. and 
D.R wrote the manuscript. 
ACKNOWLEDGEMENTS 
The authors acknowledge EPSRC National Mass Spectrometry Centre, Swansea (UK) for recording the 
HRMS spectra. To Glaxo Smith Kline, UK for undertaking the in vitro DMPK assays. The group of 
Prof Soichi Kojima (RIKEN, Japan) for kindly providing the TG2 ko endothelial cells. To Dr Raj K. 
Singh Badhan (Aston University) for help in calculating the inhibitor concentration used in the in vivo 
experiments following pharmokinetic simulations.  Fruitful discussions with Dr Alexandre Mongeot 
and Dr Russell Collighan (Aston University) are also acknowledged.  
None of the authors of this manuscript have a financial interest related to this work.  
REFERENCES 
Arnold, K., Bordoli, L., Kopp, J.and Schwede, T. (2006). The SWISS-MODEL workspace: a web-
based environment for protein structure homology modelling, Bioinformatics 22, 195-201. 
Badarau, E., Collighan, R.J., and Griffin, M. (2013a). Recent advances in the development of tissue 
transglutaminase (TG2) inhibitors. Amino Acids 44, 119-127. 
Badarau, E., Mongeot, A., Collighan, R.J., Rathbone, D.L., and Griffin, M. (2013b). Imidazolium-based 
warheads strongly influence activity of water-soluble peptidic transglutaminase inhibitors. Eur J Med 
Chem 66, 526-530. 
Baumgartner, W., Golenhofen, N., Weth, A., Hiiragi, T., Saint, R., Griffin, M., and Drenckhahn, D. 
(2004). Role of transglutaminase 1 in stabilisation of intercellular junctions of the vascular endothelium. 
Histochem Cell Biol 122, 17-25. 
Duval, E., Case, A., Stein, R.L., and Cuny, G.D. (2005). Structure-activity relationship study of novel 
tissue transglutaminase inhibitors. Bioorg Med Chem Lett 15, 1885-1889. 
Freund, K.F., Doshi, K.P., Gaul, S.L., Claremon, D.A., Remy, D.C., Baldwin, J.J., Pitzenberger, S.M., 
and Stern, A.M. (1994). Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: 
mechanism of factor XIIIa inactivation. Biochemistry 33, 10109-10119. 
Griffin, M., Casadio, R., and Bergamini, C.M. (2002). Transglutaminases: nature's biological glues. 
Biochem J 368, 377-396. 
Griffin, M., Mongeot, A., Collighan, R., Saint, R.E., Jones, R.A., Coutts, I.G., and Rathbone, D.L. 
(2008). Synthesis of potent water-soluble tissue transglutaminase inhibitors. Bioorg Med Chem Lett 18, 
5559-5562. 
Han, B.G., Cho, J.W., Cho, Y.D., Jeong, K.C., Kim, S.Y., and Lee, B.I. (2010). Crystal structure of 
human transglutaminase 2 in complex with adenosine triphosphate. Int J Biol Macromol 47, 190-195. 
Huang, L., Haylor, J.L., Hau, Z., Jones, R.A., Vickers, M.E., Wagner, B., Griffin, M., Saint, R.E., 
Coutts, I.G., El Nahas, A.M., et al. (2009). Transglutaminase inhibition ameliorates experimental 
diabetic nephropathy. Kidney Int 76, 383-394. 
Johnson, T.S., Fisher, M., Haylor, J.L., Hau, Z., Skill, N.J., Jones, R., Saint, R., Coutts, I., Vickers, 
M.E., El Nahas, A.M., et al. (2007). Transglutaminase inhibition reduces fibrosis and preserves function 
in experimental chronic kidney disease. J. Am. Soc. Nephrol. 18, 3078–3088. 
Klock, C., Jin, X., Choi, K., Khosla, C., Madrid, P.B., Spencer, A., Raimundo, B.C., Boardman, P., 
Lanza, G., and Griffin, J.H. (2011). Acylideneoxoindoles: a new class of reversible inhibitors of human 
transglutaminase 2. Bioorg Med Chem Lett 21, 2692-2696. 
Liu, S., Cerione, R.A., and Clardy, J. (2002). Structural basis for the guanine nucleotide-binding activity 
of tissue transglutaminase and its regulation of transamidation activity. Proc Natl Acad Sci U S A 99, 
2743-2747. 
Lortat-Jacob H, Burhan I, Scarpellini A, Thomas A, Imberty A, Vivès RR, Johnson T, Gutierrez A, 
Verderio EA. (2012) Transglutaminase-2 interaction with heparin: identification of a heparin binding 
site that regulates cell adhesion to fibronectin-transglutaminase-2 matrix. J Biol Chem 287, 18005-
18017. 
Ozaki, S., Ebisui, E., Hamada, K., Goto, J., Suzuki, A.Z., Terauchi, A., and Mikoshiba, K. (2010). 
Potent transglutaminase inhibitors, aryl beta-aminoethyl ketones. Bioorg Med Chem Lett 20, 1141-
1144. 
Ozaki, S., Ebisui, E., Hamada, K., Suzuki, A.Z., Terauchi, A., and Mikoshiba, K. (2011). Potent 
transglutaminase inhibitors, dithio beta-aminoethyl ketones. Bioorg Med Chem Lett 21, 377-379. 
Pardin, C., Pelletier, J.N., Lubell, W.D., and Keillor, J.W. (2008a). Cinnamoyl inhibitors of tissue 
transglutaminase. J Org Chem 73, 5766-5775. 
Pardin, C., Roy, I., Lubell, W.D., and Keillor, J.W. (2008b). Reversible and competitive cinnamoyl 
triazole inhibitors of tissue transglutaminase. Chem Biol Drug Des 72, 189-196. 
Perez Alea, M., Kitamura, M., Martin, G., Thomas, V., Hitomi, K., and El Alaoui, S. (2009). 
Development of an isoenzyme-specific colorimetric assay for tissue transglutaminase 2 cross-linking 
activity. Analytical Biochemistry 389, 150-156. 
Pinkas, D.M., Strop, P., Brunger, A.T., and Khosla, C. (2007). Transglutaminase 2 undergoes a large 
conformational change upon activation. PLoS Biol 5, 2788-2795. 
Prime, M.E., Andersen, O.A., Barker, J.J., Brooks, M.A., Cheng, R.K., Toogood-Johnson, I., Courtney, 
S.M., Brookfield, F.A., Yarnold, C.J., Marston, R.W., et al. (2012). Discovery and structure-activity 
relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease. 
J Med Chem 55, 1021-1046. 
Schaertl, S., Prime, M., Wityak, J., Dominguez, C., Munoz-Sanjuan, I., Pacifici, R.E., Courtney, S., 
Scheel, A., and Macdonald, D. (2010). A profiling platform for the characterization of transglutaminase 
2 (TG2) inhibitors. J Biomol Screen 15, 478-487. 
Schoellmann, G., and Shaw, E. (1963). Direct evidence for the presence of histidine in the active center 
of chymotrypsin. Biochemistry 2, 252-255. 
Tran, T. T., A. Mittal, T. Gales, B. Maleeff, T. Aldinger, J. W. Polli, A. Ayrton, H. Ellens and J. Bentz 
(2004). "Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer 
modeled as a single barrier." J Pharm Sci 93, 2108-2123. 
Wang, Z., Collighan, R.J., Pytel, K., Rathbone, D.L., Li, X., and Griffin, M. (2012). Characterization 
of heparin-binding site of tissue transglutaminase: its importance in cell surface targeting, matrix 
deposition, and cell signaling. J Biol Chem 287, 13063-13083. 
Wang, Z., and Griffin, M. (2012). TG2, a novel extracellular protein with multiple functions. Amino 
Acids 42, 939-949. 
Wang, Z., and Griffin, M. (2013). The role of TG2 in regulating S100A4-mediated mammary tumour 
cell migration. PLoS One 8, e57017. 
Wang, Z., Perez, M., Caja, S., Melino, G., Johnson, T.S., Lindfors, K., and Griffin, M. (2013). A novel 
extracellular role for tissue transglutaminase in matrix-bound VEGF-mediated angiogenesis. Cell Death 
Dis 4, e808. 
Wityak, J., Prime, M.E., Brookfield, F.A., Courtney, S.M., Erfan, S., Johnsen, S., Johnson, P.D., Li, 
M., Marston, R.W., Reed, L., Vaidya, D., Schaertl, S., Pedret-Dunn, A., Beconi, M., Macdonald, D., 
Muñoz-Sanjuan, I., and Dominguez, C. (2012) SAR Development of Lysine-Based Irreversible 
Inhibitors of Transglutaminase 2 for Huntington's Disease. 
ACS Med Chem Lett 3, 1024. 
 
FIGURE LEGENDS 
Figure 1. Design and Synthesis of Lead TG2 Inhibitor Precursor 
(A) Examples of dihedral angles defined by N1-C2-C3-N4 recorded during the molecular dynamics 
trajectory. 
(B) Design of new peptidomimetic derivatives starting from the water-soluble inhibitors, R = SMe2. 
(C) Scheme 1 for the synthesis of the amine precursors. (a) p-NO2-phenylchloroformate, N-
methylmorpholine (NMM)/dichloromethane (DCM), 0_C, 2 hr; (b) piperazine, triethylamine 
(TEA)/dimethylformamide, 0_C to room temperature, 12 hr; (c) tert-butyloxycarbonyl (t-Boc)-Glu-
OH, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, HOBt, NMM/DCM, room temperature, 12 hr; 
(d) trifluoroacetic acid/DCM, room temperature, 24 hr. Commercially available alcohols were activated 
as p-nitrophenyl carbonates 7 and subsequently reacted with piperazine at room temperature in order to 
give the desired mono-carbamates 8. A peptidic coupling step with t-Boc-protected amino acids, 
followed by the acidic deprotection of the amines conducted to the key intermediates 5. 
(D) Scheme 2 for the synthesis of the final derivatives. (a) Acryloyl chloride, TEA/acetonitrile, 0_C to 
room temperature, 3 hr; (b) bromoacetyl bromide or chloroacetyl chloride, TEA/DCM, _78_C to room 
temperature, 12h r; (c) dimethylsulfide/MeOH, room temperature, 24 hr; (d) acetyl bromide, 
TEA/DCM, -78°C, 2 hr; (e) 2-chloroethylsulfonyl chloride, TEA/DCM, -60°C–0°C, 4 hr. Starting from 
the previously obtained amines 5, various acylation agents were used in order to obtain the final 
derivatives 1–4 as summarized in Scheme 2. In the case of polar dimethylsulfonium warhead, an 
additional nucleophilic substitution step was conducted on the halomethylamide precursor 6. 
(E) Toxicity profile of the fluorescent derivative 3h on HUVEC lines, after 24 hr (white), 48 hr (grey), 
and 72 hr (black) as described in the Experimental Procedures. CNTL, control. 
Figure 2. Characterization of the Lead Compounds for their Specificity and Cell Permeability 
(A) Columns 2–5 showCa2+-dependent binding of 3h with rhTG2. rhTG2 pre-treated with Ca2+ or GTP 
was incubated with 3h (10 nM) or 1h (1 mM) for 30 min at 4°C. Following removal of excessive 
inhibitors using 30-kDa cut off spin columns, bars 6 and 7 show the efficiency of the spin columns, 
where reaction mixes with inhibitor alone (either 3h or 1h) were prepared and filtered through the spin 
columns prior to assay. Bars 8–10 show the efficacy of GTP binding, where enzyme was incubated with 
250 µM Ca2+ to show activation of rhTG2 (bar 8) in the absence of GTP and showing that 1mM Ca2+ 
activates TG2 with 250 mM GTP present (bar 10). Samples with 1 mM GTP and 250 µM calcium were 
prepared in duplicate and one sample was processed through the spin column (bar 10) and the other 
sample was not (bar 9) to evaluate whether the spin column affects GTP binding. A positive control 
incubated without inhibitor was used as 100% reference (bar 1). 
(B) Effect of TG2 inhibitors 3h, 1h, 3e, and 1e on Caspase 3/7 activity. Following induction of apoptosis 
in HUVECs by staurosporine, caspase activity was measured as described in the Experimental 
Procedures. Ctrl represents the negative control without any inhibitor; addition of the caspase inhibitor 
Z-VAD-FMK to the assay represents the positive control. 
(C) Western blotting showing covalent interaction of compound 1h with TG2 and demonstrating 
targeting of the active site Cys277 by 1h as described in the Experimental Procedures. 
(D) Cell permeability of TG2 inhibitors 3h, 1f, 3f, 3e, 1e in primary HUVECs. The assay measures the 
inhibition of the TG2-mediated incorporation of N-(5-aminopentyl)biotinamide into intracellular 
proteins. R281, which is not cell permeable, was used as the 100% control. Experiments were 
undertaken as described in the Experimental Procedures. *p < 0.05. 
(E) Detection of dansyl inhibitor 3h in NIH3T3 cells. NIH3T3 cells transduced with TG2 containing 
Lentivirus were treated with 3h in the presence or absence of ionomycin and 1e. Co-IP using the cell 
cytosol fractions was performed to detect the interaction between TG2 and 3h as described in the 
Experimental Procedures. 
(F) Non-denaturing gel electrophoresis. rhTG2 pre-treated with Ca2+ or GTP (concentrations as 
indicated in the figure), followed by incubation with 3h or 1h as described in the Experimental 
Procedures. The samples were separated by non-denaturing PAGE and visualized using gel imaging. 
Figure 3. Intracellular Reactivity of Fluorescent Compound 3h with TG2 and its Effect on 
Enzyme Externalization 
(A) Detection of in situ TG2 activity using the dansyl derivative 3h, HUVECs and TG2-/- mouse 
endothelial cells (top panel) were treated as described in the Experimental Procedures. The cells were 
pre-treated with (a–i) or without ionomycin (j–l), in the presence (g, h) or absence (a–f and j–l) of non-
dansylated cellpermeable inhibitor 3e, while TG2 antigen was visualized using anti-TG2 antibody 
Cub7402 (d–l). DAPI is shown in the top right hand corner of each image. 
(B) Detection of TG2-dansyl derivative 3h complex in HUVECs and mouse TG2-/- endothelial cells 
after co-IP and western blotting. HUVECs were treated as described in (A). Cytosol fractions were 
collected and co-IP was undertaken using an anti-dansyl antibody as described in the Experimental 
Procedures. The presence of TG2 was detected via western blotting. Rabbit IgG and TG2 knockout 
endothelial cells were used as the negative controls. 
(C) Effect of inhibitor 3h on the interaction between TG2 and syndecan-4. Swiss3T3 cells transduced 
with wt TG2 were pre-treated with inhibitor 3h. Co-IP was performed using anti-syndecan-4 antibody 
to pull down the immune complex and the presence of TG2 was detected via western blotting. The 
empty vector transduced cells (vector) or the heparan sulfate binding mutant (HS2) TG2-transduced 
cells were used as the controls. 
(D) Effect of 3h on TG2 externalization and deposition. The presence of TG2 in Swiss3T3 cells from 
(C) was detected via biotinylation of cell surface (CS) proteins followed by western blotting. The matrix 
proteins were collected as described in the Experimental Procedures and the presence of TG2 was 
measured using anti-TG2 antibody Cub7402 via western blotting. WCL, whole-cell lysate. 
Figure 4. Effect of Compound 3h on Endothelial Cell Migration and Tubule Formation.  
(A) Representative images showing the effect of 3h on FN deposition by HUVECs. 7 3 104 HUVECs 
were seeded into chamber slides in the presence or absence of 3h treatment for 72 hr. 
Immunofluorescence staining was performed to detect the extracellular FN as described in the 
Experimental Procedures. Fluorescence images were captured using an epifluorescence microscope 
from three separate experiments. 
(B) Representative images showing the effect of 3h on HUVEC migration in the wound-healing assay. 
HUVECs were seeded into 12-well plates 
until confluency. Wounds were introduced into the monocell layer using 200-ml tips. The cells were 
allowed to migrate for 6 hr and the closure of 
the wounds was analyzed using ImageJ software (n = 3). *p < 0.05. 
(C) Representative images demonstrating the inhibition of HUVEC cord formation on Matrigel by 3h. 
96-well plates were pre-coated with Matrigel and HUVECs were allowed to form cord structures for 6 
hr. The images from three separate experiments were taken using a Nikon digital camera. 
Figure 5. TG2 Inhibition Attenuates Angiotensin II-Induced Renal Fibrosis Two groups of 
animals were used. In the first group, five C57BL/6 male mice (14 weeks old) were infused with AngII 
1.1 mg/kg/day in 50% DMSO in PBS (pH 7.4) for 2 weeks without TG2 inhibitor via a subcutaneously 
implanted osmotic pump (Alzet 1002) as previously described (Murdoch et al., 2014). In the second 
group, compound 3h was infused in a similar manner at 25 mg/kg/day in 50% DMSO in PBS (pH 7.4) 
together with AngII over 14 days. 
(A) Representative images of kidneys from the inhibitor- (lower panel) and non-inhibitor-(upper panel) 
treated animals. 
(B and C) Averaged data of Sirius red/collagen staining in kidney sections showing staining (B) around 
arterioles (n = 4) and (C) total collagen staining (n = 5). *p < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Table 1. TG2 inhibition data upon varying: (A) the central amino acid, (B) the warhead on the initial 
hit and (C) varying the substituents in the carbamate region. 
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O
N
N
O
Aa
N
H
O
S Br
(A)
 Lig
 
Cpd Aa 
IC50 ± SD 
[µM] 
Cpd R 
IC50 ± SD 
[µM] 
1a Gly 1.4 ± 0.5 1a 
 
1.4 ± 0.5 
1j D-Ala 6.8 ± 2.0 1q 
 
1.85 ± 0 
1i L-Ala 0.7 ± 0.3 1s 
 
100 
1l D-Phe > 100 2a 
 
1.725 ± 0.11 
1k L-Phe > 100 3a 
 
5.925 ± 0.11 
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3d 
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3.3 ± 0.3 
 
3b 
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O
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0.775 ± 0.035 
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1.625 ± 0.035 
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O
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3.15 ± 0.92 
 
 
3g 
 
0.9 ± 0.14 
 
1m 
 
 
0.273 ± 0.11 
 
 
  
 
 
 
 
 
 
 
 
Table 2. Characterisation of  compounds 3h,1h and 3e for inhibition of different TGs and PSA values 
(A) and inhibition profiles for other selected potent TG2 inhibitors (B). 
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FXIIIa 
(µM) 
TG1 
(µM) 
TG3 
(µM) 
TG6 
(µM) 
TG2* (µM) 
 
PSA (Å2) 
R 
3h > 100 25 20 5 0.0061 ± 0.00042 
 
90 Lig  
1h 
 
  > 100 
> 100 > 100 >10 
 
0.38± 0.057 
 
 
112 
S
Lig  
3e 
 
37 2.2 11 2µM 0.125 ±0.066 
70 
Lig  
 
Cpd 
 
IC50 (µM) 
 
TG1 (µM) TG3 (µM) TG6 (µM) FXIIIa (µM) 
1a >100 >100 NT >100 
1c >100 >100 NT >100 
3c >100 >100 NT >100 
6d 5 65 NT >100 
1d >100 >100 NT >100 
3d >100 >100 NT >100 
1b >100 >100 NT >100 
6e 1 70 NT >100 
1e >100 >100 >10µM >100 
6g 3 50 NT >100 
1f >100 >100 >10µM >100 
3f >100 >100 >10µM >100 
3g >100 >100 NT >100 
1m >100 >100 NT >100 
 
(A) 
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SUPPLEMENTAL FIGURES  
 
 
 
Supplemental Figure 1 (related to Figure 1E). The toxicity of the inhibitors shown in following 
Figure was measured in HUVEC cells using the XTT assay for measuring cell viability at the time 
periods and inhibitor concentrations shown as described in the Supplemental Experimental procedures. 
The histograms show mean values ± S.D. from 3 separate experiments at the concentration of the 
inhibitors shown at three time points. DMSO was used as the vehicle control treatment.  
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Supplemental Figure 2 (related to Figure 1E). The toxicity of the inhibitors 3h, 1h and 1e was 
measured using the XTT assay for measurement of cell viability in HUVEC cells cultured in serum free 
endothelial cell culture medium as described in the Supplemental Experimental procedures. The 
histograms show mean values ± S.D. from 3 separate experiments at the concentration of the inhibitors 
shown at three different time points. DMSO was used as the vehicle control treatment. 
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Supplemental Figure 3 (related to Table 2A). The interaction between compounds dansyl-labelled 
1h or 3h and transglutaminase family members TG1, TG3 and FXIII (1µg of total protein/each). 
Recombinant human TG1, TG3 and FXIII were incubated with 1h (A) or 3h (B) in the presence of Ca2+ 
or EDTA for 30 min at room temperature. The detection of dansyl was performed as described in the 
Experimental procedures using Western blotting.  
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Supplemental Figure 4 (related to Figure 5). Inhibition profile for FN deposition in human 
HUVEC cells and mouse endothelial cells by compound 3h. (A) HUVEC cells or mouse endothelial 
cells were treated with compound 3h for 72 h, the extracellular matrices were collected as described in 
Supplemental Experimental Procedures and Western blotting was performed to detect the presence of 
FN which was quantified by densitometry and plotted as shown in B. (B) Percentage of the FN present 
in the 3h treated endothelial cells compared to the vehicle control treatment DMSO (0 µM).     
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SUPPLEMENTAL TABLES   
Supplemental Table 1 (related to Figure 1 and Table 1). Toxicity data for the compounds listed 
measured over 72 h. 
* The toxicity of the inhibitors shown in the above Table and as shown in Supplemental Figure 1 was 
measured in HUVEC cells as described in the Experimental Procedures using the XTT assay to measure 
cell viability and also shown in Supplemental  Figure 1. 
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Supplemental Table 2 (related to Table 2A). Characterisation of compounds 3h, 1h and 3e by in 
vitro ADME assays.  
 
 
The ADME assays undertaken on compounds 3h, 1h and 3e, included Cell Health (pIC50), 
consisting of Mitochondrial Potential, Nuclear Morphology, Microsomal Stability, 3A4 (Flint 
Red), 3A4 (Flint Green), hERG, Protein Binding, HSA (%), Alpha-Glycoprotein, which were 
undertaken as described in the Supplemental Experimental Procedures. For the Cell Health 
Screens the values shown are the mean from 4 experiments, for microsomal stability the mean 
value is from two experiments and for hERG the mean is shown from 3 experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cpd 3h 1h 3e 
Cell Health (pIC50)    
Mitochondrial Potential <3.7 <3.7 <3.7 
Nuclear Morphology <3.7 <3.7 <3.7 
Microsomal Stability  3.5 0.5   1.0 
3A4 (Flint Red) 4.6 4.9 <4.3 
3A4 (Flint Green) 4.5 4.7 <4.3 
hERG <4.3 <4.3 <4.3 
Protein Binding    
HSA (%) 89 79 61 
Alpha-Glycoprotein 66 80 40 
 SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Chemistry Experimental Procedures 
Analytical methodology 
The newly synthesized derivatives were characterised by infra-red spectroscopy (IR), proton and 
carbon-13 NMR spectroscopy (1H- and 13C-NMR), melting points (m.p.), high resolution mass 
spectrometry (HRMS). They had properties consistent with the proposed structures and are described 
below. 
The infrared (IR) spectra were recorded on a Thermo Scientific Nicolet iS5 FT-IR spectrometer 
equipped with an ID5 Diamond ATR accessory. Signal intensities were abbreviated as follows: weak 
(w), medium (m) and strong(s). 
1H NMR and 13C NMR were recorded with Bruker Avance DPX250 (at 250.131 MHz and 62.895 MHz, 
respectively) in deuterated chloroform (CDCl3) and deuterated dimethyl sulfoxide (DMSO), using 
tetramethylsilane (TMS) as an internal standard. Chemical shifts are reported in parts per million (ppm) 
and the coupling constants are reported in units of Hertz [Hz]. Multiplicities were abbreviated as 
follows: singlet (s), doublet (d), triplet (t), quartet (q), pentuplet (p), sextet (sx), septet (sp), apparent 
singlet (as), apparent doublet (ad), apparent triplet (at). 
Low-resolution mass spectra (MS) were recorded with a Waters - LCT Premier. High resolution mass 
spectra (HRMS) were recorded with a Thermo Fischer Scientific LTQ Orbitrap XL at EPSRC National 
Mass Spectrometry Centre, Swansea (UK).  
Melting points were recorded using a Reichert-Jung Thermo Galen - Hot Stage Microscope equipped 
with a Pt 100/RTD temperature sensor.  
Flash chromatography was performed on Merck 40–70 nM (230–400 mesh) silica gel under nitrogen 
pressure. Thin-layer chromatography (TLC) was carried out on Merck silica gel 60 F254 precoated 
plates. Visualization was made with ultraviolet light (λ = 254/365 nm) and, if necessary, using an 
ethanolic solution of potassium permanganate.  
 
Synthetic methodology 
General method for the synthesis of the p-nitrophenyl-carbonates (A) 
Under nitrogen atmosphere, N-methylmorpholine (1.6 eq.) was added to a solution of the corresponding 
alcohols (1 eq., 3 mmol) in DCM (20 ml). The mixture was cooled to 0°C and subsequently a solution 
of p-nitrophenyl chloroformate (1.5 eq.) in DCM (5 ml) was added slowly, and the mixture was 
vigorously stirred at 0°C until the complete consumption of the starting material (usually 1-2 h). The 
reaction mixture was diluted with DCM (75 ml) and subsequently washed with sodium bicarbonate 
(aqueous satd. soln., 3 x 100 ml). The recovered organic layer was dried over magnesium sulfate and 
the solvent evaporated under vacuum.  
(a) methyl 4-[(4-nitrophenoxy)carbonyloxymethyl]benzoate (7b) 
The crude product obtained following the general protocol was washed with methanol, then with diethyl 
ether and further dried under reduced pressure to remove traces of solvents. C16H13NO7; yield 88%; 
white solid; m.p. 95-96°C; M = 331.28 g/mol; IR (ATR):  ν =  1763 (s), 1706 (s), 1527 (s), 1448 (m), 
1430 (m), 1281 (m), 1208 (m-s), 980 (m), 853 (m-s), 753 (s) cm -1; 1H NMR (250 MHz, CDCl3) δ 8.28 
(d, J = 9.2 Hz, 2H), 8.08 (d, J = 8.3 Hz, 2H), 7.51 (d, J = 8.3 Hz, 2H), 7.38 (d, J = 9.2 Hz, 2H), 5.35 
(s, 2H), 3.93 (s, 3H); 13C NMR (63 MHz, CDCl3) δ 166.7 (Cq), 155.5 (Cq), 152.5 (Cq), 145.6 (Cq), 139.2 
(Cq), 130.8 (Cq), 130.2 (2CH), 128.2 (2CH), 125.5 (2CH), 121.9 (2CH), 70.2 (CH2), 52.4 (CH3); MS: 
m/z = 354 [M + Na]+; 
(b) 2-naphthylmethyl (4-nitrophenyl) carbonate (7c) 
The crude product obtained following the general protocol was washed with methanol, then with diethyl 
ether and further dried under reduced pressure to remove traces of solvents. C18H13NO5; yield 67%; 
white solid; m.p. 151-152 °C; M = 323.30 g/mol; ; IR (ATR):  ν = 1748 (s), 1524 (m), 1351 (m), 1263 
(s), 1214 (s), 953 (m), 859 (m), 750 (m) cm–1; 1H NMR (250 MHz, CDCl3) δ 8.31-8.24 (m, 2H), 7.92-
7.84 (m, 4H), 7.56-7.50 (m, 3H), 7.42-7.36 (m, 2H), 5.47 (s, 2H); 13C NMR (63 MHz, CDCl3) δ 155.7 
(Cq), 152.6 (Cq), 145.5 (Cq), 133.6 (Cq), 133.2 (Cq), 131.7 (Cq), 128.9 (CH), 128.3 (CH), 128.3 (CH), 
127.9 (CH), 126.9 (CH), 126.7 (CH), 126.0 (CH), 125.4 (2CH), 121.9 (2CH), 71.3 (CH2); MS: m/z = 
346 [M + Na]+; 
(c) methyl 6-[(4-nitrophenoxy)carbonyloxymethyl]naphthalene-2-carboxylate (7d) 
The crude product obtained following the general protocol was used for the next steps without further 
purification. C20H15NO7; white solid; yield 88%; M = 381.34 g/mol; IR (ATR):  ν =  1754 (s), 1715 (s), 
1515 (s), 1384 (m), 1254 (m), 1208 (m-s), 853 (m-s), 750 (w) cm -1; 1H NMR (250 MHz, CDCl3) δ 8.63 
(s, 1H), 8.31-8.25 (m, 2H), 8.11 (dd, J = 8.6 Hz, J = 1.6 Hz, 1H), 8.01 (d, J = 8.5 Hz, 1H), 7.95 (as, 
1H), 7.91 (d, J = 8.7 Hz, 1H), 7.60 (dd, J = 8.4 Hz, J = 1.7 Hz, 1H), 7.43-7.36 (m, 2H), 5.48 (s, 2H), 
4.00 (s, 3H);  13C NMR (63 MHz, CDCl3) δ 167.2 (Cq), 155.6 (Cq), 152.6 (Cq), 145.6 (Cq), 135.4 (Cq), 
134.3 (Cq), 132.6 (Cq), 131.0 (CH), 130.3 (CH), 128.5 (CH), 128.4 (Cq), 127.8 (CH), 126.6 (CH), 126.1 
(CH), 125.5 (2CH), 121.9 (2CH), 70.9 (CH2), 52.5 (CH3); MS: m/z = 404 [M + Na]+; 
(d) 1-adamantylmethyl (4-nitrophenyl) carbonate (7f) 
The crude product obtained following the general protocol was washed with methanol, then with diethyl 
ether and further dried under reduced pressure to remove traces of solvents. C18H21NO5; yield 82 %; 
white solid; m.p. 102-103 °C; M = 331.36 g/mol; IR (ATR): ν = 2913 (m), 2847 (m), 1748 (s), 1518 
(s), 1342 (m-s), 1266 (m-s), 1217 (s), 856 (m), 762 (w), 729 (w) cm–1; 1H NMR (250 MHz, CDCl3) δ 
8.31-8.25 (m, 2H), 7.42-7.36 (m, 2H), 3.89 (s, 2H), 2.03 (s, 3H), 1.79-1.70 (m, 6H), 1.61 (d, J = 2.6 
Hz, 6H); 13C NMR (63 MHz, CDCl3) δ 155.9 (Cq), 152.9 (Cq), 145.4 (Cq), 125.4 (2CH), 121.9 (2CH), 
79.1 (CH2), 39.0 (3CH2), 36.9 (3CH2), 33.5 (Cq), 28.0 (3CH); MS: m/z = 354 [M + Na]+; 
(e) 2-(1-adamantyl)ethyl (4-nitrophenyl) carbonate (7g) 
The crude product obtained following the general protocol was washed with methanol, then with diethyl 
ether and further dried under reduced pressure to remove traces of solvents. C19H23NO5; yield 81%; 
white solid; m.p. 94-95 °C; M = 345.39 g/mol; IR (ATR):  ν = 2898 (m), 2841 (w), 1757 (s), 1527 (s), 
1342 (s), 1260 (s), 1205 (s), 950 (m), 856 (s), 668 (m)  cm–1; 1H NMR (250 MHz, CDCl3) δ 8.31-8.35 
(m, 2H), 7.41-7.34 (m, 2H), 4.35 (t, J = 7.5 Hz, 2H), 1.98 (as, 3H), 1.75-1.62 (m, 6H), 1.59-1.53 (m, 
8H); 13C NMR (63 MHz, CDCl3) δ 155.7 (Cq), 152.6 (Cq), 145.4 (Cq), 125.4 (2CH), 121.9 (2CH), 66.4 
(CH2), 42.5 (3CH2), 42.3 (CH2), 37.0 (3CH2), 31.8 (Cq), 28.6 (3CH); MS: m/z = 368 [M + Na]+; 
General method for the piperazine alkylation step (B) 
Under inert atmosphere and at 0°C, the previously obtained carbonate (1 eq., 1.5 mmol) was added to 
a solution of piperazine (2eq.) and TEA (5 eq.) in DMF (20 ml). The mixture was allowed to come back 
to room temperature and stirred vigorously overnight. After the complete consumption of the starting 
material, the mixture was diluted with ethyl acetate (100 ml) and washed with sodium chloride (aqueous 
satd. soln., 3 x 200 ml). The organic layer was dried over magnesium sulfate, filtered and the solvent 
evaporated under reduced pressure. 
(a) (4-methoxycarbonylphenyl)methyl piperazine-1-carboxylate (8b) 
The crude product obtained following the general protocol was further purified by flash 
chromatography (eluent: DCM / MeOH 9/1) to conduct to the final derivative. C14H18N2O4; yield 64%; 
light yellow solid; m.p. 69-70 °C; M = 278.30 g/mol; IR (ATR):  ν = 3338 (w), 2950 (w), 1709 (s), 
1687 (s), 1433 (s), 1423 (s), 1405 (s), 1275 (s), 1226 (s), 1129 (s), 1105 (s), 798 (m), 762 (s), 750 (s) 
cm -1; 1H NMR (250 MHz, CDCl3) δ 8.03 (d, J = 8.3 Hz, 2H), 7.41 (d, J = 8.1 Hz, 2H), 5.18 (s, 2H), 
3.91 (s, 3H), 3.49 (t, J = 5.1 Hz, 4H), 2.84 (t, J = 4.7 Hz, 4H), 1.86 (s, 1H); 13C NMR (63 MHz, CDCl3) 
δ 166.9 (Cq), 155.2 (Cq), 142.0 (Cq), 130.0 (2CH), 129.9 (Cq), 127.5 (2CH), 66.5 (CH2), 52.3 (CH3), 
45.9 (2CH2), 45.1 (2CH2); MS: m/z = 279 [M + H]+; 
(b) 2-naphthylmethyl piperazine-1-carboxylate (8c) 
The crude product obtained following the general protocol was further purified by flash 
chromatography (eluent: DCM / MeOH 9/1) to conduct to the final derivative. C16H18N2O2; yield 92%; 
white solid; m.p. 44-45°C; M = 270.33 g/mol; IR (ATR):  ν =  3259 (w), 2913 (w), 1681 (s), 1442 (m), 
1417 (m), 1229 (s), 1129 (m), 1111 (m), 1084 (m), 744 (m) cm–1; 1H NMR (250 MHz, CDCl3) δ 7.85-
7.81 (m, 4H), 7.51-7.44 (m, 3H), 5.29 (s, 2H), 3.49 (t, J = 5.1 Hz, 4H), 2.82 (as, 4H), 2.25 (s, 1H); 13C 
NMR (63 MHz, CDCl3) δ 155.4 (Cq), 134.2 (Cq), 133.3 (Cq), 133.2 (Cq), 128.4 (CH), 128.1 (CH), 127.8 
(CH), 127.1 (CH), 126.3 (CH), 126.3 (CH), 125.9 (CH), 67.7 (CH2), 45.8 (2CH2), 44.8 (2CH2); MS: 
m/z = 271 [M + H]+;  
(c) (6-methoxycarbonyl-2-naphthyl)methyl piperazine-1-carboxylate (8d) 
The crude product obtained following the general protocol was further purified by flash 
chromatography (eluent: DCM / MeOH 9/1) to conduct to the final derivative. C18H20N2O4; yield 85%; 
white solid; m.p. 94-95 °C; M = 328.36 g/mol; IR (ATR):  ν = 3320 (w), 2950 (w), 1712 (m), 1681 (s), 
1433 (m), 1287 (m), 1226 (m), 1193 (m), 1120 (m), 1075 (m), 756 (m) cm-1; 1H NMR (250 MHz, 
CDCl3) δ 8.60 (s, 1H), 8.07 (dd, J = 8.6 Hz, J = 1.7 Hz, 1H), 7.95 (d, J = 8.5 Hz, 1H), 7.88 (d, J = 8.7 
Hz, 1H), 7.84 (s, 1H), 7.53 (dd, J = 8.5 Hz, J = 1.6 Hz, 1H), 5.31 (s, 2H), 3.98 (s, 3H), 3.51 (t, J = 5.1 
Hz, 4H), 2.85 (at, J = 4.6 Hz, 4H); 13C NMR (63 MHz, CDCl3) δ 167.3 (Cq), 155.3 (Cq), 137.0 (Cq), 
135.5 (Cq), 132.3 (Cq), 130.9 (CH), 129.9 (CH), 128.4 (CH), 127.8 (Cq), 126.6 (CH), 126.5 (CH), 125.8 
(CH), 67.1 (CH2), 52.4 (CH3), 46.0 (2CH2), 45.1 (2CH2); MS: m/z = 329 [M + H]+ and 351 [M + Na]+; 
(d) 1-adamantylmethyl piperazine-1-carboxylate (8f) 
The crude product obtained following the general protocol was subsequently used without further 
purification. C16H26N2O2; yield 62%; light yellow solid; M = 278.39 g/mol; IR (ATR): ν = 2883 (m-s), 
2841 (m), 1678 (s), 1427 (s), 1232 (s), 1120 (m), 765 (m) cm–1;  1H NMR (250 MHz, CDCl3) δ 3.66 (s, 
2H), 3.44 (t, J = 5.1 Hz, 4H), 2.82 (t, J = 5.1 Hz, 4H), 2.13 (s, 1H), 1.96 (as, 3H), 1.73-1.60 (m, 6H), 
1.51 (d, J = 2.5 Hz, 6H); 13C NMR (63 MHz, CDCl3) δ 155.9 (Cq), 75.2 (CH2), 46.0 (2CH2), 44.9 
(2CH2), 39.5 (3CH2), 37.1 (3CH2), 33.6 (Cq), 28.2 (3CH); MS: m/z = 279 [M + H]+;  
(e) 2-(1-adamantyl)ethyl piperazine-1-carboxylate (8g) 
The crude product obtained following the general protocol was further purified by flash 
chromatography (eluent: DCM / MeOH 95/5) to conduct to the final derivative. C17H28N2O2; yield 77%; 
light yellow oil becoming a light yellow solid on standing; m.p. 56-57 °C; M = 292.42 g/mol; IR (ATR):  
ν = 2895 (s), 2837 (m), 1687 (s), 1436 (s), 1232 (s), 1120 (s), 1087 (m) cm–1; 1H NMR (250 MHz, 
CDCl3) δ 4.12 (t, J = 7.3 Hz, 2H), 3.42 (t, J = 5.0 Hz, 4H), 2.81 (t, J = 5.0 Hz, 4H), 1.93 (as, 3H), 1.71-
1.58 (m, 6H), 1.52-1.51 (m, 6H), 1.41 (t, J = 7.3 Hz, 2H); 13C NMR (63 MHz, CDCl3) δ 155.8 (Cq), 
61.9 (CH2), 46.0 (2CH2), 44.9 (2CH2), 43.0 (CH2), 42.7 (3CH2), 37.2 (3CH2), 31.9 (Cq), 28.7 (3CH); 
MS: m/z = 293 [M + H]+; 
(f) tert-butyl N-[2-[4-[[5-(dimethylamino)-1-naphthyl]sulfonyl]piperazin-1-yl]-2-oxo-ethyl]-
carbamate (8h) 
The coupling compound was obtained following the general protocol described before. The crude 
product was purified by flash-chromatography (DCM/MeOH 98/2) to give the titled derivative. 
C23H32N4O5S; yield 89%; light yellow solid; m.p. 176-177 °C; M = 476.59 g/mol; IR (ATR):  ν =  3287 
(w), 2977 (w), 1703 (m), 1642 (s), 1339 (m), 1232 (m), 1160 (s), 1141 (s), 932 (m), 798 (s), 710 (m), 
616 (m) cm–1; 1H NMR (250 MHz, CDCl3) δ 8.58 (d, J = 8.5 Hz, 1H), 8.35 (d, J = 8.7 Hz, 1H), 8.19 
(dd, J = 7.4 Hz, J = 1.3 Hz, 1H), 7.54 (dd, J = 8.6 Hz, J = 7.5 Hz, 2H), 7.19 (d, J = 7.0 Hz, 1H), 5.36 
(as, 1H), 3.86 (d, J = 4.5 Hz, 2H), 3.67 – 3.63 (m, 2H), 3.44 – 3.40 (m, 2H), 3.19 – 3.15 (m, 4H), 2.88 
(s, 6H), 1.40 (s, 9H);13C NMR (63 MHz, CDCl3) δ 167.0 (Cq), 155.8 (Cq), 152.0 (Cq), 132.2 (Cq), 131.3 
(CH), 131.0 (CH), 130.4 (Cq), 130.2 (Cq), 128.5 (CH), 123.3 (CH), 119.4 (CH), 115.5 (CH), 79.9 (Cq), 
45.6 (CH2), 45.5 (2CH3), 45.4 (CH2), 44.2 (CH2), 42.2 (CH2), 41.6 (CH2), 28.4 (3CH3); MS: m/z = 499 
[M + Na]+;  
General method for the peptide coupling step (C) 
Under inert atmosphere and at room temperature, to a solution of the previously obtained piperazine 
(1.85 mmol, 1 eq.) in dichloromethane (DCM, 15 ml) were successively added: N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide (EDC, 1.85 mmol, 1 eq.), 1-hydroxybenzotriazole (0.37 
mmol, 0.2 eq.), the corresponding Boc-protected aminoacid (1.85 mmol, 1 eq.) and N-
methylmorpholine (5.55 mmol, 3 eq.). After 12 hours of stirring, the reaction mixture was diluted by 
addition of 75 ml of DCM and washed with citric acid (aq soln. 10%, 3 x 50 ml) and then with brine. 
The organic phase was subsequently dried over magnesium sulfate, filtered and the solvent evaporated 
under vacuum. The crude product was purified by flash-chromatography to give the desired coupling 
product.     
(a) benzyl 4-[2-(tert-butoxycarbonylamino)acetyl]piperazine-1-carboxylate (9a) 
The crude derivative obtained following the general protocol described before was purified by flash-
chromatography (eluent: EtOAc/PE 5/5). C19H27N3O5; yield 95%; white solid; m.p. 66-67 °C; M = 
377.43 g/mol; IR (ATR):  ν = 3329 (w), 2971 (w), 1691 (s), 1627 (m), 1527 (m), 1420 (m), 1223 (s), 
1153 (m), 756 (m), 695 (m) cm -1; 1H NMR (250 MHz, CDCl3) δ 7.40-7.32 (m, 5H), 5.48 (as, 1H), 5.14 
(s, 2H), 3.96 (d, J = 4.4 Hz, 2H), 3.69-3.60 (m, 2H), 3.53-3.49 (m, 4H), 3.45-3.47 (m, 2H), 1.44 (s, 
9H); 13C NMR (63 MHz, CDCl3) δ 167.2 (Cq), 155.9 (Cq), 155.2 (Cq), 136.4 (Cq), 128.7 (2CH), 128.4 
(CH), 128.2 (2CH), 79.9 (Cq), 67.7 (CH2), 44.3 (CH2), 43.7 (CH2), 43.6 (CH2), 42.4 (CH2), 41.8 (CH2), 
28.5 (3CH3); MS: m/z = 400 [M + Na]+; 
(b) (4-methoxycarbonylphenyl)methyl 4-[2-(tert-butoxycarbonylamino)acetyl]piperazine-1-
carboxylate (9b) 
The crude derivative obtained following the general protocol described before was purified by flash-
chromatography (eluent: EtOAc/PE 5/5) C21H29N3O7; yield 80%; white solid; m.p. 90-91 °C;  M = 
435.47 g/mol; IR (ATR): ν = 2977 (w), 1703 (s), 1651 (s), 1430 (m), 1278 (m), 1223 (m), 1160 (m), 
1105 (m), 1017 (m), 756 (m) cm -1; 1H NMR (250 MHz, CDCl3) δ 8.04 (d, J = 8.4 Hz, 2H) , 7.41 (d, J 
= 8.4 Hz, 2H), 5.47 (as, 1H), 5.20 (s, 2H), 3.97 (d, J = 4.5 Hz, 2H), 3.92 (s, 3H), 3.70-3.62 (m, 2H), 
3.56-3.50 (m, 4H), 3.41-3.37 (m, 2H), 1.44 (s, 9H); 13C NMR (63 MHz, CDCl3) δ 167.3 (Cq), 166.8 
(Cq), 154.9 (Cq), 141.4 (2Cq), 130.1 (Cq), 130.0 (2CH), 127.7 (2CH), 80.0 (Cq), 67.0 (CH2), 52.3 (CH3), 
44.3 (CH2), 43.7 (2CH2), 42.4 (CH2), 41.8 (CH2), 28.5 (3CH3); MS: m/z = 458 [M + Na]+; 
(c) 2-naphthylmethyl 4-[2-(tert-butoxycarbonylamino)acetyl]piperazine-1-carboxylate (9c) 
The crude derivative obtained following the general protocol described before was purified by flash-
chromatography (eluent: EtOAc/PE 5/5). C23H29N3O5; yield 91%; white solid; m.p. 41-42°C; M = 
427.49 g/mol; IR (ATR):  ν = 3332 (w), 2971 (w), 1697 (s), 1645 (s), 1460 (m), 1427 (s), 1214 (s), 1160 
(m), 1117 (w), 1017 (w), 747 (w) cm–1; 1H NMR (250 MHz, CDCl3) δ 7.87-7.82 (m, 4H), 7.53-7.45 
(m, 3H), 5.48 (as, 1H), 5.31 (s, 2H), 3.96 (d, J = 4.4 Hz, 2H), 3.69-3.61 (m, 2H), 3.56-3.50 (4H), 3.42-
3.33 (m, 2H), 1.44 (s, 9H); 13C NMR (63 MHz, CDCl3) δ 167.3 (Cq), 155.9 (Cq), 155.2 (Cq), 133.8 (Cq), 
133.3 (Cq), 133.3 (Cq), 128.6 (CH), 128.1 (CH), 127.9 (CH), 127.5 (CH), 126.5 (CH), 126.5 (CH), 126.0 
(CH), 79.9 (Cq), 67.9 (CH2), 44.3 (CH2), 43.7 (2CH2), 42.4 (CH2), 41.8 (CH2), 28.5 (3CH3); MS: m/z = 
450 [M + Na]+;  
(d) (6-methoxycarbonyl-2-naphthyl)methyl 4-[2-(tert-butoxycarbonylamino)acetyl]-piperazine-1-
carboxylate  (9d). 
The crude derivative obtained following the general protocol described before was purified by flash-
chromatography (eluent: DCM/MeOH 95/5). C25H31N3O7; yield 97%; white solid; m.p. 43-44 °C; M = 
485.53 g/mol; IR (ATR):  ν = 3350 (w), 2974 (w), 1697 (s), 1651 (s), 1460 (m), 1423 (s), 1366 (m), 
1284 (m), 1220 (m-s), 1163 (m), 762 (w) cm-1; 1H NMR (250 MHz, CDCl3) δ 8.60 (s, 1H), 8.08 (dd, J 
= 8.6 Hz, J = 1.6 Hz, 1H), 7.96 (d, J = 8.5 Hz, 1H), 7.88 (d, J = 1Hz, 1H), 7.84 (s, 1H), 7.52 (dd, J = 
8.4 Hz, J = 1.6 Hz, 1H), 5.47 (s, 1H), 5.33 (s, CH2), 3.99-3.98 (m, 5H), 3.70-3.62 (m, 2H), 3.58-3.52 
(m, 4H), 3.41-3.36 (m, 2H), 1.44 (s, 9H); 13C NMR (63 MHz, CDCl3) δ 167.3 (Cq), 155.1 (Cq), 136.4 
(Cq), 135. (Cq), 132.3 (Cq), 130.9 (CH), 130.0 (CH), 128.4 (CH), 128.0 (Cq), 127.0 (CH), 126.6 (CH), 
125.9 (CH), 80.0 (Cq), 67.6 (CH2), 52.4 (CH3), 44.3 (CH2), 43.8 (CH2), 43.7 (CH2), 42.4 (CH2), 41.8 
(CH2), 28.5 (3CH3); MS: m/z = 508 [M + Na]+; 
(e) tert-butyl N-[2-[4-(adamantane-1-carbonyl)piperazin-1-yl]-2-oxo-ethyl]carbamate  (9e) 
The crude derivative obtained following the general protocol described before was subsequently 
purified by flash chromatography (eluent: PE/EtOAc 5/5) to conduct to the desired derivative. 
C22H35N3O4; yield 78 %; white solid; m.p. 187-188 °C; M = 405.53 g/mol; IR (ATR):  ν = 3423 (w), 
2904 (m), 1712 (s), 1642 (s), 1615 (s), 1442 (m-s), 1399 (m), 1153 (m), 1008 (m) cm-1; 1H NMR (250 
MHz, DMSO) δ 6.75 (t, J = 5.7 Hz, 1H), 3.78 (d, J = 5.8Hz, 2H), 3.65-3.49 (m, 4H), 3.47-3.36 (m, 
4H), 1.97 (as, 3H), 1.90 (as, 6H), 1.73-1.63 (m, 6H), 1.38 (s, 9H); 13C NMR (63 MHz, DMSO) δ 174.6 
(Cq), 167.6 (Cq), 155.8 (Cq), 77.9 (Cq), 44.6 (2CH2), 44.1 (CH2), 41.7 (2CH2), 40.9 (Cq), 28.4 (3CH2), 
36.0 (3CH2), 28.2 (3CH), 27.9 (3CH3); MS: m/z = 428 [M + Na]+; 
(f) 1-adamantylmethyl 4-[2-(tert-butoxycarbonylamino)acetyl]piperazine-1-carboxylate (9f) 
The crude derivative obtained following the general protocol described before was subsequently 
purified by flash chromatography (eluent: PE/EtOAc 5/5). C23H37N3O5; yield 78%; white solid; m.p. 
156-157 °C; M = 435.56 g/mol; IR (ATR):  ν = 3405 (w), 2907 (m), 1712 (s), 1678 (s), 1639 (s), 1475 
(m-s), 1430 (s), 1229 (m-s), 1163 (m-s) cm–1;  1H NMR (250 MHz, CDCl3) δ 5.48 (as, 1H), 3.97 (d, J 
= 4.4 Hz, 2H), 3.71 (s, 2H), 3.65-3.59 (m, 2H), 3.53-3.47 (m, 4H), 3.40-3.37 (m, 2H), 1.99 (as, 3H), 
1.76-1.62 (m, 6H), 1.53 (d, J = 2.5 Hz, 6H), 1.45 (s, 9H);  13C NMR (63 MHz, CDCl3) δ 167.3 (Cq), 
155.9 (Cq), 155.7 (Cq), 79.9 (Cq), 75.6 (CH2), 44.3 (CH2), 43.7 (CH2), 43.6 (CH2), 42.4 (CH2), 41.9 
(CH2), 39.5 (3CH2), 37.1 (3CH2), 33.6 (Cq), 28.5 (3CH3), 28.1 (3CH); MS: m/z = 458 [M + Na]+; 
(g) 2-(1-adamantyl)ethyl 4-[2-(tert-butoxycarbonylamino)acetyl]piperazine-1-carboxylate (9g) 
The crude derivative obtained following the general protocol described before was subsequently 
purified by flash chromatography (eluent: PE/EtOAc 5/5). C24H39N3O5; yield 78%; white solid; m.p. 
167-168 °C; M = 449.58 g/mol; IR (ATR):  ν = 3362 (w), 2898 (m), 2844 (w), 1706 (m-s), 1687 (m-s), 
1645 (s), 1463 (m), 1427 (m-s), 1217 (s), 1156 (m), 1123 (m) cm–1; 1H NMR (250 MHz, CDCl3) δ 5.48 
(as, 1H), 4.14 (t, J = 7.3 Hz, 2H), 3.95 (d, J = 4.4 Hz, 2H), 3.62-3.58 (m, 2H), 3.47-3.41 (m, 4H), 3.37-
3.34 (m, 2H), 1.93 (as, 3H), 1.72-1.58 (m, 6H), 1.51 (d, J = 2.5 Hz, 6H), 1.43-1.39 (m, 11H);  13C NMR 
(63 MHz, CDCl3) δ 167.2 (Cq), 155.9 (Cq), 155.5 (Cq), 79.9 (Cq), 62.5 (CH2), 44.3 (CH2), 43.6 (CH2), 
43.5 (CH2), 42.9 (CH2), 42.7 (3CH2), 42.4 (CH2), 41.9 (CH2), 37.1 (3CH2), 31.9 (Cq), 28.7 (3CH), 28.5 
(3CH3); MS: m/z = 472 [M + Na]+; 
(h) benzyl 4-[(2R)-2-(tert-butoxycarbonylamino)propanoyl]piperazine-1-carboxylate (9i) 
The crude derivative obtained following the general protocol described before was subsequently used 
without any further purification. C20H29N3O5; colorless viscous oil; yield 90%; M = 391.46 g/mol; IR 
(ATR):  ν = 2980 (w), 1700 (s), 1645 (s), 1423 (m), 1217 (m), 1160 (m), 1014 (m), 765 (w), 695 (w) 
cm -1; 1H NMR (250 MHz, CDCl3) δ 7.39-7.32 (m, 5H), 5.49 (d, J = 8.1 Hz, 1H), 5.15 (s, 2H), 4.60 (p, 
J = 7.1 Hz, 1H), 3.74-3.39 (m, 8H), 1.43 (s, 9H), 1.29 (d, J = 6.9 Hz, 3H); 13C NMR (63 MHz, CDCl3) 
δ 171.6 (Cq), 155.2 (2Cq), 136.4 (Cq), 128.7 (2CH), 128.4 (CH), 128.2 (2CH), 79.9 (Cq), 67.7 (CH2), 
46.2 (CH), 45.3 (CH2), 44.0 (CH2), 43.7 (CH2), 42.0 (CH2), 28.5 (3CH3), 19.3 (CH3); MS: m/z = 414 
[M + Na]+;  
(i) benzyl 4-[(2S)-2-(tert-butoxycarbonylamino)propanoyl]piperazine-1-carboxylate (9j) 
The crude derivative obtained following the general protocol described before was subsequently used 
without any further purification. C20H29N3O5; colorless viscous oil; yield 90%; M = 391.46 g/mol; IR 
(ATR):  ν = 2974 (w), 1694 (s), 1639 (s), 1433 (m), 1220 (m), 1163 (m), 1014 (m), 762 (w), 698 (w) 
cm -1; 1H NMR (250 MHz, CDCl3) δ 7.40-7.30 (m, 5H), 5.47 (d, J = 7.9 Hz, 1H), 5.15 (s, 2H), 4.60 (p, 
J = 7.1 Hz, 1H), 3.76-3.39 (m, 8H), 1.43 (s, 9H), 1.29 (d, J = 6.9 Hz, 3H); 13C NMR (63 MHz, CDCl3) 
δ 184.8 (Cq), 171.6 (Cq), 155.2 (2Cq), 136.4 (Cq), 128.7 (2CH), 128.4 (CH), 128.2 (2CH), 79.9 (Cq), 
67.7 (CH2), 46.2 (CH), 45.3 (CH2), 44.0 (CH2), 43.7 (CH2), 42.0 (CH2), 28.5 (3CH3), 19.5 (CH3); MS: 
m/z = 414 [M + Na]+; 
(j) benzyl 4-[(2R)-2-(tert-butoxycarbonylamino)-3-phenyl-propanoyl]piperazine-1-carboxylate (9k) 
The crude derivative obtained following the general protocol described before was subsequently used 
without any further purification. C26H33N3O5; colorless viscous oil; yield 97%; M = 467.56 g/mol; IR 
(ATR):  ν = 3314 (w), 2968 (w), 1700 (s), 1636 (s), 1423 (m), 1220 (m-s), 1163 (m-s), 1011 (w-m), 750 
(w), 698 (m) cm -1; 1H NMR (250 MHz, CDCl3) δ 7.41-7.17 (m, 10H), 5.41 (d, J = 8.6 Hz, 1H), 5.10 
(s, 2H), 4.85-4.75 (m, 1H), 3.60-3.14 (m, 6H), 3.06-2.87 (m, 3H), 2.66-2.57 (m, 1H), 1.42 (s, 9H); 13C 
NMR (63 MHz, CDCl3) δ 170.6 (Cq), 155.2 (Cq), 155.1 (Cq), 136.5 (Cq), 136.4 (Cq), 129.7 (2CH), 128.8 
(2CH), 128.7 (2CH), 128.4 (CH), 128.2 (2CH), 127.3 (CH), 80.1 (Cq), 67.6 (CH2), 51.1 (CH), 45.4 
(CH2), 43.4 (CH2), 43.4 (CH2), 41.8 (CH2), 40.6 (CH2), 28.5 (3CH3); MS: m/z = 490 [M + Na]+; 
(k) benzyl 4-[(2S)-2-(tert-butoxycarbonylamino)-3-phenyl-propanoyl]piperazine-1-carboxylate (9l) 
The crude derivative obtained following the general protocol described before was subsequently used 
without any further purification. C26H33N3O5; colorless viscous oil; yield 97%; M = 467.56 g/mol; IR 
(ATR):  ν = 2971 (w), 1700 (s), 1633 (s), 1420 (m), 1220 (s), 1163 (s), 1011 (m), 695 (s) cm -1; 1H NMR 
(250 MHz, CDCl3) δ 7.41-7.17 (m, 10H), 5.41 (d, J = 8.5 Hz, 1H), 5.10 (s, 2H), 4.85-4.75 (m, 1H), 
3.60-3.38 (m, 3H), 3.33-3.14 (m, 3H), 3.06-2.87 (m, 3H), 2.67-2.57 (m, 1H), 1.42 (s, 9H); 13C NMR 
(63 MHz, CDCl3) δ 170.6 (Cq), 155.2 (Cq), 155.1 (Cq), 136.5 (Cq), 136.4 (Cq), 129.7 (2CH), 128.8 
(2CH), 128.7 (2CH), 128.4 (CH), 128.2 (2CH), 127.3 (CH), 80.1 (Cq), 67.6 (CH2), 51.1 (CH), 45.4 
(CH2), 43.4 (2CH2), 41.8 (CH2), 40.6 (CH2), 28.5 (3CH3); MS: m/z = 490 [M + Na]+; 
General protocol for the carbamate deprotection step (D) 
The previously obtained carbamate (1.2 mmol) was dissolved in DCM (15 ml) and reacted with an 
excess of trifluoroacetic acid (9.6 mmol, 8 eq.) at room temperature, until the complete consumption of 
the starting material (generally 3h). At the end of the reaction, the mixture was diluted with DCM (35 
ml) and washed with hydrogen chloride (aq. soln. 0.5 M, 3 x 50 ml). The pH of the combined aqueous 
layers was adjusted to 9-10 by addition of potassium carbonate (satd. soln.), then extracted with DCM 
(3 x 75 ml). The combined organic layers were dried over magnesium sulfate and the solvent evaporated 
under reduced pressure. The obtained amine was used further without any other purification. 
(a) benzyl 4-(2-aminoacetyl)piperazine-1-carboxylate (5a) 
C14H19N3O3; yield 82%; white solid; m.p. 52-53 °C;  M = 277.32 g/mol; IR (ATR):  ν = 3526 (w), 2901 
(w), 1678 (s), 1642 (s), 1420 (m-s), 1363 (w), 1281 (w), 1229 (s), 1123 (m-s) cm -1; 1H NMR (250 MHz, 
CDCl3) δ 7.38-7.32 (m, 5H), 5.14 (s, 2H), 3.70-3.58 (m, 2H), 3.52-3.50 (m, 4H), 3.47 (s, 2H), 3.43-3.30 
(m, 2H), 1.80 (s, 2H); 13C NMR (63 MHz, CDCl3) δ 171.5 (Cq), 155.2 (Cq), 136.4 (Cq), 128.6 (2CH), 
128.3 (CH), 128.1 (2CH), 67.6 (CH2), 44.1 (CH2), 43.7 (2CH2), 43.4 (CH2), 41.8 (CH2); MS: m/z = 278 
[M + H]+; 
(b) (4-methoxycarbonylphenyl)methyl 4-(2-aminoacetyl)piperazine-1-carboxylate (5b) 
C16H21N3O5; yield 88%; light-yellow solid; m.p. 94-95 °C; M = 335.36 g/mol; IR (ATR):  ν = 3520 
(w), 3350 (w), 2904 (w), 1715 (s), 1691 (s), 1624 (m-s), 1448 (m-s), 1430 (s), 1275 (s), 1226 (s), 1111 
(s), 1065 (m), 759 (s) cm -1; 1H NMR (250 MHz, CDCl3) δ 8.03 (d, J = 8.3 Hz, 2H), 7.41 (d, J = 8.3 
Hz, 2H), 5.20 (s, 2H), 3.92 (s, 3H), 3.69-3.59 (m, 2H), 3.54-3.52 (m, 4H), 3.47 (s, 2H), 3.40-3.33 (m, 
2H), 1.62 (s, 2H); 13C NMR (63 MHz, CDCl3) δ 171.6 (Cq), 166.8 (Cq), 155.0 (Cq), 141.5 (Cq), 130.1 
(Cq), 130.0 (2CH), 127.7 (2CH), 66.9 (CH2), 52.3 (CH3), 44.1 (CH2), 43.8 (2CH2), 43.5 (CH2), 41.8 
(CH2); MS: m/z = 336 [M + H]+; 
(c) 2-naphthylmethyl 4-(2-aminoacetyl)piperazine-1-carboxylate (5c) 
C18H21N3O3; yield 61%; white solid; m.p. 109-110°C; M = 327.38 g/mol; IR (ATR):  ν = 3526 (w), 
3350 (w), 2907 (w), 1691 (s), 1618 (s), 1445 (m), 1433 (s), 1281 (m-s), 1220 (s), 804 (s), 735 (m) cm–
1; 1H NMR (250 MHz, CDCl3) δ 7.86-7.82 (m, 4H), 7.53-7.45 (m, 3H), 5.31 (s, 2H), 3.70-3.58 (m, 2H), 
3.57-3.50 (m, 4H), 3.46 (s, 2H), 3.43-3.30 (m, 2H), 1.64 (s, 2H); 13C NMR (63 MHz, CDCl3) δ 171.6 
(Cq), 133.8 (Cq), 133.3 (Cq), 128.6 (CH), 128.1 (CH), 127.9 (CH), 127.4 (CH), 126.5 (CH), 126.5 (CH), 
126.0 (CH), 67.9 (CH2), 44.1 (CH2), 43.8 (2CH2), 43.5 (CH2), 41.9 (CH2); MS: m/z = 328 [M + H]+; 
(d) (6-methoxycarbonyl-2-naphthyl)methyl 4-(2-aminoacetyl)piperazine-1-carboxylate  (5d) 
C20H23N3O5; yield 79%; light yellow solid; m.p. 91-92 °C; M = 385.41 g/mol; IR (ATR):  ν = 2953 (w), 
1718 (m), 1687 (s), 1639 (m), 1423 (m), 1281 (m), 1226 (m), 1196 (m), 1126 (m), 1075 (w), 759 (w-
m) cm-1; 1H NMR (250 MHz, CDCl3) δ 8.60 (s, 1H), 8.08 (dd, J = 8.6 Hz, J = 1.7 Hz, 1H), 7.96 (d, J 
= 8.5 Hz, 1H), 7.88 (d, J = 8.7 Hz, 1H), 7.84 (s, 1H), 7.53 (dd, J = 8.5 Hz, J = 1.6 Hz, 1H), 5.33 (s, 
2H), 3.99 (s, 3H), 3.69-3.63 (m, 2H), 3.57-3.54 (m, 4H), 3.47 (s, 2H), 3.40-3.34 (m, 2H), 1.60 (s, 2H); 
13C NMR (63 MHz, CDCl3) δ 171.7 (Cq), 167.3 (Cq), 155.1 (Cq), 136.5 (Cq), 135.5 (Cq), 132.3 (Cq), 
130.9 (CH), 130.0 (CH), 128.4 (CH), 128.0 (Cq), 126.9 (CH), 126.6 (CH), 125.9 (CH), 67.5 (CH2), 52.4 
(CH3), 44.1 (CH2), 43.8 (2CH2), 43.5 (CH2), 41.9 (CH2); MS: m/z = 386 [M + H]+; 
(e) 1-[4-(adamantane-1-carbonyl)piperazin-1-yl]-2-amino-ethanone  (5e) 
C17H27N3O2; yield 47 %; white solid; m.p. 231-132 °C; M = 305.42 g/mol; IR (ATR):  ν = 2904 (m), 
2844 (w), 1697 (w), 1606 (s), 1414 (m), 1226 (m), 1005 (m-s) cm-1; 1H NMR (250 MHz, CDCl3) δ 
3.70-3.62 (m, 6H), 3.47 (s, 2H), 3.38-3.34 (m, 2H), 2.04 (as, 3H), 1.98-1.97 (m, 6H), 1.77-1.66 (m, 
6H), 1.60 (s, 2H); 13C NMR (63 MHz, CDCl3) δ 176.2 (Cq), 171.7 (Cq), 45.6 (CH2), 44.8 (CH2), 44.4 
(CH2), 43.5 (CH2), 42.3 (CH2), 41.9 (Cq), 39.2 (3CH2), 36.7 (3CH2), 28.5 (3CH); MS: m/z = 306 [M + 
H]+; 
(f) 1-adamantylmethyl 4-(2-aminoacetyl)piperazine-1-carboxylate (5f) 
C18H29N3O3; yield 60%; colorless viscous oil; M = 335.44 g/mol; IR (ATR):  ν = 3384 (w), 2901 (m-s), 
2847 (m), 1694 (s), 1627 (s), 1457 (m), 1423 (s), 1223 (s) cm–1; 1H NMR (250 MHz, CDCl3) δ 3.70 (s, 
2H), 3.66-3.59 (m, 2H), 3.53-3.48 (m, 6H), 3.41-3.35 (m, 2H), 2.04 (as, 3H), 1.76-1.61 (m, 8H), 1.53 
(d, J = 2.5 Hz, 6H); 13C NMR (63 MHz, CDCl3) δ 171.5 (Cq), 155.7 (Cq), 75.6 (CH2), 44.1 (CH2), 43.6 
(2CH2), 43.4 (CH2), 41.9 (CH2), 39.5 (3CH2), 37.1 (3CH2), 33.6 (Cq), 28.1 (3CH); MS: m/z = 336 [M 
+ H]+; 
(g) 2-(1-adamantyl)ethyl 4-(2-aminoacetyl)piperazine-1-carboxylate (5g). 
C19H31N3O3; yield 72%; light yellow viscous oil becoming light yellow solid on standing; m.p. 58-59 
°C; M = 349.47 g/mol; IR (ATR):  ν = 3375 (m), 2892 (s), 2844 (m), 1697 (s), 1639 (s), 1448 (m), 1417 
(s), 1375 (m), 1220 (s), 1123 (m) cm–1; 1H NMR (250 MHz, CDCl3) δ 4.15 (t, J = 7.2 Hz, 2H), 3.67-
3.59 (m, 2H), 3.54-3.48 (m, 6H), 3.37-3.33 (m, 2H), 1.93 (as, 3H), 1.72-1.58 (m, 6H), 1.51 (d, J = 2.5 
Hz, 6H), 1.42 (t, J = 7.3 Hz, 2H); 13C NMR (63 MHz, CDCl3) δ 171.1 (Cq), 155.5 (Cq), 62.4 (CH2), 
44.2 (CH2), 43.6 (2CH2), 43.2 (CH2), 42.9 (CH2), 42.7 (3CH2), 41.9 (CH2), 37.1 (3CH2), 31.9 (Cq), 28.7 
(3CH); MS: m/z = 350 [M + H]+;  
(h) 2-amino-1-[4-[[5-(dimethylamino)-1-naphthyl]sulfonyl]piperazin-1-yl]ethanone (5h) 
C18H24N4O3S; yield 95%; yellow solid; m.p. 82-83°C; M = 376.47 g/mol; IR (ATR):  ν = 3441 (w), 
2932 (w), 1654 (m-s), 1636 (m-s), 1451 (m), 1342 (m), 1323 (m), 1156 (s), 1144 (s), 941 (m-s), 896 
(m), 789 (s), 707 (s), 619 (m) cm–1; 1H NMR (250 MHz, CDCl3) δ 8.58 (d, J = 8.5 Hz, 1H), 8.36 (d, J 
= 8.7 Hz, 1H), 8.19 (dd, J = 7.4 Hz, J = 1.2 Hz, 1H), 7.53 (dd, J = 8.5 Hz, J = 7.6 Hz, 2H), 7.18 (d, J 
= 7.5 Hz, 1H), 3.72-3.57 (m, 2H), 3.50-3.31 (m, 4H), 3.23-3.10 (m, 4H), 2.88 (s, 6H); 13C NMR (63 
MHz, CDCl3) δ 171.2 (Cq), 152.0 (Cq), 132.2 (Cq), 131.2 (CH), 130.9 (CH), 130.4 (Cq), 130.2 (Cq), 
128.4 (CH), 123.3 (CH), 119.4 (CH), 115.5 (CH), 45.6 (CH2), 45.5 (2CH3), 45.5 (CH2), 44.0 (CH2), 
43.2 (CH2), 41.6 (CH2); MS: m/z = 377 [M + H]+; 
(i) benzyl 4-[(2R)-2-aminopropanoyl]piperazine-1-carboxylate (5i) 
C15H21N3O3; colorless viscous oil; yield 41%; M = 291.35 g/mol; IR (ATR):  ν = 3372 (w), 2922 (w), 
1694 (s), 1639 (s), 1466 (w), 1417 (m-s), 1223 (s), 1117 (m), 1072 (m), 1020 (m), 729 (m), 698 (m) cm 
-1; 1H NMR (250 MHz, CDCl3) δ 7.38-7.31 (m, 5H), 5.15 (s, 2H), 3.90-3.36 (m, 9H), 1.83 (s, 2H), 1.25 
(d, J = 6.7 Hz, 3H); 13C NMR (63 MHz, CDCl3) δ 174.9 (Cq), 155.2 (Cq), 136.4 (Cq), 128.7 (2CH), 
128.4 (CH), 128.2 (2CH), 67.7 (CH2), 47.1 (CH), 45.0 (CH2), 44.0 (CH2), 43.8 (CH2), 42.0 (CH2), 21.7 
(CH3); MS: m/z = 292 [M + H]+; 
 
(j) benzyl 4-[(2S)-2-aminopropanoyl]piperazine-1-carboxylate (5j) 
C15H21N3O3; colorless viscous oil becoming white solid on standing; m.p.: 53-54 °C; yield 35%; M = 
291.35 g/mol; IR (ATR):  ν = 2965 (w), 1697 (s), 1633 (s), 1420 (s), 1366 (m), 1223 (s), 1129 (m-s), 
984 (m), 886 (m), 732 (m) cm -1; 1H NMR (250 MHz, CDCl3) δ 7.40-7.31 (m, 5H), 5.14 (s, 2H), 3.85-
3.36 (m, 9H), 1.81 (s, 2H), 1.25 (d, J = 6.8 Hz, 3H); 13C NMR (63 MHz, CDCl3) δ 174.9 (Cq), 155.2 
(Cq), 136.4 (Cq), 128.7 (2CH), 128.4 (CH), 128.2 (2CH), 67.7 (CH2), 47.1 (CH), 45.0 (CH2), 44.0 (CH2), 
43.8 (CH2), 41.9 (CH2), 21.8 (CH3); MS: m/z = 292 [M + H]+; 
(k) benzyl 4-[(2R)-2-amino-3-phenyl-propanoyl]piperazine-1-carboxylate (5k) 
C21H25N3O3; light yellow viscous oil; yield 64%; M = 367.44 g/mol; IR (ATR):  ν = 3365 (w), 2913 
(w), 1697 (s), 1633 (s), 1427 (m), 1223 (s), 1117 (w), 747 (m), 695 (m-s); 1H NMR (250 MHz, CDCl3) 
δ 7.41-7.16 (m, 10H), 5.10 (s, 2H), 3.94 (as, 1H), 3.66-3.19 (m, 6H), 3.05-2.97 (m, 1H), 2.94-2.81 (m, 
2H), 2.76-2.68 (m, 1H), 1.89 (broad s, 2H); MS: m/z = 368 [M + H]+; 
(l) benzyl 4-[(2S)-2-amino-3-phenyl-propanoyl]piperazine-1-carboxylate (5l). 
C21H25N3O3; light yellow viscous oil; yield 46%; M = 367.44 g/mol; IR (ATR):  ν = 3372 (w), 2919 
(w), 1694 (s), 1636 (s), 1423 (s), 1226 (s), 1114 (m), 741 (m), 692 (s) cm -1; 1H NMR (250 MHz, CDCl3) 
δ 7.41-7.16 (m, 10H), 5.11 (CH2), 3.69-2.83 (m, 10H), 2.74-2.67 (m, 1H), 1.76 (broad s, 2H); MS: m/z 
= 368 [M + H]+;  
(m) Synthesis of tert-butyl 4-(2-aminoacetyl)piperazine-1-carboxylate (5m). 
4-(2-bromoacetyl)piperazine-1-carboxylate (9.77 mmol, 1 eq.) in methanol (26 ml) at 0°C. The reaction 
vial was sealed and the mixture stirred vigorously overnight at room temperature. The solvent was 
subsequently evaporated, the residue dissolved in hydrogen chloride (aqueous soln., 0.1 N, 100 ml) and 
extracted with ethyl acetate (3 x 100 ml). The pH of the recovered aqueous layer was adjusted to 10 by 
addition of sodium hydroxide (aqueous soln., 1N), then the organics extracted with ethyl acetate (3 x 
100 ml). The combined organic layers were dried over magnesium sulfate, filtered and the solvent 
evaporated under vacuum to give a light yellow crude product. Further trituration in diethyl ether 
conducted to the desired amine as a white solid used for the next step without additional purification. 
C11H21N3O3; yield 58%; white solid; m.p. 159-160 °C; M = 243.30 g/mol; IR (ATR):  ν = 2974 (w), 
1675 (s), 1627 (s), 1417 (m), 1360 (m), 1235 (m), 1172 (m), 1123 (m), 990 (m), 759 (m) cm -1; 1H NMR 
(250 MHz, CDCl3) δ 3.71-3.41 (m, 10H), 1.46 (s, 9H); 13C NMR (63 MHz, CDCl3) δ 169.5 (Cq), 154.6 
(Cq), 80.5 (Cq), 50.4 (CH2), 44.6 (2CH2), 41.7 (2CH2); HRMS: calcd. for C11H21N3O3 244.1661, found. 
244.1657; 
Synthesis of the acrylamide derivatives (E) 
Triethylamine (1.25 mmol, 5 eq.) was added to a solution of the previously obtained amine (0.25 mmol, 
1 eq.) in acetonitrile (5 ml). The mixture was cooled to 0°C and acryloyl chloride (0.63 mmol, 2.5 eq.) 
was subsequently added under nitrogen. After 3h of stirring at 0°C, the reaction mixture was diluted 
with ethyl acetate (100 ml) and washed with sodium bicarbonate (satd. aq. soln., 3 x 50 ml). The 
recovered organic phase was dried over magnesium sulfate and then the solvent evaporated under 
reduced pressure to give the crude product.    
(a) benzyl 4-[2-(prop-2-enoylamino)acetyl]piperazine-1-carboxylate (3a)  
The crude derivative obtained following the general protocol described before was subsequently 
purified by flash chromatography (eluent: DCM/MeOH 96/4). C17H21N3O4; yield 56%; colorless 
viscous oil; M = 331.37 g/mol; IR (ATR): ν = 3004 (w), 1691 (s), 1636 (s), 1420 (s), 1223 (s), 744 (s) 
cm -1; 1H NMR (250 MHz, CDCl3) δ 7.42-7.32 (m, 5H), 6.73 (as, 1H), 6.32 (dd, J = 17.0 Hz, J = 1.9 
Hz, 1H), 6.18 (dd, J = 17.0 Hz, J = 9.8 Hz, 1H), 5.68 (dd, J = 9.8 Hz, J = 1.9 Hz, 1H), 5.15 (s, 2H), 
4.15 (d, J = 4.0 Hz, 2H), 3.70-3.62 (m, 2H), 3.57-3.50 (m, 4H), 3.43-3.36 (m, 2H); 13C NMR (63 MHz, 
CDCl3) δ 166.8 (Cq), 165.5 (Cq), 155.2 (Cq), 136.3 (Cq), 130.4 (CH), 128.7 (2CH), 128.4 (CH), 128.2 
(2CH), 127.1 (CH2), 67.8 (CH2), 44.4 (CH2), 43.7 (CH2), 43.6 (CH2), 41.9 (CH2), 41.4 (CH2); MS: m/z 
= 354 [M + Na]+; HRMS: calcd. for C17H22O4N3 332.1605, found 332.1610 (1.6 ppm). 
(b) (4-methoxycarbonylphenyl)methyl 4-[2-(prop-2-enoylamino)acetyl]piperazine-1-carboxylate (3b) 
The crude derivative obtained following the general protocol described before was subsequently 
purified by flash chromatography (eluent: DCM/MeOH 97/3). C19H23N3O6; yield 60%; white solid; 
m.p. 159-160 °C; M = 389.40 g/mol; IR (ATR):  ν = 3284 (w), 2898 (w), 1703 (s), 1648 (s), 1427 (s), 
1278 (m), 1214 (m), 1105 (m), 759 (m) cm -1; 1H NMR (250 MHz, CDCl3) δ 8.04 (d, J = 8.4 Hz, 2H), 
7.42 (d, J = 8.4 Hz, 2H), 6.68 (as, 1H), 6.33 (dd, J = 17.0 Hz, J = 1.9 Hz, 1H), 6.18 (dd, J = 17.0 Hz, 
9.9 Hz, 1H), 5.69 (dd, J = 9.8 Hz, J = 1.9 Hz, 1H), 5.21 (s, 2H), 4.15 (d, J = 4.1 Hz, 2H), 3.92 (s, 3H), 
3.68-3.63 (m, 2H), 3.59-3.52 (m, 4H), 3.49-3.39 (m, 2H); 13C NMR (63 MHz, CDCl3) δ 166.8 (Cq), 
165.5 (Cq), 154.9 (Cq), 141.4 (Cq), 130.4 (CH), 130.2 (Cq), 130.0 (2CH), 127.7 (2CH), 127.0 (CH2), 
67.0 (CH2), 52.3 (CH3), 44.3 (CH2), 43.8 (CH2), 43.7 (CH2), 41.9 (CH2), 41.4 (CH2); MS: m/z = 412 
[M + Na]+; HRMS: calcd. for C19H24O6N3 390.1660, found 390.1663 (0.9 ppm). 
(c) 2-naphthylmethyl 4-[2-(prop-2-enoylamino)acetyl]piperazine-1-carboxylate  (3c) 
The crude derivative obtained following the general protocol described before was subsequently 
purified by flash chromatography (eluent: EtOAc). C21H23N3O4; yield 59%; white solid; m.p. 125-126 
°C; M = 381.43 g/mol; IR (ATR):  ν = 3332 (w), 2925 (w), 1703 (s), 1663 (m), 1642 (s), 1621 (s), 1460 
(m), 1436 (m), 1417 (m), 1220 (s), 817 (w), 750 (w) cm–1; 1H NMR (250 MHz, CDCl3) δ 7.86-7.82 (m, 
4H), 7.53-7.54 (m, 3H), 6.71 (as, 1H), 6.31 (dd, J = 17.0 Hz, J = 2.0 Hz, 1H), 6.18 (dd, J = 17.0 Hz, J 
= 9.7 Hz, 1H), 5.67 (dd, J = 9.7 Hz, J = 2.0 Hz, 1H), 5.32 (s, 2H), 4.14 (d, J = 4.0 Hz, 2H), 3.65 -3.42 
(m, 8H); 13C NMR (63 MHz, CDCl3) δ 166.7 (Cq), 165.5 (Cq), 155.2 (Cq), 133.7 (Cq), 133.3 (Cq), 133.3 
(Cq), 130.4 (CH), 128.6 (CH), 128.1 (CH), 127.9 (CH), 127.5 (CH), 127.1 (CH2), 126.5 (CH), 126.5 
(CH), 126.0 (CH), 68.0 (CH2), 44.4 (CH2), 43.8 (CH2), 43.6 (CH2), 41.9 (CH2), 41.4 (CH2); MS: m/z = 
404 [M + Na]+; HRMS: calcd. for C21H24O4N3 382.1761, found 382.1765 (1.0 ppm). 
(d) (6-methoxycarbonyl-2-naphthyl)methyl 4-[2-(prop-2-enoylamino)acetyl]piperazine-1-carboxylate 
(3d) 
The crude derivative obtained following the general protocol described before was subsequently 
purified by flash chromatography (eluent: EtOAc). C23H25N3O6; yield 71%; white solid; m.p. 159-160 
°C; M = 439.46 g/mol; IR (ATR):  ν = 3338 (w), 2938 (w), 1697 (s), 1666 (s), 1648 (s), 1618 (s), 1430 
(s), 1290 (s), 1217 (m), 1123 (m), 804 (s) cm-1; 1H NMR (250 MHz, CDCl3) δ 8.60 (s, 1H), 8.08 (dd, J 
= 8.6 Hz, J = 1.7 Hz, 1H), 7.96 (d, J = 8.5 Hz, 1H), 7.88 (d, J = 8.7 Hz, 1H), 7.85 (s, 1H), 7.53 (dd, J 
= 8.5 Hz, J = 1.6 Hz, 1H), 6.70 (as, 1H), 6.32 (dd, J = 17.0 Hz, J = 1.9 Hz, 1H), 6.18 (dd, J = 17.0 Hz, 
J = 9.8 Hz, 1H), 5.68 (dd, J = 9.8 Hz, J = 1.9 Hz, 1H), 5.33 (s, 2H), 4.15 (d, J = 4.1 Hz, 2H), 3.98 (s, 
3H), 3.68-3.64 (m, 2H), 3.60-3.53 (m, 4H), 3.50-3.38 (m, 2H); 13C NMR (63 MHz, CDCl3) δ 167.2 
(Cq), 166.8 (Cq), 165.5 (Cq), 155.1 (Cq), 136.4 (Cq), 135.5 (Cq), 132.2 (Cq), 130.9 (CH), 130.4 (CH), 
130.0 (CH), 128.4 (CH), 128.0 (Cq), 127.1 (CH2), 127.0 (CH), 126.6 (CH), 125.9 (CH), 67.6 (CH2), 
52.4 (CH3), 44.3 (CH2), 43.8 (CH2), 43.7 (CH2), 41.9 (CH2), 41.4 (CH2); MS: m/z = 462 [M + Na]+; 
HRMS: calcd. for C23H26O6N3 440.1816 , found 440.1814 (0.5 ppm). 
(e) N-[2-[4-(adamantane-1-carbonyl)piperazin-1-yl]-2-oxo-ethyl]prop-2-enamide (3e) 
The crude derivative obtained following the general protocol described before was subsequently 
purified by flash chromatography (eluent: EtOAc).C20H29N3O3; yield 41%; white solid; m.p. 195-196 
°C; M = 359.46 g/mol; IR (ATR):  ν = 3311 (w), 2910 (m), 1675 (m-s), 1642 (m), 1599 (s), 1557 (m), 
1417 (m), 1223 (s), 1008 (m-s), 947 (m) cm-1; 1H NMR (250 MHz, CDCl3) δ 6.68 (as, 1H), 6.32 (dd, J 
= 17.0 Hz, J = 1.9 Hz, 1H), 6.18 (dd, J = 17.0 Hz, J = 9.9 Hz, 1H), 5.69 (dd, J = 9.8 Hz, J = 1.9 Hz, 
1H), 4.15 (d, J = 4.1 Hz, 2H), 3.75-3.71 (m, 4H), 3.66-3.63 (m, 2H), 3.45-3.41 (m, 2H), 2.06 (as, 3H), 
1.99-1.98 (m, 6H), 1.79-1.68 (m, 6H); 13C NMR (63 MHz, CDCl3) δ 176.3 (Cq), 166.8 (Cq), 165.5 (Cq), 
130.5 (CH), 127.1 (CH2), 45.3 (CH2), 44.9 (CH2), 44.7 (CH2), 42.4 (CH2), 42.0 (Cq), 41.4 (CH2), 39.2 
(3CH2), 36.7 (3CH2), 28.5 (3CH); MS: m/z = 382 [M + Na]+; HRMS: calcd. for C20H30O3N3 360.2282 
, found 360.2287 (1.5 ppm). 
(f) 1-adamantylmethyl 4-[2-(prop-2-enoylamino)acetyl]piperazine-1-carboxylate (3f) 
The crude derivative obtained following the general protocol described before was subsequently 
purified by flash chromatography (eluent: EtOAc). C21H31N3O4; yield 48%; white solid; m.p. 176-177 
°C; M = 389.49 g/mol; IR (ATR): ν = 3335 (w), 2892 (m), 2844 (w), 1687 (s), 1672 (m), 1621 (s), 1469 
(m), 1420 (s), 1251 (m), 1223 (s) cm–1; 1H NMR (250 MHz, CDCl3) δ 6.70 (as, 1H), 6.32 (dd, J = 17.0 
Hz, J = 1.9 Hz, 1H), 6.18 (dd, J = 17.0 Hz, J = 9.8 Hz, 1H), 5.68 (dd, J = 9.8 Hz, J = 1.9 Hz, 1H), 4.16 
(d, J = 4.1 Hz, 2H), 3.71 (s, 2H), 3.68-3.62 (m, 2H), 3.56-3.49 (m, 4H), 3.46-3.42 (m, 2H), 1.99 (as, 
3H), 1.77-1.62 (m, 6H), 1.53 (d, J = 2.5 Hz, 6H);  13C NMR (63 MHz, CDCl3) δ 166.8 (Cq), 165.5 (Cq), 
155.7 (Cq), 130.5 (CH), 127.1 (CH2), 75.7 (CH2), 44.4 (CH2), 43.7 (CH2), 43.5 (CH2), 42.0 (CH2), 41.5 
(CH2), 39.5 (3CH2), 37.1 (3CH2), 33.6 (Cq), 28.1 (3CH); MS: m/z = 412 [M + Na]+; HRMS: calcd. for 
C21H32O4N3 390.2387, found 390.2391 (0.9 ppm). 
(g) 2-(1-adamantyl)ethyl 4-[2-(prop-2-enoylamino)acetyl]piperazine-1-carboxylate (3g) 
The crude derivative obtained following the general protocol described before was subsequently 
purified by flash chromatography (eluent: EtOAc). C22H33N3O4; yield 54 %; white solid; m.p. 155-156 
°C; M = 403.52 g/mol; IR (ATR):  ν = 3317 (w), 2901 (m-s), 2847 (w), 1684 (s), 1624 (s), 1469 (m), 
1427 (s), 1223 (s) cm–1; 1H NMR (250 MHz, CDCl3) δ 6.73 (as, 1H), 6.32 (dd, J = 17.0 Hz, J = 1.9 Hz, 
1H), 6.18 (dd, J = 17.0 Hz, J = 9.8 Hz, 1H), 5.68 (dd, J = 9.8 Hz, J = 1.9 Hz, 1H), 4.19-4.13 (m, 4H), 
3.65-3.61 (m, 2H), 3.50-3.46 (m, 4H), 3.43-3.39 (m, 2H), 1.94 (as, 3H), 1.73-1.59 (m, 6H), 1.52 (d, J 
= 2.4 Hz, 6H), 1.43 (t, J = 7.3 Hz, 2H); 13C NMR (63 MHz, CDCl3) δ 166.7 (Cq), 165.5 (Cq), 155.5 
(Cq), 130.5 (CH), 127.0 (CH2), 62.5 (CH2), 44.4 (CH2), 43.6 (CH2), 43.5 (CH2), 42.9 (CH2), 42.7 
(3CH2), 42.0 (CH2), 41.4 (CH2), 37.1 (3CH2), 31.9 (Cq), 28.7 (3CH); MS: m/z = 426 [M + Na]+; HRMS: 
calcd. for C22H34O4N3 404.2544, found 404.2547 (0.8 ppm). 
(h) N-[2-[4-[[5-(dimethylamino)-1-naphthyl]sulfonyl]piperazin-1-yl]-2-oxo-ethyl]prop-2-enamide 
(3h) 
The crude derivative obtained following the general protocol described before was subsequently 
purified by flash chromatography (eluent: EtOAc). C18H24N4O3S; yield 39%; light yellow solid; m.p. 
185-186°C; M = 430.52 g/mol; IR (ATR): ν = 2935 (w), 1651 (s), 1454 (m), 1436 (m), 1311 (m), 1141 
(s), 941 (s), 789 (s), 704 (m) cm–1;  1H NMR (250 MHz, CDCl3) δ 8.59 (d, J = 8.5 Hz, 1H), 8.35 (d, J 
= 8.7 Hz, 1H), 8.21 (dd, J = 7.4 Hz, J = 1.2 Hz, 1H), 7.55 (dd, J = 8.5 Hz, J = 7.5 Hz, 2H), 7.19 (d, J 
= 7.5 Hz, 1H), 6.58 (as, 1H), 6.28 (dd, J = 17.0 Hz, J = 1.8 Hz, 1H), 6.13 (dd, J = 17.0 Hz, J = 9.9 Hz, 
1H), 5.65 (dd, J = 9.9 Hz, J = 1.8 Hz, 1H), 4.05 (d, J = 4.1 Hz, 2H), 3.68 (t, J = 5.1 Hz, 2H), 3.47 (t, J 
= 5.0 Hz, 2H), 3.21 (dt, J = 9.8 Hz, J = 4.7 Hz, 4H), 2.89 (s, 6H); 13C NMR (63 MHz, CDCl3) δ 166.5 
(Cq), 165.4 (Cq), 152.1 (Cq), 132.2 (Cq), 131.4 (CH), 131.0 (CH), 130.4 (Cq), 130.3 (CH), 130.3 (Cq), 
128.5 (CH), 127.1 (CH2), 123.3 (CH), 119.3 (CH), 115.6 (CH), 45.6 (CH2), 45.6 (2CH3), 45.4 (CH2), 
44.3 (CH2), 41.8 (CH2), 41.3 (CH2); MS: m/z = 453 [M + Na]+; HRMS: calcd. for C21H27O4N4S 
431.1748, found 431.1751 (0.8 ppm). 
(i) benzyl 4-[(2R)-2-(prop-2-enoylamino)propanoyl]piperazine-1-carboxylate (3i) 
The crude derivative obtained following the general protocol described before was subsequently 
purified by flash chromatography (eluent: EtOAc). C18H23N3O4; colorless viscous oil; yield 73%; M = 
345.39 g/mol; IR (ATR):  ν = 3290 (w), 2929 (w), 1697 (s), 1621 (s), 1423 (s), 1220 (s), 1020 (m), 759 
(m), 695 (m) cm-1; 1H NMR (250 MHz, CDCl3) δ 7.41-7.32 (m, 5H), 6.71 (d, J = 7.1 Hz, 1H), 6.30 (dd, 
J = 17.0 Hz, J = 1.7 Hz, 1H), 6.12 (dd, J = 17.0 Hz, J = 10.0 Hz, 1H), 5.66 (dd, J = 10.0 Hz, J = 1.7 
Hz, 1H), 5.15 (s, 2H), 4.96 (p, J = 6.9 Hz, 1H), 3.79-3.40 (m, 8H), 1.36 (d, J = 6.8 Hz, 3H); 13C NMR 
(63 MHz, CDCl3) δ 171.2 (Cq), 164.7 (Cq), 155.2 (Cq), 136.4 (Cq), 130.7 (CH), 128.7 (2CH), 128.4 
(CH), 128.2 (2CH), 127.0 (CH2), 67.7 (CH2), 45.4 (CH2), 45.3 (CH), 44.0 (CH2), 43.7 (CH2), 42.1 
(CH2), 19.2 (CH3); MS: m/z = 368 [M + Na]+; HRMS: calcd. for C18H24O4N3 346.1761, found 346.1767 
(1.6 ppm). 
(j) benzyl 4-[(2S)-2-(prop-2-enoylamino)propanoyl]piperazine-1-carboxylate (3j) 
The crude derivative obtained following the general protocol described before was subsequently 
purified by flash chromatography (eluent: EtOAc). C18H23N3O4; white solid; m.p. 121-122 °C; yield 72 
%; M = 345.39 g/mol; IR (ATR):  ν = 3271 (w), 2929 (w), 1697 (s), 1624 (s), 1423 (s), 1223 (s), 1117 
(w-m), 1011 (m), 759 (m), 695 (m) cm -1; 1H NMR (250 MHz, CDCl3) δ 7.40-7.35 (m, 5H), 6.71 (d, J 
= 7.1 Hz, 1H), 6.29 (dd, J = 17.0 Hz, J = 1.6 Hz, 1H), 6.12 (dd, J = 17.0 Hz, J = 10.0 Hz, 1H), 5.66 
(dd, J = 10.0 Hz, J = 1.6 Hz, 1H), 5.15 (d, 2H), 4.96 (p, J = 7.0 Hz, 1H),  3.81-3.40 (m, 8H), 1.35 (d, 
J = 6.8 Hz, 3H); 13C NMR (63 MHz, CDCl3) δ 171.1 (Cq), 164.6 (Cq), 155.1 (Cq), 136.3 (Cq), 130.7 
(CH), 128.7 (2CH), 128.4 (CH), 128.2 (2CH), 127.0 (CH2), 67.7 (CH2), 45.3 (CH2), 45.2 (CH), 43.9 
(CH2), 43.6 (CH2), 42.0 (CH2), 19.2 (CH3); MS: m/z = 368 [M + Na]+; HRMS: calcd. for C18H24O4N3 
346.1761, found  346.1767 (1.6 ppm). 
(k) benzyl 4-[(2R)-3-phenyl-2-(prop-2-enoylamino)propanoyl]piperazine-1-carboxylate (3k) 
The crude derivative obtained following the general protocol described before was subsequently 
purified by flash chromatography (eluent: EtOAc). C24H27N3O4; colorless viscous oil; yield 79 %; M = 
421.49 g/mol; IR (ATR):  ν = 3284 (w), 2929 (w), 1700 (s), 1621 (s), 1423 (s), 1220 (s), 729 (m), 692 
(m) cm-1; 1H NMR (250 MHz, CDCl3) δ 7.41-7.18 (m, 10H), 6.77 (d, J = 8.0 Hz, 1H), 6.31 (dd, J = 
17.0 Hz, J = 1.6 Hz, 1H), 6.12 (dd, J = 17.0 Hz, J = 10.1 Hz, 1H), 5.67 (dd, J = 10.1 Hz, J = 1.6 Hz, 
1H), 5.20 (td, J = 9.0 Hz, J = 5.3 Hz, 1H), 5.10 (s, 2H), 3.59-2.92 (m, 9H), 2.68-2.58 (m, 1H); 13C 
NMR (63 MHz, CDCl3) δ 170.2 (Cq), 164.9 (Cq), 155.0 (Cq), 136.4 (Cq), 136.0 (Cq), 130.5 (CH), 129.6 
(2CH), 128.8 (2CH), 128.7 (2CH), 128.3 (CH), 128.1 (2CH), 127.5 (CH), 127.3 (CH2), 67.6 (CH2), 
49.9 (CH), 45.4 (CH2), 43.3 (2CH2), 41.8 (CH2), 40.1 (CH2); MS: m/z = 444 [M + Na]+; HRMS: calcd. 
for C24H28O4N3 422.2074, found 422.2077 (0.6 ppm).  
(l) benzyl 4-[(2S)-3-phenyl-2-(prop-2-enoylamino)propanoyl]piperazine-1-carboxylate (3l) 
The crude derivative obtained following the general protocol described before was subsequently 
purified by flash chromatography (eluent: EtOAc). C24H27N3O4; colorless viscous oil; yield  65 %; M = 
421.49 g/mol; IR (ATR):  ν = 3287 (w), 2925 (w), 1697 (s), 1621 (s), 1423 (s), 1220 (s), 1123 (w), 729 
(m), 695 (m) cm-1; 1H NMR (250 MHz, CDCl3) δ 7.41-7.18 (m, 10H), 6.77 (d, J = 8.0 Hz, 1H), 6.31 
(dd, J = 17.0 Hz, J = 1.6 Hz, 1H), 6.12 (dd, J = 17.0 Hz, J = 10.1 Hz, 1H), 5.67 (dd, J = 10.1 Hz, J = 
1.6 Hz, 1H), 5.23 (td, J = 9.0 Hz, J = 5.3 Hz, 1H), 5.10 (s, 2H), 3.64-2.92 (m, 9H), 2.68-2.58 (m, 1H); 
13C NMR (63 MHz, CDCl3) δ 170.2 (Cq), 164.9 (Cq), 155.0 (Cq), 136.4 (Cq), 136.0 (Cq), 130.5 (CH), 
129.6 (2CH), 128.8 (2CH), 128.7 (2CH), 128.3 (CH), 128.1 (2CH), 127.5 (CH), 127.3 (CH2), 67.6 
(CH2), 49.9 (CH), 45.4 (CH2), 43.3 (2CH2), 41.8 (CH2), 40.1 (CH2); MS: m/z = 444 [M + Na]+; HRMS: 
calcd. for C24H28O4N3 422.2074, found 422.2077 (0.6 ppm). 
General method for the acetylation step (F) 
Under inert atmosphere and at -78°C, the corresponding acetylation reagent, bromoacetyl bromide or 
chloroacetyl chloride, (1.65 mmol, 1.1 eq.) was slowly added to a solution of the corresponding amine 
(1.5 mmol, 1 eq.) and TEA (7.5 mmol, 5 eq.) in DCM (15 ml). The reaction mixture was stirred at -
78°C for 3h, diluted with DCM (75 ml) and washed with hydrogen chloride (aqueous soln. 0.2 M, 3 x 
50 ml). The recovered organic layer was dried over magnesium sulfate and the solvent was evaporated 
under vacuum to give the crude product.  
(a) benzyl 4-[2-[(2-bromoacetyl)amino]acetyl]piperazine-1-carboxylate (6a) 
The crude derivative obtained using the general protocol described previously was further triturated in 
diethyl ether to give the desired acetylated compound as a solid. C16H20BrN3O4; yield 84%; white solid; 
m.p. 132-133 °C; M = 398.25 g/mol; IR (ATR):  ν = 3344 (w), 2904 (w), 1681 (s), 1621 (s), 1478 (m), 
1423 (s), 1263 (m-s), 1223 (s), 750 (m) cm -1; 1H NMR (250 MHz, CDCl3) δ 7.51 (as, 1H), 7.38-7.32 
(m, 5H), 5.15 (s, 2H), 4.08 (d, J = 4.1 Hz, 2H), 3.89 (s, 2H), 3.70-3.62 (m, 2H), 3.57-3.48 (m, 4H), 
3.46-3.32 (m, 2H); 13C NMR (63 MHz, CDCl3) δ 166.1 (Cq), 165.8 (Cq), 155.1 (Cq), 136.3 (Cq), 128.7 
(2CH), 128.4 (CH), 128.2 (2CH), 67.8 (CH2), 44.3 (CH2), 43.7 (CH2), 43.6 (CH2), 42.0 (CH2), 41.9 
(CH2), 28.6 (CH2); MS: m/z = 420 [M + Na]+ for 79Br and 422 [M + Na] for 81Br; HRMS: calcd. for 
C16H21O4N3Br 398.0710, found 398.0713 (0.8 ppm). 
(b) (4-methoxycarbonylphenyl)methyl 4-[2-[(2-bromoacetyl)amino]acetyl]piperazine-1-carboxylate 
(6b) 
The crude derivative obtained using the general protocol described previously was further triturated in 
diethyl ether to give the desired acetylated compound as a solid. C18H22BrN3O6; yield 95%; light beige 
solid, m.p. 134-135 °C;  M = 456.29 g/mol; IR (ATR):  ν = 3284 (m), 2898 (w), 1715 (m), 1697 (s), 
1675 (m), 1642 (s), 1433 (m), 1278 (m), 1223 (s), 1102 (m), 1026 (m), 759 (s) cm -1; 1H NMR (250 
MHz, CDCl3) δ 8.04 (d, J = 8.4 Hz, 2H), 7.51 (as, 1H), 7.41 (d, J = 8.4 Hz, 2H), 5.20 (s, 2H), 4.09 (d, 
J = 4.1 Hz, 2H), 3.92 (s, 3H), 3.90 (s, 2H), 3.68-3.62 (m, 2H), 3.59-3.52 (m, 4H), 3.46-3.36 (m, 2H); 
13C NMR (63 MHz, CDCl3) δ 166.2 (Cq), 165.9 (Cq), 154.9 (Cq), 141.3 (Cq), 130.2 (Cq), 130.1 (2CH), 
127.8 (2CH), 67.0 (CH2), 52.3 (CH3), 44.3 (CH2), 43.8 (CH2), 43.7 (CH2), 41.9 (2CH2), 28.6 (CH2); 
MS: m/z = 480 [M + Na]+; HRMS: calcd. for C18H23O6N3Br 456.0765, found 456.0768 (0.7 ppm).  
(c) 2-naphthylmethyl 4-[2-[(2-bromoacetyl)amino]acetyl]piperazine-1-carboxylate (6c) 
The crude derivative obtained using the general protocol described previously was further triturated in 
diethyl ether to give the desired acetylated compound as a solid. C20H22BrN3O4; yield 77%; light beige 
solid; m.p. 133-134°C; M = 448.31 g/mol; IR (ATR):  ν = 3338 (w), 2922 (w), 1687 (s), 1621 (s), 1478 
(w), 1423 (s), 1217 (s), 826 (w), 765 (m) cm–1; 1H NMR (250 MHz, CDCl3) δ 7.87-7.83 (m, 4H), 7.52-
7.45 (m, 4H), 5.31 (s, 2H), 4.08 (d, J = 4.0 Hz, 2H), 3.90 (s, 2H), 3.66-3.40 (m, 8H); 13C NMR (63 
MHz, CDCl3) δ 166.1 (Cq), 165.8 (Cq), 155.2 (Cq), 133.7 (Cq), 133.3 (2Cq), 128.6 (CH), 128.1 (CH), 
127.9 (CH), 127.5 (CH), 126.5 (CH), 126.5 (CH), 126.0 (CH), 68.0 (CH2), 44.3 (CH2), 43.7 (CH2), 43.6 
(CH2), 42.0 (CH2), 41.9 (CH2), 28.6 (CH2); MS: m/z = 472 [M + Na]+; HRMS: calcd. for C20H23O4N3Br 
448.0866, found 448.0867 (0.1 ppm). 
(d) (6-methoxycarbonyl-2-naphthyl)methyl 4-[2-[(2-bromoacetyl)amino]acetyl]piperazine-1-
carboxylate  (6d) 
The crude derivative obtained using the general protocol described previously was further triturated in 
diethyl ether to give the desired acetylated compound as a solid. C22H24BrN3O6; yield 80%; white solid; 
m.p. 136-137 °C; M = 506.35 g/mol; IR (ATR):  ν = 3326 (w), 2916 (w), 1706 (s), 1621 (s), 1423 (s), 
1214 (m), 1202 (m), 814 (m) cm-1; 1H NMR (250 MHz, CDCl3) δ 8.61 (s, 1H), 8.08 (dd, J = 8.6 Hz, J 
= 1.6 Hz, 1H), 7.96 (d, J = 8.5 Hz, 1H), 7.88 (d, J = 8.7 Hz, 1H), 7.85 (s, 1H), 7.53 (dd, J = 8.5 Hz, 
1H), 7.53-7.47 (m, 1H), 5.33 (s, 2H), 4.09 (d, J = 4.1 Hz, 2H), 3.98 (s, 3H), 3.90 (s, 2H), 3.69-3.65 (m, 
2H), 3.60-3.54 (m, 4H), 3.43-3.36 (m, 2H); 13C NMR (63 MHz, CDCl3) δ 167.2 (Cq), 166.1 (Cq), 165.9 
(Cq), 155.1 (Cq), 136.4 (Cq), 135.5 (Cq), 132.3 (Cq), 130.9 (CH), 130.0 (CH), 128.4 (CH), 128.0 (Cq), 
127.0 (CH), 126.6 (CH), 125.9 (CH), 67.6 (CH2), 52.4 (CH3), 44.3 (CH2), 43.7 (CH2), 43.7 (CH2), 42.0 
(CH2), 41.9 (CH2), 28.6 (CH2); MS: m/z = 528 [M + Na]+ for 79Br and 530 [M + Na]+ for 81Br; HRMS: 
calcd. for C22H25O6N3Br 506.0921, found 506.0918 (0.6 ppm). 
(e) 2-N-[2-[4-(adamantane-1-carbonyl)piperazin-1-yl]-2-oxo-ethyl]-2-bromo-acetamide  (6e) 
The crude derivative obtained using the general protocol described previously was further triturated in 
diethyl ether to give the desired acetylated compound as a solid. C19H28BrN3O3; yield 86%; white solid; 
m.p. 203-204 °C; M = 426.35 g/mol; IR (ATR):  ν = 3305 (m-s), 2932 (m-s), 1681 (s), 1645 (s), 1590 
(s), 1563 (m), 1420 (s), 1223 (s), 1205 (m-s), 1014 (s) cm-1; 1H NMR (250 MHz, CDCl3) δ 7.50 (as, 
1H), 4.09 (d, J = 4.1 Hz, 2H), 3.90 (s, 2H), 3.74-3.70 (m, 4H), 3.66-3.63 (m, 2H), 3.43-3.39 (m, 2H), 
2.06 (as, 3H), 1.99-1.97 (m, 6H), 1.79-1.67 (m, 6H);  13C NMR (63 MHz, CDCl3) δ 176.3 (Cq), 166.2 
(Cq), 165.8 (Cq), 45.4 (CH2), 44.8 (CH2), 44.7 (CH2), 42.4 (CH2), 41.9 (CH2), 41.9 (Cq), 39.2 (3CH2), 
36.7 (3CH2), 28.6 (CH2), 28.5 (3CH); MS: m/z = 448 [M + Na]+ for 79Br and 450 [M + Na] for 81Br; 
HRMS: calcd. for C19H29O3N3Br 426.1387, found  426.1389 (0.5 ppm). 
(f) 1-adamantylmethyl 4-[2-[(2-bromoacetyl)amino]acetyl]piperazine-1-carboxylate (6f) 
The crude derivative obtained using the general protocol described previously was further triturated in 
diethyl ether to give the desired acetylated compound as a solid. C20H30BrN3O4; yield 76%; light beige 
solid; m.p. 210-211 °C; M = 456.37 g/mol; IR (ATR):  ν = 3335 (w), 2898 (m-s), 2847 (w), 1678 (s), 
1621 (s), 1466 (m), 1430 (m), 1247 (m), 1220 (s), 1205 (m) cm–1; 1H NMR (250 MHz, CDCl3) δ 7.52 
(s, 1H), 4.09 (d, J = 4.0 Hz, 2H), 3.90 (s, 2H), 3.71 (s, 2H), 3.68-3.64 (m, 2H), 3.56-3.50 (m, 4H), 3.45-
3.41 (m, 2H), 1.99 (as, 3H), 1.76-1.61 (m, 6H), 1.53 (d, J = 2.9 Hz, 6H); 13C NMR (63 MHz, CDCl3) δ 
166.2 (Cq), 165.8 (Cq), 155.6 (Cq), 75.7 (CH2), 44.4 (CH2), 43.7 (CH2), 43.5 (CH2), 42.0 (CH2), 42.0 
(CH2), 39.5 (3CH2), 37.1 (3CH2), 33.6 (Cq), 28.6 (CH2), 28.1 (3CH); MS: m/z = 480 [M + Na]+; HRMS: 
calcd. for C20H31O4N3Br 456.1492, found 456.1491 (0.3 ppm). 
(g) 2-(1-adamantyl)ethyl 4-[2-[(2-bromoacetyl)amino]acetyl]piperazine-1-carboxylate (6g) 
The crude derivative obtained using the general protocol described previously was further triturated in 
diethyl ether to give the desired acetylated compound as a solid. C21H32BrN3O4; yield 39 %; light beige 
solid; m.p. 111-112 °C; M = 470.40 g/mol; IR (ATR):  ν = 3335 (w),  2895 (m-s), 2844 (m), 1700 (s), 
1612 (s), 1427 (s), 1284 (w), 1226 (s) cm–1; 1H NMR (250 MHz, CDCl3) δ 7.51 (as, 1H), 4.16 (t, J = 
7.3 Hz, 2H), 4.09 (d, J = 4.0 Hz, 2H), 3.90 (s, 2H), 3.66-3.59 (m, 2H), 3.57-3.45 (m, 4H), 3.41-3.34 
(m, 2H), 1.95 (as, 3H), 1.73-1.59 (m, 6H), 1.52 (as, 6H), 1.43 (t, J = 7.3 Hz, 2H); 13C NMR (63 MHz, 
CDCl3) δ 166.1 (Cq), 165.8 (Cq), 155.5 (Cq), 62.6 (CH2), 44.4 (CH2), 43.6 (CH2), 43.5 (CH2), 42.9 
(CH2), 42.7 (3CH2), 42.1 (CH2), 42.0 (CH2), 37.1 (3CH2), 31.9 (Cq), 28.7 (3CH), 28.6 (CH2); MS: m/z 
= 494 [M + Na]+; HRMS: calcd. for C21H33O4N3Br 470.1649, found 470.1646 (0.6 ppm). 
(h) 22-bromo-N-[2-[4-[[5-(dimethylamino)-1-naphthyl]sulfonyl]piperazin-1-yl]-2-oxo-ethyl]-
acetamide (6h) 
The crude compound obtained after the aqueous work-up (sodium bicarbonate satd. soln. / DCM 
extraction) was triturated in diethyl ether to conduct to the desired derivative. C20H25BrN4O4S; yield 79 
%; yellow solid; m.p. 173-174 °C; M = 497.41 g/mol; IR (ATR):  ν = 3381 (w), 2925 (w), 1651 (s), 
1451 (m), 1339 (m), 1144 (s), 941 (s), 792 (s), 707 (s) cm–1; 1H NMR (250 MHz, CDCl3) δ 8.64 (d, J 
= 8.1 Hz, 1H), 8.38 (d, J = 8.6 Hz, 1H), 8.21 (dd, J = 7.4 Hz, J = 1.2 Hz, 1H), 7.60-7.53 (m, 2H), 7.39 
(as, 1H), 7.22 (d, J = 7.4 Hz, 1H), 3.99 (d, J = 4.1 Hz, 2H), 3.85 (s, 2H), 3.70-3.66 (m, 2H), 3.47-3.43 
(m, 2H), 3.21 (dd, J = 10.1 Hz, J = 5.2 Hz, 4H), 2.92 (s, 6H); 13C NMR (63 MHz, CDCl3) δ 165.9 (Cq), 
165.9 (Cq), 132.1 (Cq), 131.2 (CH), 131.0 (CH), 130.3 (Cq), 129.9 (Cq), 128.4 (CH), 123.5 (CH), 119.7 
(CH), 115.7 (CH), 45.6 (2CH3), 45.5 (CH2), 45.3 (CH2), 44.2 (CH2), 41.7 (2CH2), 28.5 (CH2);  
(i) benzyl 4-[(2R)-2-[(2-bromoacetyl)amino]propanoyl]piperazine-1-carboxylate (6i) 
The crude derivative obtained using the general protocol described previously was further triturated in 
diethyl ether to give the desired acetylated compound as a solid. C17H22BrN3O4; light beige solid; m.p. 
104-105 °C; yield  78 %; M = 412.28 g/mol; IR (ATR):  ν = 3302 (m), 2929 (w), 1700 (s), 1678 (s), 
1615 (s), 1475 (m), 1427 (s), 1257 (m), 1226 (s), 1120 (m), 741 (m) cm-1; 1H NMR (250 MHz, CDCl3) 
δ 7.53 (d, J = 6.9 Hz, 1H), 7.40-7.30 (m, 5H), 5.15 (s, 2H), 4.83 (p, J = 6.9 Hz, 1H), 3.85 (ad, J = 1.3 
Hz, 2H), 3.70-3.35 (m, 8H), 1.35 (d, J = 6.8 Hz, 3H); 13C NMR (63 MHz, CDCl3) δ 170.5 (Cq), 165.0 
(Cq), 155.1 (Cq), 136.3 (Cq), 128.7 (2CH), 128.4 (CH), 128.2 (2CH), 67.7 (CH2), 46.1 (CH), 45.3 (CH2), 
43.9 (CH2), 43.6 (CH2), 42.1 (CH2), 28.8 (CH2), 18.9 (CH3); MS: m/z =  434 [M + Na]+ for 79Br and 
436 [M + Na]+ for 81Br; HRMS: calcd. for C17H23O4N3Br 412.0866, found 412.0870 (0.9 ppm). 
(j) benzyl 4-[(2S)-2-[(2-bromoacetyl)amino]propanoyl]piperazine-1-carboxylate (6j) 
The crude derivative obtained using the general protocol described previously was further triturated in 
diethyl ether to give the desired acetylated compound as a solid. C17H22BrN3O4; light beige solid; m.p. 
104-105 °C; yield 83 %; M = 412.28 g/mol; IR (ATR):  ν = 3305 (m), 2929 (w), 1697 (s), 1675 (s), 
1612 (s), 1484 (m), 1427 (s), 1254 (m), 1226 (s), 1120 (m), 741 (m) cm-1; 1H NMR (250 MHz, CDCl3) 
δ 7.55 (d, J = 4.7 Hz, 1H), 7.47-7.28 (m, 5H), 5.14 (s, 2H), 4.92-4.74 (m, 1H), 3.85 (s, 2H), 3.79-3.33 
(m, 8H), 1.34 (m, J = 6.1 Hz, 3H); 13C NMR (63 MHz, CDCl3) δ 170.5 (Cq), 165.0 (Cq), 155.1 (Cq), 
136.3 (Cq), 128.7 (2CH), 128.4 (CH), 128.2 (2CH), 67.7 (CH2), 46.0 (CH), 45.3 (CH2), 43.9 (CH2), 
43.6 (CH2), 42.1 (CH2), 28.8 (CH2), 18.9 (CH3); MS: m/z = 434 [M + Na]+ for 79Br and 436 [M + Na]+ 
for 81Br; HRMS: calcd. for C17H23O4N3Br 412.0866, found 412.0871 (1.1 ppm). 
(k) benzyl 4-[(2R)-2-[(2-bromoacetyl)amino]-3-phenyl-propanoyl]piperazine-1-carboxylate (6k) 
The crude derivative obtained using the protocol described previously was subsequently used without 
any further purification. C23H26BrN3O4; colorless viscous oil; yield 85%; M = 488.37 g/mol; IR (ATR):  
ν = 3293 (w), 3026 (w), 1694 (s), 1621 (s), 1420 (s), 1226 (s), 1120 (w), 750 (w), 732 (w), 695 (m-s) 
cm-1; 1H NMR (250 MHz, CDCl3) δ 7.46 (d, J = 8.0 Hz, 1H), 7.41-7.17 (m, 10H), 5.14-5.05 (m, 3H), 
3.85 (s, 2H), 3.66-3.39 (m, 3H), 3.34-3.15 (m, 3H), 3.11-2.88 (m, 3H), 2.70-2.60 (m, 1H); 13C NMR 
(63 MHz, CDCl3) δ 169.8 (Cq), 165.5 (Cq), 155.0 (Cq), 136.3 (Cq), 135.6 (Cq), 129.7 (2CH), 128.9 
(2CH), 128.7 (2CH), 128.4 (CH), 128.2 (2CH), 127.7 (CH), 67.7 (CH2), 50.6 (CH), 45.5 (CH2), 43.3 
(2CH2), 42.0 (CH2), 39.9 (CH2), 28.7 (CH2); MS: m/z = 510 [M + Na]+ for 79Br and 512 [M + Na]+ for 
81Br; HRMS: calcd. for C23H27O4N3Br 488.1179, found 488.1178 (0.3 ppm). 
(l) benzyl 4-[(2S)-2-[(2-bromoacetyl)amino]-3-phenyl-propanoyl]piperazine-1-carboxylate (6l) 
The crude derivative obtained using the general protocol described previously was subsequently used 
without any further purification. C23H26BrN3O4; colorless viscous oil; yield  98 %; M = 488.37 g/mol; 
IR (ATR):  ν = 3274 (w), 3032 (w), 1697 (s), 1624 (s), 1427 (s), 1223 (s), 1117 (m), 750 (m), 695 (s) 
cm-1;  1H NMR (250 MHz, CDCl3) δ 7.41-7.17 (m, 11H), 5.14-5.05 (m, 3H), 3.85 (s, 2H), 3.62-3.40 
(m, 3H), 3.34-3.18 (m, 3H), 3.11-2.88 (m, 3H), 2.72-2.62 (m, 1H); 13C NMR (63 MHz, CDCl3) δ 169.6 
(Cq), 165.3 (Cq), 155.0 (Cq), 136.3 (Cq), 135.6 (Cq), 129.7 (2CH), 128.9 (2CH), 128.7 (2CH), 128.4 
(CH), 128.2 (2CH), 127.6 (CH), 67.6 (CH2), 50.6 (CH), 45.5 (CH2), 43.3 (2CH2), 42.0 (CH2), 39.9 
(CH2), 28.7 (CH2); MS: m/z = 510 [M + Na]+ for 79Br and 512 [M + Na]+ for 81Br; HRMS: calcd. for 
C23H27O4N3Br 488.1179, found 488.1178 (0.3 ppm).  
(m) tert-butyl 4-[2-[(2-bromoacetyl)amino]acetyl]piperazine-1-carboxylate (6m) 
The crude derivative obtained using the general protocol described previously was further triturated in 
diethyl ether to give the desired acetylated compound as a solid. C13H22BrN3O4; yield 42%; white solid; 
m.p. 148-149 °C; M = 364.24 g/mol; IR (ATR):  ν = 3323 (w), 2968 (w), 1687 (m), 1615 (s), 1405 (m), 
1247 (m), 1223 (m), 1156 (s), 1123 (m), 1023 (m), 859 (w) cm -1; 1H NMR (250 MHz, CDCl3) δ 7.52 
(as, 1H), 4.09 (d, J = 4.0 Hz, 2H), 3.90 (s, 2H), 3.65-3.61 (m, 2H), 3.49-3.42 (m, 4H), 3.40-3.36 (m, 
2H), 1.47 (s, 9H); 13C NMR (63 MHz, CDCl3) δ 166.1 (Cq), 165.8 (Cq), 154.5 (Cq), 80.7 (Cq), 44.4 
(2CH2), 42.1 (2CH2), 41.9 (CH2), 28.6 (CH2), 28.5 (3CH3); MS: m/z = 386 [M + Na]+ for 79Br and MS: 
m/z = 388 [M + Na]+ for 81Br; HRMS: calcd. for C13H23O4N3Br 364.0866, found 364.0872 (1.5 ppm). 
(n) (6-methoxycarbonyl-2-naphthyl)methyl 4-[2-[(2-chloroacetyl)amino]acetyl]piperazine-1-
carboxylate  (6n) 
The crude derivative obtained using the general protocol described previously was further purified by 
flash chromatography (eluent: EtOAc). C22H24ClN3O6; yield 96 %; white solid; m.p. 56-57 °C; M = 
461.90 g/mol; IR (ATR):  ν = 2950 (w), 1697 (s), 1642 (s), 1430 (m-s), 1284 (m), 1223 (m-s), 753 (w) 
cm-1; 1H NMR (250 MHz, CDCl3) δ 8.61 (s, 1H), 8.09 (dd, J = 8.6 Hz, J = 1.7 Hz, 1H), 7.96 (d, J = 
8.5 Hz, 1H), 7.88 (d, J = 8.7 Hz, 1H), 7.85 (s, 1H), 7.60 (as, 1H), 7.53 (dd, J = 8.5 Hz, J = 1.6 Hz, 1H), 
5.33 (s, 2H), 4.10 (d, J = 4.2 Hz, 2H), 4.08 (s, 2H), 3.99 (s, 3H), 3.69-3.65 (m, 2H), 3.60-3.54 (m, 4H), 
3.44-3.41 (m, 2H); 13C NMR (63 MHz, CDCl3) δ 167.2 (Cq), 166.3 (Cq), 166.1 (Cq), 155.1 (Cq), 136.4 
(Cq), 135.4 (Cq), 132.3 (Cq), 130.9 (CH), 130.0 (CH), 128.4 (CH), 128.0 (Cq), 127.0 (CH), 126.6 (CH), 
125.9 (CH), 67.6 (CH2), 52.4 (CH3), 44.3 (CH2), 43.7 (CH2), 43.6 (CH2), 42.5 (CH2), 42.0 (CH2), 41.6 
(CH2); MS: m/z = 484 [M + Na]+; HRMS: calcd. for C22H24O6N3ClNa 484.1246, found 484.1246 (0.0 
ppm). 
(o) N-[2-[4-(adamantane-1-carbonyl)piperazin-1-yl]-2-oxo-ethyl]-2-chloro-acetamide (6o) 
The crude material obtained following the general procedure was purified by flash chromatography 
using ethyl acetate as eluent. C19H28ClN3O3; yield 36 %; white solid; m.p. 201-202 °C; M = 381.90 
g/mol; IR (ATR):  ν = 3305 (m), 2904 (m), 1687 (s), 1648 (s), 1599 (s), 1560 (m), 1451 (m), 1414 (m-
s), 1223 (s), 1011 (s) cm-1; 1H NMR (250 MHz, CDCl3) δ 7.60 (as, 1H), 4.11 (d, J = 4.2 Hz, 2H), 4.08 
(s, 2H), 3.74-3.70 (m, 4H), 3.67-3.63 (m, 2H), 3.43-3.39 (m, 2H), 2.06 (as, 3H), 1.99 (d, J = 2.6 Hz, 
6H), 1.79-1.68 (m, 6H); 13C NMR (63 MHz, CDCl3) δ 176.3 (Cq), 166.3 (Cq), 166.2 (Cq), 45.4 (CH2), 
44.8 (CH2), 44.7 (CH2), 42.5 (CH2), 42.4 (CH2), 41.9 (Cq), 41.6 (CH2), 39.2 (3CH2), 36.7 (3CH2), 28.5 
(3CH); MS: m/z = 404 [M + Na]+; HRMS: calcd. for C19H29O3N3Cl 382.1892, found 382.1896 (1.1 
ppm). 
(p) 2-chloro-N-[2-[4-[[5-(dimethylamino)-1-naphthyl]sulfonyl]piperazin-1-yl]-2-oxo-ethyl]-
acetamide (6p) 
The crude material obtained following the general protocol mentioned above was further purified by 
flash-chromatography (eluent: AcOEt) to conduct to the titled compound. C20H25ClN4O4S; yield 80 %; 
yellow-green solid; m.p. 68-69 °C; M = 452.95 g/mol; IR (ATR):  ν =  3314 (w), 2938 (w), 1648 (s), 
1454 (m), 1436 (m), 1141 (s), 938 (m-s), 786 (s) cm–1; 1H NMR (250 MHz, CDCl3) δ 8.59 (d, J = 8.5 
Hz, 1H), 8.35 (d, J = 8.7 Hz, J = 1H), 8.20 (dd, J = 7.4 Hz, J = 1.3 Hz, 1H), 7.56 (d, J = 7.4 Hz, 1H), 
7.53 (d, J = 7.5 Hz, 1H), 7.49 (as, 1H), 7.19 (d, J = 7.5 Hz, 1H), 4.02 (s, 2H), 4.00 (d, J = 4.2 Hz, 2H), 
3.70-3.66 (m, 2H), 3.47-3.43 (m, 2H), 3.24-3.18 (m, 4H), 2.89 (s, 6H); 13C NMR (63 MHz, CDCl3) δ 
166.2 (Cq), 165.9 (Cq), 152.1 (Cq), 132.1 (Cq), 131.4 (CH), 131.0 (CH), 130.4 (Cq), 130.2 (Cq), 128.5 
(CH), 123.3 (CH), 119.3 (CH), 115.6 (CH), 45.5 (2CH3), 45.5 (CH2), 45.4 (CH2), 44.3 (CH2), 42.4 
(CH2), 41.8 (CH2),41.4 (CH2); MS: m/z = 475 [M + Na]+; HRMS: calcd. for C20H26O4N4SCl 453.1358 
, found 453.1358  (0.0 ppm).  
(q) tert-butyl 4-(2-bromoacetyl)piperazine-1-carboxylate (6q) 
Under inert atmosphere and at -78°C, bromoacetyl bromide (53.7 mmol, 1 eq.) was slowly added to a 
solution of Boc-piperazine (53.7 mmol, 1 eq.) and TEA (59.1 mmol, 1.1 eq.) in DCM (150 ml). The 
reaction mixture was stirred at -78°C for 3h, diluted with DCM (75 ml) and washed with water. The 
recovered organic layer was dried over magnesium sulfate and the solvent was evaporated under 
vacuum. The obtained crude product was further triturated with diethyl ether, filtered and dried under 
vacuum to conduct to the desired acetylated compound. C11H19BrN2O3; yield 78%; white solid; m.p. 
243-244 °C; M = 307.18 g/mol; IR (KBr):  ν = 2965 (m), 1689 (s), 1632 (s), 1417 (s), 1246 (s), 1167 
(s), 1023 (m); cm -1; 1H NMR (250 MHz, CDCl3) δ 3.87 (s, 2H), 3.61-3.57 (m, 2H), 3.55-3.47 (m, 4H), 
3.46-3.41 (m, 2H), 1.46 (s, 9H); 13C NMR (63 MHz, CDCl3) δ 165.5 (Cq), 154.5 (Cq), 80.5 (Cq), 46.6 
(2CH2), 40.9 (2CH2), 28.4 (3CH3), 25.7 (CH2); 
(r) benzyl 4-(2-acetamidoacetyl)piperazine-1-carboxylate (4) 
Under inert atmosphere and at -78°C, acetyl bromide (1.1 eq.) was slowly added to a solution of the 
corresponding amine (0.36 mmol, 1 eq.) and TEA (1.5 eq.) in DCM (5 ml). The reaction mixture was 
stirred at -78°C for 2h, diluted with DCM (50 ml) and subsequently washed with hydrogen chloride 
(aq. soln. 0.1 M, 3 x 50 ml). The recovered organic layer was dried over magnesium sulfate and the 
solvent was evaporated under vacuum to give the crude product further triturated in diethyl ether to 
conduct to the desired acetylated derivative. C16H21N3O4; yield 90%; white solid; m.p. 134-135 °C; M 
= 319.36 g/mol; IR (ATR):  ν = 3356 (m), 2919 (s), 1681 (m), 1657 (s), 1636 (s), 1563 (m), 1420 (m), 
1229 (s), 1120 (m), 1068 (m), 1023 (m) cm -1;  1H NMR (250 MHz, CDCl3) δ 7.39-7.33 (m, 5H), 6.56 
(as, 1H), 5.15 (s, 2H), 4.06 (d, J = 3.8 Hz, 2H), 3.64-3.59 (m, 2H), 3.56-3.50 (m, 4H), 3.45-3.40 (m, 
2H), 2.05 (s, 3H); 13C NMR (63 MHz, CDCl3) δ 170.3 (Cq), 166.9 (Cq), 155.2 (Cq), 136.4 (Cq), 128.8 
(2CH), 128.5 (CH), 128.3 (2CH), 67.8 (CH2), 44.3 (CH2), 43.7 (CH2), 43.6 (CH2), 41.9 (CH2), 41.5 
(CH2), 23.2 (CH3); MS: m/z = 342 [M + Na]+; HRMS: calcd. for C16H22O4N3 320.1605, found 320.1608 
(1.0 ppm). 
Preparation of the dimethylsulfonium salts (G) 
Dimethyl sulfide (2.5 mmol, 10 eq.) was added to a solution of the previously obtained bromo-
acetylated compounds (0.25 mmol, 1 eq.) in methanol (5 ml). The reaction vessel was sealed and the 
mixture vigorously stirred for 48 h at room temperature. The solvent was evaporated, the residue was 
dissolved in water (15 ml) and washed with ethyl acetate (3 x 20 ml). The recovered aqueous layer was 
freeze-dried to give the final dimethylsulfonium bromide salts as solids.          
(a) [2-[[2-(4-benzyloxycarbonylpiperazin-1-yl)-2-oxo-ethyl]amino]-2-oxo-ethyl]-dimethyl-sulfonium 
bromide (1a) 
C18H26BrN3O4S; yield 83%; white solid / hygroscopic; M = 460.39 g/mol; IR (ATR):  ν = 2919 (w), 
1681 (s), 1642 (s), 1427 (m), 1223 (s), 1123 (w), 1020 (w), 762 (w), 695 (w) cm-1; 1H NMR (250 MHz, 
DMSO3) δ 7.38-7.32 (m, 5H), 5.10 (s, 2H), 4.47 (s, 2H), 4.08 (d, J = 5.4 Hz, 2H), 3.53-3.40 (m, 8H), 
2.94 (s, 6H); 13C NMR (63 MHz, DMSO3) δ 166.2 (Cq), 163.2 (Cq), 154.4 (Cq), 136.7 (Cq), 128.4 (2CH), 
127.9 (CH), 127.6 (2CH), 66.4 (CH2), 46.4 (CH2), 43.7 (CH2), 43.4 (CH2), 43.1 (CH2), 41.1 (CH2), 41.0 
(CH2), 24.5 (2CH3); MS: m/z = 380 [M-Br]+; HRMS: calcd. for C18H26O4N3S 380.1639, found 380.1638 
(0.1 ppm). 
(b) [2-[[2-[4-[(4-methoxycarbonylphenyl)methoxycarbonyl]piperazin-1-yl]-2-oxo-ethyl]-amino]-2-
oxo-ethyl]-dimethyl-sulfonium bromide (1b) 
C20H28BrN3O6S; yield 94%; light beige solid / hygroscopic; M = 518.42 g/mol; IR (ATR):  ν = 3211 
(w), 2913 (w), 1694 (s), 1645 (s), 1423 (m-s), 1407 (m), 1278 (m-s), 1220 (m-s), 1102 (m), 1017 (m), 
753 (m) cm -1; 1H NMR (250 MHz, DMSO) δ 8.90 (t, J = 5.4 Hz, 1H), 7.96 (d, J = 8.4 Hz, 2H), 7.51 
(d, J = 8.4 Hz, 2H), 5.19 (s, 2H), 4.48 (s, 2H), 4.09 (d, J = 5.4 Hz, 2H), 3.85 (s, 3H), 3.86-3.38 (m, 8H), 
2.94 (s, 6H); 13C NMR (63 MHz, DMSO) δ 166.3 (Cq), 166.0 (Cq), 163.2 (Cq), 154.2 (Cq), 142.3 (Cq), 
129.3 (2CH), 129.0 (Cq), 127.4 (2CH), 65.7 (CH2), 52.2. (CH3), 46.4 (CH2), 43.7 (CH2), 43.4 (CH2), 
43.2 (CH2), 41.1 (CH2), 41.0 (CH2), 24.5 (2CH3); MS: m/z = 438 [M]+; HRMS: calcd. for C20H28O6N3S 
438.1693, found 438.1693  (0.1 ppm). 
(c) dimethyl-[2-[[2-[4-(2-naphthylmethoxycarbonyl)piperazin-1-yl]-2-oxo-ethyl]amino]-2-oxo-
ethyl]sulfonium bromide  (1c) 
C22H28BrN3O4S; yield 47%; light beige solid / hydroscopic; M = 510.44 g/mol; IR (ATR):  ν = 2910 
(w), 1678 (s), 1639 (s), 1463 (m), 1427 (s), 1223 (s), 817 (w), 747 (m) cm–1; 1H NMR (250 MHz, 
CDCl3) δ 8.88 (t, J = 4.9 Hz, 1H), 7.86-7.80 (m, 4H), 7.51-7.43 (m, 3H), 5.29 (s, 2H), 5.05 (s, 2H), 4.12 
(d, J = 5.3 Hz, 2H), 3.61-3.41 (m, 8H), 3.32 (s, 6H); 13C NMR (63 MHz, CDCl3) δ 166.3 (Cq), 163.3 
(Cq), 154.5 (Cq), 134.3 (Cq), 132.7 (Cq), 132.6 (Cq), 128.1 (CH), 127.8 (CH), 127.6 (CH), 126.5 (CH), 
126.4 (CH), 126.3 (CH), 125.8 (CH), 66.6 (CH2), 46.5 (CH2), 43.8 (CH2), 43.4 (CH2), 43.2 (CH2), 41.2 
(CH2), 41.1 (CH2), 24.6 (2CH3); MS: m/z = 430 [M-Br]+; HRMS: calcd. for C22H28O4N3S 430.1795, 
found 430.1793 (0.5 ppm). 
(d) [2-[[2-[4-[(6-methoxycarbonyl-2-naphthyl)methoxycarbonyl]piperazin-1-yl]-2-oxo-ethyl]amino]-
2-oxo-ethyl]-dimethyl-sulfonium bromide (1d) 
C24H30BrN3O6S; yield 81%; white solid; m.p. 125-126 °C;  M = 568.48 g/mol; IR (ATR):  ν = 3320 
(w), 2980 (w), 1712 (m), 1675 (m), 1639 (s), 1433 (m), 1287 (m), 1232 (s), 1199 (m), 1126 (m), 759 
(w) cm-1; 1H NMR (250 MHz, DMSO) δ 8.88 (t, J = 5.4 Hz, 1H), 8.65 (s, 1H), 8.16 (d, J = 8.6 Hz, 1H), 
8.08-7.99 (m, 3H), 7.62 (dd, J = 8.5 Hz, J = 1.6 Hz, 1H), 5.30 (s, 2H), 4.43 (s, 2H), 4.10 (d, J = 5.4 
Hz, 2H), 3.92 (s, 3H), 3.56-3.40 (m, 8H), 2.91 (s, 6H); 13C NMR (63 MHz, DMSO) δ 166.3 (Cq), 166.3 
(Cq), 163.2 (Cq), 154.3 (Cq), 137.3 (Cq), 134.9 (Cq), 131.6 (Cq), 130.4 (CH), 129.7 (CH), 128.5 (CH), 
127.1 (Cq), 126.5 (CH), 125.9 (CH), 125.2 (CH), 66.3 (CH2), 52.3 (CH3), 46.5 (CH2), 43.7 (CH2), 43.4 
(CH2), 43.3 (CH2), 41.1 (CH2), 41.1 (CH2), 24.6 (2CH3). MS: m/z = 488 [M]+; HRMS: calcd. for 
C24H30O6N3S 488.1850, found 488.1841 (1.8 ppm). 
(e) [2-[[2-[4-(adamantane-1-carbonyl)piperazin-1-yl]-2-oxo-ethyl]amino]-2-oxo-ethyl]-dimethyl-
sulfonium bromide (1e) 
C21H34BrN3O3S; yield 98%; white solid; m.p. 157-158 °C; M = 488.48 g/mol; IR (ATR):  ν =  3417 
(w), 2901 (m-s), 2844 (w), 1645 (s), 1612 (s), 1445 (w), 1408 (m), 1241 (m), 1214 (m), 1008 (s) cm-1; 
1H NMR (250 MHz, DMSO) δ 8.87 (t, J = 5.3 Hz, 1H), 4.42 (s, 2H), 4.08 (d, J = 5.3 Hz, 2H), 3.65-
3.54 (m, 4H), 3.48-3.38 (m, 4H), 2.90 (s, 6H), 1.98 (as, 3H), 1.92-1.86 (m, 6H), 1.74-1.62 (m, 6H);13C 
NMR (63 MHz, DMSO) δ 174.6 (Cq), 166.2 (Cq), 163.2 (Cq), 46.5 (CH2), 44.5 (2CH2), 44.2 (CH2), 41.7 
(CH2), 41.0 (CH2), 40.9 (Cq), 38.4 (3CH2), 36.0 (3CH2), 27.9 (3CH), 24.6 (2CH3); MS: m/z = 408 [M-
Br]+; HRMS: calcd. for C21H34O3N3S 408.2315, found 408.2317 (0.4 ppm). 
(f) [2-[[2-[4-(1-adamantylmethoxycarbonyl)piperazin-1-yl]-2-oxo-ethyl]amino]-2-oxo-ethyl]-
dimethyl-sulfonium bromide (1f) 
C22H36BrN3O4S; yield 67%; light beige solid / hygroscopic; M = 518.51 g/mol; IR (ATR):  ν = 3414 
(w), 2895 (s), 2844 (m), 1669 (s), 1642 (s), 1466 (m), 1423 (m-s), 1220 (s) cm–1;  1H NMR (250 MHz, 
DMSO) δ 8.89 (t, J = 5.3 Hz, 1H), 4.46 (s, 2H), 4.08 (d, J = 5.4 Hz, 2H), 3.62 (s, 2H), 3.54-3.40 (m, 
8H), 2.93 (s, 6H), 1.94 (as, 3H), 1.71-1.58 (m, 6H), 1.50 (as, 6H);  13C NMR (63 MHz, DMSO) δ 166.3 
(Cq), 163.2 (Cq), 154.8 (Cq), 74.3 (CH2), 46.4 (CH2), 43.7 (CH2), 43.3 (CH2), 43.0 (CH2), 41.1 (CH2), 
41.0 (CH2), 38.7 (3CH2), 36.4 (3CH2), 33.1 (Cq), 27.4 (3CH), 24.6 (2CH3); MS: m/z = 438 [M-Br]+; 
HRMS: calcd. for C22H36O4N3S 438.2421, found 438.2419 (0.5 ppm). 
(g) [2-[[2-[4-[2-(1-adamantyl)ethoxycarbonyl]piperazin-1-yl]-2-oxo-ethyl]amino]-2-oxo-ethyl]-
dimethyl-sulfonium bromide  (1g) 
C23H38BrN3O4S; yield 75 %; light beige solid / hygroscopic; M = 532.53 g/mol; IR (ATR):  ν =  2895 
(m-s), 2847 (w), 1684 (s), 1423 (s), 1226 (s), 1020 (w) cm–1; 1H NMR (250 MHz, DMSO) δ 8.89 (t, J 
= 5.3 Hz, 1H), 4.47 (s, 2H), 4.09-4.03 (m, 4H), 3.50-3.38 (m, 8H), 2.93 (s, 6H), 1.91 (as, 3H), 1.69-
1.57 (m, 6H), 1.49 (as, 6H), 1.37 (t, J = 7.3, 2H);  13C NMR (63 MHz, DMSO) δ 166.2 (Cq), 163.2 (Cq), 
154.6 (Cq), 61.2 (CH2), 46.4 (CH2), 43.7 (CH2), 43.3 (CH2), 43.0 (CH2), 42.4 (CH2), 41.9 (3CH2), 41.1 
(CH2), 41.0 (CH2), 36.5 (3CH2), 31.3 (Cq), 27.9 (3CH), 24.6 (2CH3); MS: m/z = 452 [M-Br]+; HRMS: 
calcd. for C23H38O4N3S 452.2578, found 452.2575 (0.6 ppm). 
(h) [2-[[2-[4-[[5-(dimethylamino)-1-naphthyl]sulfonyl]piperazin-1-yl]-2-oxo-ethyl]amino]-2-oxo-
ethyl]-dimethyl-sulfonium bromide (1h) 
C22H31BrN4O4S2; yield 76%; light yellow solid; m.p. 98-99 °C; M = 559.54 g/mol; IR (ATR):  ν = 3475 
(m), 2992 (w), 1672 (s), 1648 (s), 1345 (s), 1153 (s), 1144 (s), 935 (s), 795 (s), 713 (s) cm–1; 1H NMR 
(250 MHz, DMSO) δ 8.79 (t, J = 5.4 Hz, 1H), 8.54 (d, J = 8.5 Hz, 1H), 8.30 (d, J = 8.7 Hz, 1H), 8.14 
(dd, J = 7.4 Hz, J = 1.1 Hz, 1H), 7.68 (dd, J = 8.5 Hz, J = 7.4 Hz, 1H), 7.63 (dd, J = 8.5 Hz, J = 7.7 
Hz, 1H), 7.28 (d, J = 7.3 Hz, 1H), 4.38 (s, 2H), 4.01 (d, J = 5.3 Hz, 2H), 3.55-3.43 (m, 4H), 3.18-3.05 
(m, 4H), 2.87 (s, 6H), 2.83 (s, 6H); 13C NMR (63 MHz, DMSO) δ 166.2 (Cq), 163.2 (Cq), 151.5 (Cq), 
132.4 (Cq), 130.5 (CH), 130.2 (CH), 129.6 (Cq), 129.2 (Cq), 128.3 (CH), 123.8 (CH), 118.9 (CH), 115.4 
(CH), 46.5 (CH2), 45.3 (CH2), 45.2 (CH2), 45.1 (2CH3), 43.7 (CH2), 41.0 (CH2), 40.9 (CH2), 24.5 
(2CH3); MS: m/z = 479 [M]+; HRMS: calcd. for C22H31O4N4S2 479.1781,  found 479.1779  (0.5 ppm).  
(i) [2-[[(1S)-2-(4-benzyloxycarbonylpiperazin-1-yl)-1-methyl-2-oxo-ethyl]amino]-2-oxo-ethyl]-
dimethyl-sulfonium bromide (1j) 
C19H28BrN3O4S; light beige solid / hygroscopic; yield 78%; M = 474.41 g/mol; IR (ATR):  ν = 2986 
(w), 1694 (s), 1636 (s), 1420 (s), 1220 (s), 1020 (m), 759 (m), 698 (m) cm -1; 1H NMR (250 MHz, 
DMSO) δ 9.07 (d, J = 7.3 Hz, 1H), 7.39-7.32 (m, 5H), 5.10 (s, 2H), 4.78 (p, J = 6.6 Hz, 1H), 4.40 (s, 
2H), 3.51-3.46 (m, 8H), 2.90 (s, 3H), 2.89 (s, 3H), 1.21 (d, J = 6.9 Hz, 3H); 13C NMR (63 MHz, DMSO) 
δ 169.8 (Cq), 162.4 (Cq), 154.4 (Cq), 136.7 (Cq), 128.4 (2CH), 127.9 (CH), 127.7 (2CH), 66.4 (CH2), 
46.6 (CH2), 45.3 (CH), 44.5 (CH2), 43.6 (CH2), 43.2 (CH2), 41.3 (CH2), 24.7 (CH3), 24.6 (CH3), 17.6 
(CH3); MS: m/z = 394 [M-Br]+; HRMS: calcd. for C19H28O4N3S 394.1795, found 394.1800  (1.3 ppm).  
(j) [2-[[2-(4-tert-butoxycarbonylpiperazin-1-yl)-2-oxo-ethyl]amino]-2-oxo-ethyl]-dimethyl-sulfonium 
bromide (1m) 
C15H28BrN3O4S; light yellow solid / hygroscopic; yield 48%; M = 426.37 g/mol; IR (ATR):  ν = 3429 
(w), 2974 (w), 1672 (s), 1645 (s), 1408 (s), 1460 (w), 1363 (m), 1232 (m), 1163 (m-s), 1107 (w) cm-1; 
1H NMR (250 MHz, DMSO) δ 8.87 (t, J = 5.4 Hz, 1H), 4.43 (s, 2H), 4.08 (d, J = 5.4 Hz, 2H), 3.45-
3.32 (m, 8H), 2.91 (s, 6H), 1.41 (s, 9H); 13C NMR (63 MHz, DMSO) δ 166.2 (Cq), 163.2 (Cq), 153.8 
(Cq), 79.2 (Cq), 46.5 (2CH2), 43.8 (CH2), 41.2 (CH2), 41.0 (2CH2), 28.0 (3CH3), 24.6 (2CH3); MS: m/z 
= 346 [M]+; HRMS: calcd. for C15H28O4N3S 346.1795, found 346.1797 (0.6 ppm). 
(k) benzyl 4-[2-[[2-(1,3,4,5-tetramethylimidazol-1-ium-2-yl)sulfanylacetyl]amino]-acetyl]-piperazine-
1-carboxylate bromide (1s) 
C23H32BrN5O4S; light beige solid / hygroscopic; yield 79%; M = 554.50 g/mol; IR (ATR):  ν =  3402 
(w), 3192 (w), 2922 (w), 1696 (s), 1645 (s), 1423 (s), 1226 (s), 1026 (w) cm -1; 1H NMR (250 MHz, 
DMSO) δ 8.35 (t, J = 5.3 Hz, 1H),7.38-7.32 (m, 5H), 5.10 (s, 2H), 3.96 (d, J = 5.4 Hz, 2H), 3.77 (s, 
6H), 3.68 (s, 2H), 3.50-3.39 (m, 8H), 2.29 (s, 6H); 13C NMR (63 MHz, DMSO) δ 167.0 (Cq), 166.6 
(Cq), 154.4 (Cq), 136.7 (Cq), 135.9 (Cq), 129.2 (Cq), 128.4 (2CH), 127.9 (CH), 127.6 (2CH), 66.4 (CH2), 
43.7 (CH2), 43.3 (CH2), 43.1 (CH2), 41.0 (CH2), 40.7 (CH2), 36.8 (CH2), 33.5 (2CH3), 8.8 (2CH3); MS: 
m/z = 474 [M]+; HRMS: calcd. for C23H32O4N5S 474.2170, found 474.2161 (1.8 ppm). 
General method for the preparation of vinyl sulfonamides (H) 
Under inert atmosphere, triethylamine (1.1 eq.) was added at -60 °C to a solution of 2-chloroethyl-
sulfonyl chloride (0.3 mmol, 1 eq.) in DCM (6 mL). The mixture was stirred at -60 °C for 2h before 
adding the corresponding amine (1.1 eq.) and triethylamine (1.1 eq.), then the reaction was stirred for 
two additional hours at 0 °C. The reaction was quenched by addition of HCl (aq. soln., 0.1 N, 20 mL) 
and extracted with DCM (3 x 20 mL). The recovered organic layers were dried over magnesium sulfate 
and the solvent evaporated under reduced pressure. The crude material was further purified by flash-
chromatography (eluent: ethyle acetate) to conduct to the desired vinyl sulfonamide.    
(a) benzyl 4-[2-(vinylsulfonylamino)acetyl]piperazine-1-carboxylate (2a) 
C16H21N3O5S; yield 53%; colorless viscous oil becoming whitish solid on standing; m.p. 66-67 °C;  M 
= 367.42 g/mol; IR (ATR): ν = 3220 (w), 2865 (w), 1694 (s), 1648 (s), 1423 (m), 1326 (w), 1223 (s), 
1141 (m), 1123 (m), 762 (m), 729 (m), 695 (m) cm -1; 1H NMR (250 MHz, CDCl3) δ 7.41-7.30 (m, 5H), 
6.51 (dd, J = 16.5 Hz, J = 9.8 Hz, 1H), 6.25 (d, J = 16.5 Hz, 1H), 5.95 (d, J = 9.8 Hz, 1H), 5.44 (t, J = 
4.2 Hz, 1H), 5.15 (s, 2H), 3.84 (d, J = 4.4 Hz, 2H), 3.68-3.62 (m, 2H), 3.57-3.50 (m, 4H), 3.41-3.28 
(m, 2H); 13C NMR (63 MHz, CDCl3) δ 165.9 (Cq), 155.1 (Cq), 136.3 (Cq), 135.5 (CH), 128.8 (2CH), 
128.5 (CH), 128.3 (2CH), 127.2 (CH2), 67.8 (CH2), 44.3 (CH2), 43.9 (CH2), 43.7 (CH2), 43.6 (CH2), 
42.2 (CH2); MS: m/z = 390 [M + Na]+; HRMS: calcd. for C16H22O5N3S 368.1275, found  368.1280 (1.4 
ppm). 
(b) N-[2-[4-(adamantane-1-carbonyl)piperazin-1-yl]-2-oxo-ethyl]ethenesulfonamide (2e) 
C19H29N3O4S; yield 49%; white solid; m.p. 159-160 °C; M = 395.52 g/mol; IR (ATR):  ν = 3232 (w), 
2895 (m), 2850 (w), 1645 (m-s), 1612 (m-s), 1402 (m-s), 1320 (m), 1232 (m-s), 1153 (s), 1011 (m-s), 
984 (m), 738 (m) cm-1; 1H NMR (250 MHz, DMSO) δ 7.35 (t, J = 5.5 Hz, 1H), 6.71 (dd, J = 16.6 Hz, 
J = 10.0 Hz, 1H), 6.03 (d, J = 16.6 Hz, 1H), 5.94 (d, J = 10.0 Hz, 1H), 3.82 (d, J = 5.6 Hz, 2H), 3.57-
3.46 (m, 4H), 3.42-3.38 (m, 4H), 1.97 (as, 3H), 1.89 (s, 6H), 1.73-1.62 (m, 6H); 13C NMR (63 MHz, 
DMSO) δ  174.6 (Cq), 166.4 (Cq), 137.0 (CH), 125.1 (CH2), 44.5 (2CH2), 44.3 (CH2), 43.7 (CH2), 41.7 
(CH2), 40.9 (Cq), 38.4 (3CH2), 36.0 (3CH2), 27.9 (3CH); HRMS: calcd. for C19H30O4N3S 396.1952, 
found 396.1954 (0.6 ppm). 
Measurement of Thermodynamic Solubility  
Inhibitor (1-1.5mg) in a suitable 2ml vial was shaken with 1.0ml of Phosphate Buffered Saline (PBS), 
pH 7.4. After 2hours, the vial and contents were centrifuged at 4,000 xg for 10 min. Approximately 
150-200 µl of supernatant was then filtered through a 0.22 µm PTFE into a microvial for DAD-LCMS 
analysis. The original 2 ml vial and contents are then shaken again for another 22 h. After a total of 24 
h, the vial and contents were centrifuged again for 10min. Approximately 150-200 µl of supernatant 
was then filtered through a 0.22 µm PTFE into a microvial for DAD-LCMS analysis. A1,000 µg/ml 
standard solution of the inhibitor was prepared in 100% DMSO. A further dilution was prepared to 
provide an additional standard of 100 µg/ml in DMSO. The concentration of compound in the PBS 
filtrate was determined by comparing the UV DAD (210-400 nm) absorbance peak area with that of the 
two DMSO calibration standards. A range of injection volumes (typically 1-40 µl) was performed to 
ensure an appropriate match between the analyte and standard peak areas. Mass spectrometry was used 
to confirm the presence of the expected molecular ion in the UV DAD (210-400 nm) peak measured. 
The effective range of the assay is typically 1- 2,000 µM dependent upon the chromophore present.  
Molecular Modelling Methodology 
The core region (GLU155 - GLU585) of the open-conformation of tissue tranglutaminase (PDB code: 
2Q3Z, Pinkas et al., 2009) was used in our studies. The crystal structure was prepared by removing the 
covalently-bound irreversible inhibitor and other co- crystalisation factors. The catalytic cysteine 
residue (CYS 277) was modelled in its deprotonated state and the HIS335 in its protonated state, 
respectively. Docking was conducted with the Gold software (GOLD, version 5.1; CCDC, 
http://www.ccdc.cam.ac.uk.), using a distance constraint between the sulphur atom (CYS277) and the 
electrophilic carbon (inhibitor). The default settings as implemented in Gold were used (ChemPLP 
scoring function), except for the GA runs (20) and search efficiency (200%). The highly ranked poses 
were subsequently validated by molecular dynamics. The missing loops of the enzyme were constructed 
by homology with a TG2 closed-conformation (PDB code: 1KV3, Liu et al., 2002) using SwissPDB 
server (Arnold et al., 2006), and then minimized using MM3FF in Cache (CAChe, version 7.5; Fujitsu 
Ltd). The ligand-enzyme complex was subjected to unrestrained molecular dynamics in explicit water 
using Sander module of Amber package (Amber, version 11, http://ambermd.org/), as follows: input 
files were prepared with the Antechamber module using ff99SB force field; the systems were 
neutralized by addition of 10 Na+ counter ions then solvated using a TIP3P water model. The complexes 
were subsequently minimized for 2,000 steps using a nonbonding cut-off of 12 Å, then gradually heated 
from 0 to 300 K over 20 ps (constant volume, time step = 1 fs). Molecular dynamics trajectories were 
carried out for 4 ns (constant pressure, SHAKE on, time step = 2 fs) using the Particle– Mesh–Ewald 
(PME) method to treat the long range electrostatic interactions with a 12 Å non-bonded cut-off. The 
MD simulation was analyzed with VMD (Humphrey et al., 1996) and the same distance described 
before was monitored. 
In vitro microsomal stability 
The metabolic stability of 3h, 1h, 3e was tested in male Wistar Han rat and mixed gender pooled human 
liver microsomes. Microsomes (final protein concentration 0.5 mg/mL), 0.1 M phosphate buffer pH 7.4 
and test compound (final substrate concentration = 0.5 µM) were pre-incubated at 37°C prior to the 
addition of NADPH (final concentration = 1 mM) to initiate the reaction. The test compound was 
incubated for 0, 5, 15, 30 and 45 min. The control (minus NADPH) was incubated for 45 min only. The 
reactions were stopped by the addition of 50 µl methanol containing internal standard at the appropriate 
time points. Following protein precipitation, the compound remaining in the supernatants was measured 
using specific LC-MS/MS methods as a ratio to the internal standard in the absence of a calibration 
curve. Peak area ratios (Compound to IS) were fitted to an unweighted logarithmic decline in substrate. 
Using the first order rate constant, clearance was calculated by adjustment for protein concentration, 
volume of the incubation and hepatic scaling factor (52.5 mg microsomal protein/g liver for all species). 
Protein binding assay 
Chemically bonded Human Serum Albumin (HSA) and Alpha-1-acidglycoprotein HPLC stationary 
phases (Chiral Technologies, France) were used for measuring compounds' binding to plasma proteins, 
applying linear gradient elution up to 30% iso-propanol. The run time was 6 minutes including the re-
equilibration of the stationary phases with the 50 mM pH7.4 ammonium acetate buffer.  The obtained 
gradient retention times were standardised using a calibration set of mixtures as described in the 
references [4]. The average standard error of the assay depends on the bindings strength and kinetic of 
the compounds. It ranges from ±5% in the medium binding range which reduces to 0.1% at binding 
above 99% with fast kinetic. 
hERG Electrophysiological Methods 
Compounds 3h, 1h and 3e were assessed for potential hERG liabilities in a high-throughput 
electrophysiological assay, using the Molecular Devices (Sunnyvale, CA) Barracuda™ platform, as 
fully described in Gillies et al (2013).  The concentration – response relationship was determined for 
each compound on 3 separate occasions, and in each instance the test compounds were completely 
inactive in this assay. 
Cell Health Profiling  
HepG2 cells were seeded at 5,000 cells/well/50 µl in 384-well black, clear bottomed plates in growth 
media (EMEM + 10 % FBS + 1 % NEAA) and incubated at 37 oC, 5% CO2 for 24 h.  Compounds 
stamped at 10 mM, 0.5 µl in V bottomed PP plates were intermediately diluted with 100 µl assay media 
(EMEM + 1 % NEAA, +1 % Pen/Strep). 80 µl of this compound solution was transferred to the cell 
plates yielding a final assay concentration of 200 µM.  Cells were incubated for 72 h at 37 oC, 5 % CO2.  
On the day of acquision, a cocktail of dyes was made in PBS – 0.22 % pluronic acid, 16.5 µM Hoechst 
33342, 880 nM TMRM, 6.25 µM TOTO-3.  5 µl of this solution was added to all wells and left for 45 
min at 37 oC, 5 % CO2. 
Images were acquired using the INCell Analyzer 2000 system with the following filter settings Hoechst: 
DAPI, TMRM: Cy3, TOTO-3: Cy 5. These images were then analysed using the INCell Investigator 
protocol to determine three parameters: nuclear morphology (Hoechst), mitochondrial potential 
(TMRM) and membrane permeability (TOTO-3). Data were normalised to controls treated with a 
known toxicant (100%) or DMSO (0%) for each parameter individually to determine the percentage of 
dead cells.  
Calculation of logP values 
The calculated logP values of inhibitors were obtained using MarvinView 5.1.1.4 (ChemAxon Ltd) and 
are an equally-weighted average of three methods: the calculation method derived from Viswanadhan 
et al (Viswanadhan et al., 1989); a method using logP data from Klopman et al (Klopman et al., 1994); 
a method using logP data from the PHYSPROP© database (Syracuse Research Corporation, SRC 
Environmental Science Center: Syracuse, NY, 1994).  
The polar surface area (PSA) values were calculated using MarvinView 5.5.1.0. 
 
Biology Experimental Procedures  
Cell culture  
Human umbilical vein endothelial cells (HUVECs) (Lonza, Ghent, Belgium) were cultured as described 
previously (Wang et al., 2013) using endothelial growth medium EGM containing endothelial cell basal 
medium, 2 % foetal bovine serum (FBS), hydrocortisone, bFGF, VEGF, hEGF, ascorbic acid, R3-IGF, 
heparin, and GA-100 (Lonza, Ghent, Belgium).  
NIH3T3 cells were cultured in DMEM medium supplemented with 10 % (v/v) heat-inactivated FBS, 2 
mM L-glutamine, MEM non-essential amino acids100 U/ml of penicillin and 100 μg/ml of 
streptomycin. Cells were maintained at 37°C in a 5 % CO2 humidified atmosphere (Wang et al., 2012). 
Western blotting for the dansyl inhibitor interaction with TG1, TG3 and FXIII 
To study the specificity of the inhibitors toward TG2, recombinant human TG1, TG3 and FXIIIa pre-
treated with 10 mM Ca2+ or 10  mM EDTA were incubated with TG2 inhibitor 1h and 3h for 30 min at 
room temperature. The presence of dansyl was detected as described above following denaturing SDS–
PAGE and Western Blotting. 
Lentiviral transduction of wild type TG2 into NIH3T3 cells 
Lentiviral particles were produced as described previously by Wang et al. (2013). NIH3T3 cells were 
transduced with wild type TG2 containing virus or the empty vector and used in subsequent studies. 
Non-denaturing gel electrophoresis 
RhTG2 was pre-incubated for 30 min on ice with either GTP (10mM, unless specified in the figure 
legend) or Calcium (10mM), followed by incubation with inhibitors 1h or 3h at the specified 
concentrations for further 30 min on ice. The enzyme conformation was analyzed by their mobility in 
a non-denaturing polyacrylamide gel electrophoresis system using Laemmli buffer without SDS and 
then stained with PageBlue. The gels were imaged using a Gel Doc system. 1µM of inhibitor R281 was 
used as the control treatment.  
Cell toxicity assay 
The toxicity of the TG2 inhibitors were studied using the XTT assay as described previously (Wang 
and Griffin, 2013). Briefly, 3,000 HUVEC cells/well were seeded into 96-well tissue culture plates in 
endothelial growth medium EGM containing endothelial cell basal medium, 2 % foetal bovine serum 
(FBS), hydrocortisone, bFGF, VEGF, hEGF, ascorbic acid, R3-IGF, heparin, and GA-100 (Lonza, 
Ghent, Belgium) and allowed to settle and spread overnight. The inhibitors dissolved in DMSO were 
diluted with complete endothelial growth medium EGM to the required concentration so that the final 
DMSO concentration in the medium was  0.01% and incubated for up to 72 h. Fresh medium was 
replaced every 24 h during the culture period. DMSO used at the same concentration as that used for 
delivery of the inhibitor was used as the vehicle control treatment. 30 μl of XTT reagent mixture (Roche, 
East Sussex, UK) was added to the cells after the indicated culture period and incubated for 4 h before 
measuring the absorbance at 490 nm. In order to rule out the possibility that TG2 or Factor XIIIa might 
be present in the media that might react with the inhibitor, toxicity for some of the inhibitors was 
repeated using culture medium without serum for endothelial cell lines (Sigma-Aldrich, Dorset, UK).  
Caspase 3/7 assay 
2×104 cells/ well HUVEC cells were seeded into 96-well plates overnight and were treated with the 
apoptosis inducing agent Staurosporine (100 nM) for 3 h to induce apoptosis and activation of Caspase, 
in the presence or absence of 10 µM of the TG2 inhibitors  3h, 1h, 3e and 1e while Caspase inhibitor 
Z-VAD-FMK at the concentration of 25 µM (Promega, UK) and DMSO (the vehicle control) was used 
as the positive and negative control treatments, respectively. The TG inhibitor R283 (250 µM) was used 
as a negative reference compound. Caspase activity was measured using the Caspase-Glo3/7 Assay 
(Promega, Southampton, UK). Briefly, the cultures were incubated with 100 µl of the caspase assay 
reagent for 45 min at room temperature after mixing at 300 rpm for 30 sec. The luminescence was 
recorded using an Orion II Microplate Luminometer (Berthod Technologies, UK). 
Co-IP for detection of TG2 and syndecan-4 binding 
To detect protein-protein interactions, co-IP was performed as described previously (Wang et al., 2010; 
Wang and Griffin, 2013). After the appropriate treatments, cells were washed twice with PBS pH 7.4, 
then collected and lysed for 30 min on ice in lysis buffer (Tris-HCl 50mM pH 7.4 containing 1% 
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM NaF, 1 mM sodium orthovanadate, 0.1 
mM PMSF and 1% protease inhibitor cocktail). Anti-syndecan-4 antibody was used to pull down the 
immune-complex and Western blotting was performed to detect the presence of TG2 in the immune-
complex.   
Biotinylation of cell surface proteins 
Biotinylation of cell surface proteins was performed as previously described by Wang et al. (2012). 
Briefly, after specified treatments, cell monolayers were rinsed once with ice-cold PBS pH 8.0 and 
labelled with 450 μM sulfo-NHS-SS-Biotin in PBS pH 8.0 at 4°C for 30 min. Cells were lysed in PBS 
pH 8.0 containing 1% SDS, 0.1 mM PMSF, 1% protease inhibitor cocktail and benzonase (1:1000 
dilution, Merck). Biotinylated proteins were bound to NeutrAvidin-Agarose resin beads (Thermo 
Scientific) and extracted via heating at 100°C for 5 min in Laemmli sample Buffer. Western blotting 
was performed using anti-TG2 antibody Cub74002 to detect the presence of TG2.  
Detection of TG2 and FN in the ECM and calculation of cell EC50 for fibronectin deposition using 
compound 3h 
After the indicated treatments, cells were detached with 2 mM EDTA in PBS pH 7.4 and the ECM was 
extracted in 30 µl of 2× Laemmli Buffer sample buffer. Proteins were then separated by denaturing 
SDS-PAGE and proteins detected by Western blotting (Wang et al., 2013).  
For calculation of cell the EC50 for fibronectin deposition for compound 3h, HUVEC cells or mouse 
endothelial cells were treated with different concentrations of 3h (0.1, 0.5, 1, 2.5 and 5 µM) for 72 h 
and the ECM fractions collected as described above and the presence of FN in the ECM detected after 
separation of proteins by denaturing SDS-PAGE and fibronectin detected by Western blotting (Wang 
et al., 2013). Band intensity was measured using densitometry. DMSO was used as the vehicle control 
treatment (0 µM).   
To detect the presence of FN via immunofluorescence staining, HUVECs were seeded into 8-well 
chambers at a density of 7×104 cells/well in the presence or absence of inhibitor 1µM 3h for 72 h. 
Following incubation of the cells with anti-FN antibody in fresh medium for 2 h, the cells were fixed 
and stained as described previously by Wang et al (2013). 
Measurement of Ca2+ dependence of inhibitor binding  
Recombinant human TG2 was incubated for 30 min at 4°C  with either Ca2+ (1 mM) or GTP (1 mM), 
and  then for a further 30 min in  presence of compounds 3h  (10 nM) or 1h  (1 μM). Afterwards, 
samples were centrifuged in spin columns with a 30 kDa molecular weight cut off. To remove excess 
inhibitor, 3 washes were undertaken. The TG2 transamidating activity in the remaining filtrate was then 
measured via the biotin-cadaverine incorporation into immobilized FN. To evaluate the efficiency of 
the spin-columns, for inhibitor removal reaction mixes with inhibitor alone (either 3h or 1h) were 
prepared and filtered through the spin columns. The filtrate was then added to the TG2 assay reaction 
mixture and enzyme activity measured. To check the efficacy of GTP binding, enzyme was incubated 
with 250 µM Ca2+ to show activation of rhTG2 in absence of GTP but to also show that 1 mM Ca2+ 
could still activate TG2 with 250 µM GTP present. Samples with 1 mM GTP and 250 µM calcium were 
prepared in duplicate and one processed through the spin-column and the other not to evaluate whether 
the spin column affects GTP binding. A positive control incubated without inhibitor was used as 100% 
reference. 
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